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Abstract 
 
The proto-oncogene Akt/protein kinase B plays a pivotal role in cell 
growth and survival. Phosphorylation of Akt at Thr308 and Ser473 activates the 
kinase following growth factor stimulation. Delineating specific role of each 
activation site in Akt1 on kinase activation, inhibition and substrate selection 
remain elusive.  
We designed a unique set of tools, relying on genetic code expansion with 
phosphoserine and in vivo enzymatic phosphorylation, to produce differentially 
phosphorylated Akt1 variants. We found that having both sites phosphorylated 
increased the apparent catalytic rate of the enzyme by 1500-fold relative to the 
unphosphorylated enzyme. This increment was mainly due to the 
phosphorylation of Thr308 but not Ser473 which was confirmed via live cell 
imaging. We further found that the traditional use of phosphomimetics was 
unable to mimic the effect of p-Thr308 in the test tube and in cells.   
Akt1 activity is also regulated via interactions between the kinase domain 
and the N-terminal auto-inhibitory pleckstrin homology (PH) domain. Using the 
same strategy, we produced Akt1 variants containing programmed 
phosphorylation to probe the interplay between Akt1 phosphorylation status and 
the auto-inhibitory function of the PH domain. Deletion of the PH domain 
increased the enzyme activity for all three Akt1 phospho-variants. For the doubly 
phosphorylated enzyme, deletion of the PH domain relieved auto-inhibition by 
295-fold. The robustly active PH domain deleted enzyme variants were used in 
enzyme inhibition and substrate selectivity studies.  We found that 
phosphorylation at Ser473 provided resistance to chemical inhibition by the Akt 
inhibitor Akti-1/2.  
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Finally, we used both defined and randomized peptide libraries to map 
the substrate selectivity of singly and doubly phosphorylated Akt1 variants. The 
data revealed that each phospho-form of Akt1 has distinct substrate 
requirements. Surprisingly, phosphorylation of Ser473 in the context of a 
pAkt1T308 enzyme led to increased activity on some, but not all Akt1 substrates. 
We also verified a new Akt1 target as the terminal nucleotidyltransferase 
(germline development 2) Gld2.  
In conclusion, the site-specifically phosphorylated Akt1 variants that we 
produced enabled in characterizing phosphorylation-dependent activity, 
inhibition and substrate selectivity of the oncogenic kinase Akt1. Since 
phosphorylation status of Akt1 is used as a cancer biomarker, these variants can 
act as indispensable tools in further characterizing downstream oncogenic 
pathways and screening potential drug candidates. 
 
Key words: Akt, Akti1/2 inhibitor, genetic code expansion, kinase, peptide 
libraries, PH domain, phosphorylation 
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Chapter 1 
1 Introduction 
1.1 Protein kinase B (Akt) 
Murine oncogene v-AKT was initially identified from an Akt8 
transforming retrovirus in spontaneous thymomas of high leukemic mice (1). 
Later three groups independently characterized the cellular homolog of v-AKT. 
These initial studies referred to the same kinase by different names: c-Akt (2), 
related to A and C (RAC) kinase (3) or protein kinase B (PKB) since it showed 
close similarity to protein kinase A and C (4). Akt was found to be a protein 
kinase that phosphorylated multiple protein substrates involved in cell survival 
signaling (5). 
There are three isozymes of Akt found in mammalian cells: Akt1/PKBα, 
Akt2/PKBβ, Akt3/PKBγ (Figure 1.1). Isozymes 1 and 2 are ubiquitously expressed 
in all tissues while isozyme 3 is predominantly found in brain and testis (6). 
Recent studies conducted on Akt isozyme specific knock-out mice revealed that 
the isozymes contribute to functional diversity of Akt. Akt1 null mice suffered 
from growth retardation and increased apoptosis (7). When Akt2 was knocked 
out, mice suffered from type 2 diabetes related complications (8). Akt3 null mice 
had impaired brain development (9). The cellular mechanism related to 
differential activity of these isozymes is still not well established.  
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1.2 Akt structure 
All three isozymes of Akt share ~80% sequence identity and extensive 
structural similarity. Akt is composed of three functional domains: 1) the N-
terminal pleckstrin homology domain (PH domain); 2) the kinase or catalytic 
domain; and 3) the small C-terminal regulatory domain referred to as the 
hydrophobic motif (HM) (Figure 1.1). Akt1 is known to be activated by 
phosphorylation at two key sites (5), Thr308 in the catalytic domain and Ser473 in 
the hydrophobic motif. 
The PH domain was named after the pleckstrin protein, which is a major 
substrate of protein kinase C in platelets, lymphocytes, macrophages and 
monocytes (10). All three Akt isozymes possess an N-terminal PH domain. In its 
inactive confirmation, the PH domain is settled in between the N- and C-terminal 
lobes of the kinase domain, which inhibits Akt activation by upstream kinase 
phosphorylation (11,12). Solution phase hydrogen/deuterium (H/D) exchange 
coupled with mass spectrometry analysis revealed that four β sheets (β1, β2, β5, 
β6) of the PH domain bear positively charged residues that are readily available 
for solvent accessibility in the inactive state and, which also makes it easier to 
bind with the negatively charged lipid membrane. This indicates that the 
conformation of the PH domain facilitates membrane binding (13) which is 
important for Akt1 activity in cells (see Section 1.3).	 Binding of the PH domain 
with phosphatidylinositols in the plasma membrane and endomembranes 
releases the auto-inhibitory effect of the PH domain. Akt1 lacking a PH domain 
shows higher activity compared to the full-length enzyme (14,15). A mutational 
screen of the PH/kinase domain interface showed that Akt can be activated by 
disruption of this interface interactions in cells. Some of these mutations 
 3 
(Leu52Arg of PH domain, Asp323His of kinase domain) were demonstrated in 
human cancers.  Both mutations cause cellular transformation and are oncogenic 
in vivo (16).  
Structurally, the kinase domain of Akt is bilobal. The N terminal lobe is 
comprised of 5 β sheets and a partially ordered αC helix. There is a deep cleft in 
between the two lobes (17).  
In the inactive state, certain regions of the Akt1 active site exist in a 
disordered state. The disordered region of the N-terminal lobe transforms into an 
ordered state following Thr308 phosphorylation (17,18). Hydrogen bond 
formation between the phosphate group and Arg273 and Lys297 are facilitated 
when Thr308 is phosphorylated. The hydrophobic interaction of the g-methyl 
group of Thr308 with Cys310 is essential to establishing this hydrogen-bonding 
network.   
The C-terminal hydrophobic motif includes the Ser473 phosphorylation 
site. Many studies suggest that full activation of the kinase requires 
phosphorylation at both Thr308 and Ser473 (5). Once phosphorylated at Ser473 
the hydrophobic motif interacts with the kinase domain and facilitates 
disordered to ordered transition of the αC helix of the kinase domain (18).	 
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Figure 1.1 Domain structure and regulatory phosphorylation sites in Akt 
isozymes. The N-terminal pleckstrin homology (PH) domain, kinase domain 
with the activation site Thr308 and hydrophobic motif (HM) with the activation 
site Ser473 are shown. The homologous phosphorylation sites in Akt2 and Akt3 
are noted.  
 
1.3 Regulation of Akt1 activity 
1.3.1 Phosphorylation-dependent activation of Akt  
Akt1 is a major kinase in the phosphoinositide 3-kinase (PI3K)/Akt1 
signaling pathway, which controls cell growth and survival (5). The impact of 
active Akt on cell survival occurs mainly via inhibiting the activity of its 
downstream targets as a result of phosphorylation. The activation of the Akt 
enzyme occurs in response to growth factors (GF), insulin, or cytokine mediated 
stimulation (20,21). GFs bind to receptor tyrosine kinases (RTK) in the plasma 
membrane. This leads to PI3K activation via three independent pathways: i) Once 
GFs bind to RTKs, the receptor kinases dimerize and auto-phophosphorylate 
tyrosine residues. Upon phosphorylation, the p85 subunit of PI3K will bind to 
 5 
RTKs and this will lead to the activation of the p110 catalytic subunit of PI3K (22). 
ii) The next pathway of PI3K activation occurs through the effector protein 
growth factor receptor bound protein (GRB2). GRB2 is phosphorylated by 
activated RTKs (23). GRB2 also binds to the p85 subunit of PI3K, contributing to 
PI3K activation. iii) The third mode of activation is via RAS. RAS directly 
activates the p110 catalytic subunit of PI3K independent of p85 (24). PI3K then 
phosphorylates its immediate downstream target, a lipid second messenger in 
the plasma membrane, phosphatidylinositol-4, 5-bisphosphate (PIP2), converting 
PIP2 into phosphatidylinositol-4, 5-triphosphate (PIP3). PH domain containing 
proteins like Akt1 and PDK1 bind to PIP3 with high affinity (25) (Figure 1.2).  
In Akt1, upon PH domain binding to PIP3, the auto-inhibitory effect of PH 
domain is released, exposing the activation sites for phosphorylation (5) by the 
up-stream kinases, mechanistic target of rapamycin complex 2 (mTORC2) (26) 
and PDK1 (27). mTORC2 is the Ser473 kinase and PDK1 phosphorylates Thr308 
in Akt1.  
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Figure 1.2: Akt1 activation via phosphorylation at sites Thr308 and Ser473. The 
upstream kinase for the Thr308 phosphorylation is phosphoinositide dependent 
kinase 1 (PDK1). Complete activation of Akt1 requires C terminal Ser473 
phosphorylation. mTORC2 phosphorylates Ser473. 
 
PDK1 is an AGC family of kinase related to Akt. Phosphorylation at 
Ser241 is essential for PDK1 activation. This is achieved through auto-
phosphorylation and this leads to constitutively active enzyme in cell (28). The 
level of PDK1 phosphorylation does not change upon stimulation of the cells 
with insulin-like growth factors (29). PDK1 bears a PH domain which facilitates 
its binding to PIP2 and PIP3. Interestingly, PDK1 also activates kinases that lack 
PH domains, e.g., p70 ribosomal S6 kinase, p90 ribosomal S6 kinase. Instead, 
these kinases carry PDK1 docking sites in their C-terminal hydrophobic motifs 
(28). 
mTORC2 is active as an effector protein upon growth factor and insulin 
mediated PI3K activation. The Sin1 subunit of mTORC2 includes a PH domain, 
which facilitates binding with PIP3 and co-localization with Akt (30).  As with 
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Akt, upon PIP3 binding the auto-inhibition of Sin1 is released leading to the 
activation of mTORC2. mTORC2 is also responsible for phosphorylating the turn 
motif at Thr450 which leads to stabilization of newly synthesized Akt (31). 	
Since Cohen’s group discovered PDK1 for the first time in 1997 (32), no 
other kinase has been reported-as a potential phosphorylating agent for Thr308 
(27,32). PDK1 was originally extracted from rabbit skeletal muscle. Once Akt was 
incubated with this novel kinase PDK1, the level of phosphorylation and enzyme 
activity of Akt is increased. Since PDK1 activity was dependent on PIP3 
concentration in activity assays, they named this novel kinase as 
phosphoinositide dependent kinase or PDK1 (32). The kinase for Ser473 was 
debated during earlier studies. Integrin-linked kinase (ILK) (33), mechanistic 
target of rapamycin complex (mTORC2) (26) and autophosphorylation by Akt 
itself (34) are among the possibilities for Ser473 phosphorylation. mTORC2 
activation is now considered as the major route to Ser473 phosphorylation 
because the rictor-mTOR complex directly phosphorylates full length Akt1 in 
vitro, in Drosophila and human cells (26). Knocking down rictor or mTOR 
decreases Akt1 phosphorylation significantly at Ser473 in several cell lines 
including HEK293T, PC3 and HeLa (26).  
Once phosphorylated, Akt1 in its active confirmation is released to the 
cytosol and nucleus to phosphorylate its substrates. According to live cell 
imaging studies using a Förster resonance energy transfer (FRET) based reporter 
system developed for Akt1 (B kinase reporter, BKAR), active Akt1 was present in 
the cytosol up to 10 min after growth factor stimulation (35). Akt1-dependent 
phosphorylation of perhaps as many as 100 substrates is known to occur in the 
cytosol  (36) and nucleus (37). Fork head box O (FOXO) transcription factors are a 
group of well-known Akt substrates and FOXOs can be phosphorylated by Akt1 
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either in the cytosol or in the nucleus (38,39).	 Akt phosphorylation can direct 
trafficking of β-catenin in different cellular locations to the cytosol and nucleus 
(40). A recent study concluded that Akt1 is de-phosphorylated on a time scale of 
10 minutes following its dissociation from the membrane (41). Although this 
study indicated that Akt1 activity may be restricted to the plasma membrane 
(41), multiple independent reports suggest Akt1-dependent substrate 
phosphorylation occurs on the time scale of seconds to minutes in different sub-
cellular compartments (5,35,36). 
 
1.3.2 Phosphatase-dependent deactivation of Akt1 
Akt1 is deactivated following dephosphorylation of the lipid second 
messenger PIP3 by a lipid phosphatase, i.e., phosphatase and tensin homolog 
(PTEN) (42). PTEN was initially identified as a tumor suppressor gene. Its 
presence at the human chromosome 10q23.3 makes it highly susceptible to 
genetic alteration in human cancers (43). PTEN de-phosphorylates multiple 
substrates including tyrosines in proteins and lipids second messengers, e.g., 
PIP3. Further PTEN acts as a scaffolding protein in both the nucleus and 
cytoplasm. Loss of function of PTEN leads to high plasma concentrations of PIP3 
and constitutively active Akt isozymes (44,45). Other than Akt mediated cellular 
functions, PTEN regulates the activation of c-Jun-N-terminal kinase (JNK) 
pathway, which regulates cell proliferation, embryonic development and 
apoptosis (46).  
Specific phosphatases are known to dephosphorylate the regulatory sites 
in Akt1. Thr308 is dephosphorylated by protein phosphatase 2A (PP2A) (47,48). 
PP2A activity is highly regulated by a multiple regulatory subunits, which 
 9 
determine the substrate specificity of this phosphatase. The catalytic subunit and 
the regulatory subunit A comprise the core structure of the phosphatase. The 
third regulatory subunit B varies depending on the functionality (47). The 
regulatory subunit B56 of PP2A recruits PP2A to Akt1 and de-phosphorylates 
Thr308 specifically (48). Other than cell cycle regulation and apoptosis, PP2A 
activity in maintaining cell adhesion and cytoskeleton maintenance are also 
established (49). PP2A is a tumour suppressor protein. Loss of activity of PP2A is 
associated with the onset of lung carcinoma and melanoma (50). 
Phosphatases acting on Ser473 are the PH domain leucine-rich repeat 
protein phosphatases, PHLPP1 and PHLPP2. Other AGC kinases 
dephosphorylated by PHLPP family members include p70S6 kinase (S6K) and 
protein kinase C (PKC). PHLPP is also capable of suppressing histone 
phosphorylation to down regulate gene expression of RTKs (51).  
A knockdown study revealed that p27 phosphorylation by Akt3 is 
regulated by PHLPP2. In breast cancer cells, knockdown of PHLPP2 increased 
p27 phosphorylation and knockdown of Akt3 decreased p27 phosphorylation. 
Knocking down of either isoform of PHLPP decreased the phosphorylation of 
Akt1 substrates, such as FOXO1 (52). This study concluded that PHLPP isoforms 
de-phosphorylate Akt in an isozyme dependent manner: PHLPP1 de-
phosphorylates pSer473 of Akt isozymes 2 and 3 and PHLPP2 dephosphorylates 
pSer473 in Akt1 and Akt3 (52).    
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1.4 Additional post-translational modifications regulate 
Akt1 
Apart from the two activation sites Thr308 and Ser473, independent 
studies have identified 25 additional phosphorylation sites on Akt1 (Figure 1.3). 
Thr450, which is found in the turn-motif is constitutively phosphorylated by 
mTORC2 (53). Phosphorylation of Thr450 enhances proper folding and stability 
of Akt1 by preventing ubiquitin-dependent degradation of the kinase (54).  
Ser124 was also identified as constitutively phosphorylated in different cell lines 
including HEK293 cells, (55) BT74 cell lysates (56)	 and HTC116  (57,58). There are 
23 other phospho-sites identified in proteomic studies, yet for most sites the 
function is not known. Some phosphorylation sites are located in known 
substrate motifs for kinases upstream of Akt. For example, Ser129 in Akt1 is 
phosphorylated by casein kinase 2 (CK2), which increases Akt catalytic activity 
and promotes cell survival (59).  
Other types of post-translational modifications are also involved in Akt 
regulation such as acetylation, ubiquitination, sumoylation and glycosylation 
(60). Acetylation of Akt is associated with reduced levels of phosphorylation and 
Akt activity. The acetyltransferase p300 is involved in Akt acetylation while 
sirtuin 1 (SIRT1) deacetylates Akt, promoting localization with PIP3 (61). 
Ubiquitination at Lys48 degrades Akt and abolishes Akt signaling (62). It is 
thought that sumoylation is an important modification for Akt activation (60), yet 
the exact mechanism of action is not known; the enzyme can be highly activated 
in the absence of SUMO (14). Finally, glycosylation of Thr308 inhibits Akt 
activation (63).  
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1.5 Akt activity drives cell growth and survival programs 
Akt blocks pro-apoptotic proteins to promote cell survival. Key substrates 
regulated by Akt1-dependent phosphorylation include B cell lymphoma-2 (Bcl-2) 
homology domain 3 protein (BAD), the FOXO family of transcription factors, as 
well as p53 and the p53 regulating E3 ubiquitin ligase MDM2 (5).  
Akt1-dependent phosphorylation impacts target proteins through 
multiple mechanisms. For example, Akt1 phosphorylates BAD at Ser136. Once 
phosphorylated, phospho-BAD binds to the regulatory protein 14-3-3 which 
prevents heterodimerization with BCL-2 and BCL-xl.  Heterodimerization of 
BAD initiates cell death (64).  
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Figure 1.3. Structure of human Akt1. The two activation sites, Thr308 and 
Ser473; several additional phosphorylation sites (yellow highlight), GSK-3β 
peptide in complex with the kinase domain (purple) of Akt1 and a non-
hydrolyzable ATP analog (ATP’ = AMP-PNP) are shown. Structural data were 
obtained from PDB codes: 3CQU (65), 1O6K (18).  
 
 GSK-3 isoforms were the first identified substrates of Akt1 (66). 
GSK-3 was initially identified as a key regulator in glycogen synthesis (67). Later 
it was discovered that GSK-3 regulates a plethora of cellular substrates involved 
in metabolism, signaling and structural functions. Akt targets  include glycogen 
GSK3b 
peptide 	
ATP¢ 	
S473D 	
pT308 	
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synthase, β-catenin, cyclic-AMP response element binding (CREB) protein, 
insulin receptor substrate 1 (IRS1) and many others (68).  
The prototypical Akt substrate, GSK-3 is a key mediator of both insulin 
signaling and Wnt signaling pathways (6,69). Akt1 inactivates GSK-3 by 
phosphorylating the N-terminal residues Ser21 in GSK3α and Ser9 in GSK3β, 
respectively (66). Inhibition of GSK3 activates glycogen synthase and converts 
glucose into glycogen. Inhibition of GSK-3 further promotes protein synthesis by 
activating the elongation factor 2B (eEF2B) (70).  
A similar regulatory mechanism is associated with Akt1-depedent 
phosphorylation of the FOXO subfamily of fork head transcription factors, which 
includes FOXO1, FOXO3 and FOXO4. These transcription factors reside in the 
nucleus in growth factor deprived cells. The function of FOXO transcription 
factors varies depending on the cell type. In general, these factors promote 
expression of genes associated with cell differentiation, apoptosis, proliferation, 
and DNA damage (71). Once the cells are stimulated with growth factors and Akt 
is activated, Akt phosphorylates FOXO3 at phosphorylation sites Thr32, Ser253, 
and Ser315 (38). Phosphorylated FOXO3 is bound to 14-3-3, which displaces these 
transcription factors from their target apoptotic genes and facilitates their 
shuttling to the cytosol (38,72). Akt also acts on other FOXO members by a 
similar mechanism (reviewed in	(73)). 
Another target of Akt1 is the E3 ubiquitin ligase, MDM2, that negatively 
regulates the activity of the tumor suppressor protein and transcription factor 
p53 (74). MDM2 polyubiquitinates p53 and directs p53 for proteasomal 
degradation by enabling the association of p53 with p300, which is an E4 
ubiquitin ligase. Activation of p53 by cellular responses including DNA damage, 
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promote cell cycle arrest and apoptosis (75,76). Akt promotes cell survival in part 
by counteracting p53-dependent apoptosis. Akt phosphorylates MDM2 at two 
sites, Ser166 and Ser186. Phosphorylated MDM2 translocate to the nucleus where 
it triggers p53 ubiquitination and degradation (5).  
The mTORC1 protein complex acts as a central regulatory body in protein 
synthesis and cell growth. Akt phosphorylates tuberous sclerosis factor 2 (TSC2), 
a negative regulator of mTORC1 (77). Furthermore, Akt phosphorylates the 
PRAS40 subunit of mTORC1. PRAS40 is also a negative regulator of mTORC1 
and Akt1 phosphorylation stabilizes mTORC1 activity by relieving the inhibitory 
effect of the PRAS40 domain (78). Through inactivation mechanisms of TSC2 and 
PRAS40 by Akt, mTORC1 activity is stabilized to promote protein synthesis and 
cell growth	(77,78). 
 
1.6 Hyper-activation of Akt in cancer 
The significance of Akt activation in cancer has been a widely studied due 
to the prominent role of Akt1 in stimulating cell growth and survival pathways 
(79,80). Hyper-phosphorylated and hyper-active Akt1 is known to facilitate 
cancer cell survival creating a chemo-resistant environment (81).  Due to these 
reasons Akt1 hyper-activation is considered as a hallmark of cancers, including 
breast (56), lung (82,83), and head and neck (84). Certain somatic mutations also 
cause Akt mediated carcinogenesis. Glu17Lys mutation at the PH domain 
promotes Akt1 binding to plasma membrane, which constitutively activates Akt1 
(16).	The other Akt isozymes are also hyperactive in certain cancers (1,79,85).  
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The phosphorylation status of Akt1 at positions Ser473 and Thr308 are 
used as diagnostic markers for multiple cancers (82,83,86). Higher levels of 
Thr308 and Ser473 phosphorylation is correlated with poor clinical outcome with 
patients with head and neck squamous cell carcinoma  (84,87). Ser473 
phosphorylation is the most commonly used biomarker for hyper-active Akt1 
(82,88). Thr308 phosphorylation is also as a prognostic biomarker in non-small 
cell lung cancer (83) and acute myeloid leukemia (86).  
Different cancer types are associated with isozyme specific Akt activity. 
Akt1 promotes cell proliferation in breast cancers (89), Akt2 highly active in 
hepatocellular carcinoma (90) and colorectal cancers (85) and Akt3 is hyper-active 
in estrogen receptor negative breast tumors and melanoma (80).  
A somatic mutation; Glu17Lys in Akt1 was identified in breast cancers 
(91). This mutation is present in the PH domain and helps in constitutive 
membrane localization of Akt1 (91). Yet, there is no evidence of a similar PH 
domain mutation in Akt2 (80). A later study revealed the presence of Glu17Lys in 
Akt3 in two melanomas of one patient (92).   
Since more than 50% of human tumors are characterized by hyper-active 
Akt, numerous studies have been conducted to develop Akt specific anticancer 
drugs (6). After successful in vitro, cell and animal model testing, small molecule 
inhibitors for Akt have been introduced to clinical trials.  However, most of them 
failed in clinical trials. Inefficiencies during patient stratification, activation of the 
negative feed-back loops while Akt is inhibited (93), function of other PI3K 
effectors such as serum and glucocorticoid-induced protein kinase isoforms that 
activate downstream targets of PI3K/Akt pathway (94) are among the challenges 
for future work and in the development of clinically successful Akt inhibitors. 
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1.7 Investigating Akt phosphorylation in vitro and in cells 
Amino acid substitutions are often used as a genetic tool to mimic the 
function of protein modifications. In studies of protein kinases there are multiple 
challenges that exist to producing proteins with site-specific phosphorylation(s). 
It is challenging to characterize the functionality of an individual 
phosphorylation site since a functional protein may require more than one 
phosphorylation for activity. For >90% of human phosphorylation sites, the 
upstream kinases for the site is not known (95). Even when upstream kinases are 
known, they often must be activated themselves by phosphorylation and many 
kinases phosphorylate at multiple sites in one protein, thus, hampering our 
ability to generate protein with programmed phosphorylation.  
As a resolution to this problem, acidic amino acids like glutamate (Glu) or 
aspartate (Asp) are used to mimic phosphorylation. Though a phosphate adds 
two negative charges to the modified protein, the closest resemblance for this to 
be selected from the canonical amino acid pool are the acidic residues Glu or 
Asp. Ala mutations are used to mimic non-phosphorylation. Although mimics 
may be interesting mutants, they are unable to mimic true phosphorylation 
sometimes. 
Thr308Asp mutant of Akt1 expressed and purified as an 
immunoprecipitate in serum starved COS-1 cell line was 5-fold more active than 
the wild type Akt (55). When MAPKAP-kinase 2 activated this mutant in vitro, it 
was 5-fold more active relative to the activated wild type Akt1 in an in vitro 
kinase assay.  The authors conclude that the Asp308 is a suitable mutation for 
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mimicking phosphorylation (55). However, when the same construct was used to 
express Thr308Asp mutant in HEK293 cells, the enzyme was totally inactive 
according to an independent group of investigators (15). Further studies revealed 
that Asp308 mutant did not show transforming ability in contrast to the truly 
phosphorylated Akt in chicken embryonic fibroblasts (96).	 Akt studies often use 
these mimics to characterize Akt functionality (41,58), however, the 
preponderance of direct evidence suggests that in Akt1, acidic amino acids fail to 
mimic phosphorylation (96).  
To overcome the drawbacks listed above, novel synthetic biology 
approaches enable expansion of the genetic code with phosphoserine (97). 
Genetic code expansion refers to the ability to reassign codons, normally a stop 
codon, to include additional or unnatural amino acids beyond the canonical 20. 
These systems often require a tRNA and aminoacyl-tRNA synthetase pair that is 
orthogonal to the host expression system (98,99), which means the tRNA and 
synthetase enzyme pair should not cross react with the host tRNAs and tRNA 
synthatase enzymes. In these systems the unnatural or modified amino acids are 
incorporated into proteins during translation. Genetic code expansion is used to 
synthesize phosphoproteins in Escherichia coli with site-specifically introduced 
phosphoserine residues. George et al. (2016) have site specifically incorporated 
phosphoserine into ubiquitin (100). An active form of human mitogen-activated 
ERK activating kinase 1 (MEK1) was the first kinase to be produced by site-
specific incorporation of phosphoserine (97). Recent studies have reported site-
specific incorporation of phosphotyrosine and phosphothreonine following 
related methodologies (101,102). Incorporation of phosphotyrosine has confirmed 
by electron spray ionization mass spec (ESI-MS) analysis using Xenopus 
calmodulin and green fluorescent protein (GFP) (101). The yields of calmodulin 
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and GFP were 1.0 mg/L and 1.5 mg/L, respectively. Incorporation of 
phosphotyrosine produced a mixture of phosphorylated and non-
phosphorylated tyrosines. Removal of a phosphatase gene (ycdX) enabled 
production of a homogeneous mixture of phosphothreonine-incorporated 
ubiquitin (102).  
Co-expression of upstream kinases to phosphorylate its target substrates is 
another feasible method used to characterize the functionality of phosphorylation 
sites. This method has already being used to phosphorylate Thr308 of Akt1 by co-
expressing upstream kinase PDK1 in E. coli (15).  
Another method is the in vitro phosphorylation of target substrates. In this 
method the upstream kinases along with ATP are incubated to facilitate 
phosphorylation. However, in kinases like Akt there exist special cellular 
requirements like the presence of lipid second messengers and phosphorylation 
of multiple upstream kinases to facilitate phosphorylation of Akt1, limiting the 
yield of phospho-protein and  the usefulness of this approach for Akt1 (103).  
 
1.8 Scope of the thesis 
Since Akt1 is a proto-oncogene, its activation mechanisms and therapeutic 
interventions have been studied extensively (5). However, apart from the known 
contribution to activation, the specific role of each activation site, i.e., Thr308 and 
Ser473, on Akt1 activity are not known. Because the phosphorylation of each 
activation site is used as a biomarker for different types of cancers, the relevance 
of Akt1 phosphorylation status to disease is well documented (82-84). The 
inability to produce site specifically phosphorylated Akt variants have created a 
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barrier in unraveling the undiscovered and unique functionality of the two 
activation sites.  
As discussed in Section 1.7, since the methods used in recent studies (i.e. 
phosphomimetics, Ala mutations, partially active Akt produced in eukaryotic 
cells) are not the best suited candidates for this purpose, I developed a facile 
strategy to produce site-specifically and quantitatively phosphorylated Akt1 
variants in E. coli. I used a combined approach of using genetic code expansion 
strategy with upstream kinase expression to produce doubly phosphorylated 
Akt1. Expression of these systems individually enabled production of singly 
phosphorylated Akt1 variants. 
In chapter 2, I quantified how each phosphorylation site contributes to the 
overall activation of Akt1. We have used in vitro assays, mass spectrometry and, 
in collaboration with Alexandra Newton (UCSD) live cell imaging techniques to 
discover the unique role of each phosphorylation site on the activation of Akt1 in 
vitro and in mammalian cells (19).  
Chapter 3 focuses on the impact of each phosphorylation site on the auto- 
and chemical inhibition of Akt1. Deletion of PH domain to release the auto-
inhibitory effect increased the enzyme activity for all three phosphorylated Akt1 
variants. Phosphorylation of Ser473 showed resistance to chemical inhibition by 
the clinically relevant inhibitor Akti1/2.   
The exact mechanism of Akt’s substrate selection is still under 
investigation. In chapter 4, I determined how the phosphorylation status of Akt1 
modulates substrate selectivity. I used peptides derived from all known 
substrates of Akt1, alanine mutagenic scans, and oriented peptide array library 
screens to systematically reveal the ability of Akt1 phosphorylation status to 
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globally regulate substrate selectivity.  The data revealed that each phospho-form 
of Akt1 has distinct substrate requirements and Ser473 plays a key role in 
modulating global substrate selectivity.  
Using genetic code expansion and upstream kinase phosphorylation, I was 
able to produce site specifically phosphorylated Akt1 variants which act as 
indispensable tools in characterizing the functionality of each activation site of 
Akt1. This is the first time that genetic code expansion has been used to produce 
Akt1 carrying single phosphorylation at Ser473. Further we have shown that 
upstream kinase expression is a compatible mode of phosphorylation with 
genetic code expansion. This novel methodological advancement could be 
employed with other cellular proteins, especially with kinases, to generate site 
specifically phosphorylated protein variants that will help to overcome the 
existing limitations on characterizing the unique functionality of specific 
phosphorylation sites. 
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Chapter 2 
 
2 Genetic code expansion and live cell imaging reveal that  
Thr308 phosphorylation is irreplaceable and sufficient for  
Akt1 activity 
 
2.1 Abstract	
The proto-oncogene Akt/protein kinase B (PKB) is a pivotal signal transducer 
for growth and survival. Growth factor stimulation leads to Akt phosphorylation 
at two regulatory sites (Thr308, Ser473), acutely activating Akt signaling. 
Delineating the exact role of each regulatory site is, however, technically 
challenging and has remained elusive. Here, we used genetic code expansion to 
produce site-specifically phosphorylated Akt1 in order to dissect the contribution 
of each regulatory site to Akt1 activity. We achieved recombinant production of 
full length Akt1 containing site-specific pThr and pSer residues for the first time. 
Our analysis of Akt1 site-specifically phosphorylated at either or both sites 
revealed that phosphorylation at both sites increases the apparent catalytic rate 
1500-fold relative to un-phosphorylated Akt1, an increase attributable primarily 
to phosphorylation at Thr308. Live imaging of COS7 cells confirmed 
that phosphorylation of Thr308, but not Ser473, is required for cellular activation 
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of Akt. We found in vitro and in the cell that pThr308 function cannot be 
mimicked with acidic residues nor could un-phosphorylated Thr308 be 
mimicked by an Ala mutation. An Akt1 variant with pSer308 achieved only 
partial enzymatic and cellular signaling activity, revealing a critical 
interaction between the γ-methyl group of pThr308 and Cys310 in the Akt1 active 
site. Thus, pThr308 is necessary and sufficient to stimulate Akt signaling in cells 
and the common use of phosphomimetics is not appropriate for studying the 
biology of Akt signaling. Our data also indicate that pThr308 should be regarded 
as the primary diagnostic marker of Akt activity. 
 
2.2 Introduction 
The proto-oncogene Akt/protein kinase B (PKB) is a central transducer of 
growth and survival signaling (1). There are three isozymes of Akt in mammals. 
Akt1, Akt2, and Akt3 include kinase domains with extensive homology to those 
of protein kinases A, G and C, defining them as members of the AGC family of 
Ser/Thr protein kinases (2). Akt transduces signals in the phosphoinositide 3-
kinase (PI3K) signaling cascade, which is one of the most commonly deregulated 
pathways in human cancer (3,4). Thus, enormous efforts are directed at 
understanding the mechanisms of activation of Akt and how to target these 
enzymes therapeutically (5). 
Akt activity in the cell is acutely controlled by growth factor-dependent 
phosphorylation mechanisms (6). Following activation by agonist-bound 
receptor tyrosine kinases at the plasma membrane, PI3K phosphorylates 
phosphatidylinositol-4, 5-bisphosphate (PIP2) to generate the lipid second 
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messenger phosphatidylinositol-3,4,5-triphosphate (PIP3) (7). This second 
messenger engages Akt at the plasma membrane by binding its autoinhibitory 
pleckstrin homology (PH) domain, resulting in a conformational change that 
exposes the kinase domain for phosphorylation (8). The phosphoinositide 
dependent kinase 1 (PDK-1) phosphorylates a conserved Thr on the activation 
loop (Thr308 in Akt1), leading to partial activation of Akt (9). Full activation of 
Akt1 results from a second phosphorylation event in the C-terminal tail, a 
regulatory region referred to as the ‘hydrophobic motif’ (Ser473 in Akt1) that was 
originally identified in protein kinase C and S6 kinase (10-12). Phosphorylation at 
Ser473 in Akt1 depends on the mammalian target of rapamycin complex 2 
(mTORC2) (13). In addition, Akt is co-translationally and constitutively 
phosphorylated at another C-terminal site termed the ‘turn motif’ (Thr450 in 
Akt1) by mTORC2, a modification that regulates the stability of the enzyme (14). 
Given that Akt is activated by phosphorylation of Thr308 and Ser473, phospho-
specific antibodies to these sites are widely used as diagnostic markers (15-17).  
To a striking degree, many clinical (18-21) and biochemical (22) studies rely solely 
on Ser473 phosphorylation as a proxy for Akt activity. 
The activation of Akt by phosphorylation is well established (8), yet the 
contribution of each specific phosphorylation site towards the maximal Akt 
activity and pathogenesis is less well defined. This knowledge gap resulted from 
the inability previously to prepare Akt variants in site-specifically 
phosphorylated forms. Earlier work established production of partially active 
and truncated Akt1 in E. coli. The attempt was unsuccessful in producing a 
sufficient amount of full length Akt1 to determine activity (23). Instead this study 
relied on a construct lacking the PH domain with Ser473 substituted by 
glutamate, and the authors were unable to show how the phosphomimetic 
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compared to pSer at position 473 (23). A protocol for active Akt1 production in 
insect (Sf9) cells has been established (24). The ability to generate ppAkt1 
required a complex and low yield in vitro procedure to phosphorylate Akt with 2 
additional purified upstream kinases in the presence of lipid vesicles (24). Protein 
production in Sf9 cells fails to produce Akt1 with site-specific or programmed 
phosphorylation. The resulting protein is a mixture of singly and doubly 
phosphorylated species (25) and includes phosphorylation at Thr450 in addition 
to potentially other modifications, so the ability to isolate the activity of each 
regulatory site individually and in precise combinations has remained elusive. As 
demonstrated below, we have developed a facile and efficient approach that is a 
novel combination of in vivo enzymatic phosphorylation with genetic code 
expansion to produce pAkt1 and ppAkt1 variants with specifically programmed 
phosphorylation (Figure 2.1). 
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Figure 2.1 A novel route to doubly phosphorylated and active Akt1. (A) 
Schematic representation of recombinant Akt1 biosynthesis with pSer473 
genetically encoded in response to the UAG codon and pThr308 enzymatically 
phosphorylated in vivo in E. coli. Genetically encoded pSer incorporation requires 
phosphoseryl-tRNA synthetase (SepRS), a UAG-decoding tRNASep, and the 
elongation factor mutant (EFSep). (B) Enzyme activity of differentially 
phosphorylated Akt1 variants with a GSK-3β substrate peptide. Akt1 
quantitatively phosphorylated at both 308 and 473 (ppAktS473, T308, blue diamonds) 
showed maximal activity compared to the un-phosphorylated Akt1 (gray circles), 
and singly phosphorylated Akt1 variants: pAktT308 (black cross) and pAktS473 
(brown diamonds). The reported values represent the mean of triplicate 
experiments with error bars indicating 1 standard deviation. Lower activity 
variants show above background kinase activity (inset). 
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Because of the previous technological barriers to producing specifically 
phosphorylated kinase variants, a significant literature continues to accumulate 
for Akt (23,26-32) and other kinases (33), in which ‘phosphomimetic’ 
substitutions are used as a genetic tool to interrogate the biological consequences 
of phosphate on a site of interest (33). The rationale behind these experiments is 
that the acidic residues, Asp and Glu, are negatively charged like phosphate. Yet 
the carboxylate of an acidic amino acid has considerably less electronegativity 
than a phosphate and a significantly smaller hydration sphere and volume 
(34,35). A complementary approach involves nullifying the effect of a particular 
phosphorylation site by introducing a non-phosphorylatable Ala mutation (26); 
however, an Ala is considerably smaller and less polar than a Ser or Thr, and Ala 
lacks the capacity to form hydrogen bonds. In light of these observations, the 
widespread use of Ala and phosphomimetic mutants in signaling studies begs 
the question of how appropriate these mutations are to interrogate the cellular 
function of Akt or other phosphorylated proteins. 
Here we provide, for the first time, a quantitative analysis of the contribution 
of phosphate at positions 308 and 473 in the catalytic activity of Akt1 and, 
additionally, examine the effects of substitutions of acidic residues or Ala at these 
positions. To do this, we developed an optimal strategy to produce recombinant 
full-length human Akt1 in Escherichia coli with genetically encoded 
phosphoserine (pSer) introduced at specific phosphorylation sites. We measured 
the activity of singly and doubly phosphorylated Akt1 variants with phosphate 
at positions 308 (pAkt1S308, pAkt1T308) and/or 473 (pAkt1S473) in comparison to 
inactive and un-phosphorylated Akt1 as well as Akt1 variants with 
phosphomimetic Glu or Asp mutations. With a Förster resonance energy transfer 
(FRET)-based Akt activity sensor (BKAR) (36), we conducted complementary 
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experiments of specific Akt1 variants in live cells. Our data reveal that, in 
comparison to un-phosphorylated enzyme, phosphorylation of Thr308 alone 
increases the apparent catalytic rate by nearly 400-fold, which is sufficient to 
observe maximal signaling in cells. Phosphorylation of only Ser473 boosts Akt1 
activity by ~80-fold over un-phosphorylated enzyme, however, our data suggest 
that phosphorylation at Ser473 alone may not be sufficient to elicit Akt1 signaling 
in cells. Thus, phosphorylation of Thr308 is necessary and sufficient for the 
activity of Akt. Importantly, our cell based observations and biochemical data 
confirm that Ala does not mimic a non-phosphorylated Thr308 and further that 
acidic residues fail to activate Akt1. Phosphomimetic substitutions, therefore, do 
not mimic phosphorylation in Akt1 at either of its two key regulatory 
phosphorylation sites. 
 
2.3 Materials and methods 
 
2.3.1 Bacterial strains and plasmids. The full length human AKT1 gene was 
cloned into a pUC18-derived vector (pDS1(38)) and pCDFDuet1 vector (see SI 
methods). Ser473 and Thr308 sites were mutated by site-directed mutagenesis in 
E. coli DH5α to amber (TAG), Asp (GAC), or Glu (GAG) codons according to 
previously described methods (65). All clones were verified by DNA sequencing 
(London Genomics Research Center, Robarts Research Institute, London; 
Genewiz Inc. NJ, USA). Phosphoproteins were produced by genetically encoding 
pSer at UAG codons with the 2nd generation pSer incorporation system (pDS-
pSer2, kanamycin resistant) (38,66). Recombinant Akt1 and pAkt1 variants were 
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over expressed in E. coli BL21(DE3) (Invitrogen, California, USA); exogenous 
pSer (5 mM) was added to the expression media for production of pAkt1 variants 
(see SI methods for a detailed protocol). For the imaging studies, the mouse AKT1 
gene (a gift from A. Toker; 98.3% amino acid identity to human Akt1) was 
subcloned into pcDNA3 (Invitrogen) containing mCherry at its amino-terminus. 
Mutations were generated by QuikChange mutagenesis (Agilent Genomics) and 
confirmed by Sanger sequencing (Eton Bioscience). Generation of BKAR was 
previously described (36). 
 
2.3.2 Protein production and purification. For phosphoprotein production, 
pDS1-Akt1 expression plasmid variants with TAG codons at the indicated 
phospho-site were co-transformed with pDS-pSer2 into E. coli BL21(DE3). For 
unphosphorylated and phosphomimetic Akt1 variants, the appropriate pDS1-
Akt1 plasmid was transformed alone into BL21 (DE3). Cells were grown and 
pelleted at 5000 × g as described in SI methods. The cell pellets were re-
suspended in lysis buffer (20 mM Hepes, 150 mM NaCl, 3 mM β-
mercaptoethanol, 3mM Dithiothreitol (DTT), 10 mM Imidazole) at 10 ml per 
gram of cells. Lysis buffer for phosphoproteins contained phosphatase inhibitors 
(1 mM Na3VO4 and 5 mM NaF). One tablet of ethylenediaminetetraacetic acid 
(EDTA)-free mini protease inhibitor cocktail (Roche, Mississauga, ON, Canada) 
and 1 mM phenylmethylsulfonyl fluoride (PMSF) were added to the cell 
suspension (typically 200 ml). Cells were treated with lysozyme (1 mg/ml) for 20 
min, shaking at 4°C and lysed using French Pressure Cell Press (American 
Instrument Co. Inc. Maryland, USA) at 1000 psi. Cell lysates were centrifuged at 
38,000 × g for 1 h at 4°C. The supernatant was filtered through a 1.2 µm filter, 
mixed with Ni-NTA affinity beads (Thermo Scientific) and pre-equilibrated with 
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lysis buffer for 1 h. Finally, proteins bound to beads were purified under gravity 
flow. Elution fractions were further purified using Superdex200 gel filtration 
column attached to an AKTA Pure L1 fast protein liquid chromatography (FPLC) 
system (GE Healthcare, Little Chalfont, UK) (see SI Methods). Protein yields 
ranged from 20-100 µg/l E. coli culture. 
 
2.3.3 In vitro Akt1 kinase assay. For the kinase activity assay, we established a 
set of common conditions to assay a series of Akt1 variants of widely varying 
activity. To achieve this, we worked in a regime of sub-saturating ATP, thus, our 
apparent reaction constants (kapp) serve well to compare the Akt1 variants to one 
another, but these rates are significantly lower than kcat. Our data represent single 
turnover kinetics. Akt1 activity was determined using 200 µM substrate peptide 
CKRPRAASFAE (SignalChem, Vancouver, BC, Canada) derived from the natural 
Akt1 substrate, glycogen synthase kinase (GSK-3β). The reported KM of Akt1 for a 
similar substrate peptide is 18 µM (67), so the peptide concentration is in excess. 
Assays were performed in 3-(N-morpholino)propanesulfonic acid (MOPS, 25 
mM, pH 7.0), β-glycerolphosphate (12.5 mM), MgCl2 (25 mM), ethylene glycol-
bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA, 5 mM, pH 8.0), EDTA 
(2 mM), ATP (20 µM) and 0.4 µCi (33 nM) γ-[32P]-ATP in a  30 µl reaction volume, 
at 37°C in 30 min time courses. Unless otherwise indicated, reactions were 
initiated by the addition of 18 pmol of the indicated Akt1 variant (to yield a 
concentration of 600 nM) and quenched by spotting 5 µl from each reaction on 
P81 paper at specified time points (68).  Following washes with 1% phosphoric 
acid (3 × 10 min) and 95% ethanol (1 × 5 min), P81 paper was air-dried and 
exposed to a phosphor screen. The 32P-peptide products were imaged and 
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quantitated using a Storm 860 Molecular Imager and ImageQuant TL software 
(Molecular Dynamics, Caesarea, Israel). 
 
2.3.4 Cell culture media and conditions. COS-7 cells were maintained in DMEM 
(Cellgro) containing 10% fetal bovine serum and 1% penicillin/streptomycin at 
37°C in 5% CO2. For cell imaging experiments, cells were plated onto sterilized 
glass coverslips in 35-mm dishes prior to transfection with 1 µg pcDNA3-BKAR 
with or without 1 µg pcDNA3-mCherry-Akt using Lipofectamine 3000 
(Invitrogen). For experiments in which low expression levels of Cherry-Akt were 
desired, cells were transfected with 1 µg pcDNA3-BKAR and 0.05 µg pcDNA3-
mCherry-Akt. Cells were imaged within 24 hours following transfection. For 
Western blot experiments, in which average overexpressed Akt levels were 
desired to be at a similar level to endogenous Akt, COS-7 cells were transfected 
with 0.05 µg pcDNA3-mCherry-Akt using Lipofectamine 3000 (Invitrogen) in 6-
well dishes. 
 
2.3.5 Cell imaging. Transfected COS-7 cells were serum-starved at least 4 hours 
(as long as overnight) prior to imaging. Cells were washed one time in Hank’s 
Balanced Salt Solution (HBSS, Cellgro) supplemented with 1 mM CaCl2 and 
imaged in this HBSS in the dark at room temperature. Data were collected on a 
Zeiss Axiovert microscope (Carl Zeiss Microimaging, Inc) using a MicroMax 
digital camera (Roper-Princeton Instruments) controlled by MetaFluor software 
(Universal Imaging, Corp.). Optical filters were obtained from Chroma 
Technologies and Semrock. Data were collected through a 10% neutral density 
filter. Cyan fluorescent protein (CFP) and FRET images were obtained every 15 
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seconds through a 420/20 nm excitation filter, a 450 nm dichroic mirror and a 
475/40 nm or 535/25 emission filter for CFP and FRET, respectively. Cherry 
images were acquired through a 560/25 excitation filter, a 593 nm dichroic mirror 
and a 629/53 emission filter. Excitation and emission filters were switched in filter 
wheels (Lambda 10-2, Sutter). Integration times were 200 ms for CFP and FRET 
and 150 ms for mCherry. Cells were stimulated with 50 ng/ml EGF (PeproTech, 
Inc.) and then treated with 20 µM GDC 0068 (Selleckchem.com) at the indicated 
times. Data were normalized to the first 3 minutes of the experiment for each cell. 
Error bars represent 1 standard error of the mean. 
 
2.3.6 Western Blotting. Within 24 hours after COS-7 cell transfection, cells were 
serum-starved for at least 4 hours. Cells were rinsed once in HBSS/1 mM Ca2+ and 
then left untreated or stimulated with 50 ng/ml EGF for 10 minutes at room 
temperature. Cells were lysed in 50 mM Na2HPO4, 1 mM Na4P2O7, 20 mM NaF, 
2 mM EDTA, 2 mM EGTA, 1% Triton X-100 (supplemented with 1 mM DTT, 
200 µM benzamidine, 40 µg/ml leupeptin, 300 µM phenylmethylsulfonyl fluoride, 
and 1 µM microcystin) and cleared by a high-speed centrifugation for 2.5 min. 
The cleared lysates were analyzed by Western blotting to determine the relative 
amounts of Akt-Thr308 (Phospho-Akt (Thr308), Cell Signaling #9275) or Akt-
Ser473 (Phospho-Akt (Ser473)(D9E) XP, Cell Signaling #4060) phosphorylation. 
Total Akt levels were assessed with an antibody against all Akt isozymes (Anti-
AKT1/2/3, Abcam #126811). Western blots were developed using 
chemiluminescence. 
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2.4 Results 
2.4.1 Activation of full-length pAkt1 variants by genetic code expansion. We 
used in vitro radioactive kinase assays with γ-[32P]-ATP to test the activity of full 
length Akt1 variants that were made with site-specifically incorporated pSer 
residues (Figure S2.1, S2.2, S2.33). The assays quantify the ability of each Akt1 
variant to phosphorylate an Akt1 substrate peptide (CKRPRAASFAE) that is 
derived from the natural Akt1 target glycogen synthase kinase 3β (GSK-3β). 
Using genetic code expansion (37,38), we reassigned the UAG stop codon to 
genetically encode pSer in recombinant Akt1 proteins produced in E. coli. For 
example, we expressed pAkt1S473 with a genetically-encoded pSer residue 
inserted in response to a UAG codon at position 473 in the Akt1 construct. We 
used Multiple Reaction Monitoring Tandem Mass Spectrometry (MRM-MS/MS) 
to unambiguously identify pSer at position 473 (Figure S2.3). Genetically-
encoded pAkt1S473 showed a clear signal for phosphorylation at position 473 with 
no evidence of de-phosphorylation (Figure S2.3A,B). In wild type or un-
phosphorylated Akt1, Ser473 is readily detected with no evidence of pSer473 
(Figure S2.3C,D).  
For pThr incorporation at position 308, we relied on enzymatic 
phosphorylation by the upstream kinase PDK1 (23). We produced 
phosphorylated pAkt1T308 as well as the doubly-phosphorylated ppAkt1T308,S473 by 
co-expressing PDK1 in E. coli with either the wild-type Akt1 or pAkt1S473 
constructs, respectively (Figure 2.1A). We confirmed phosphorylation at Thr308 
(Figure S2.4) by Parallel Reaction Monitoring Tandem Mass Spectrometry (PRM-
MS/MS). The MS/MS data identified an insignificant level of Thr308 in the 
pAkt1T308 sample, indicating essentially quantitative phosphorylation of Thr308 
	 41	
by PDK1 in E. coli. Finally, we confirmed site-specific phosphorylation of the 
ppAkt1T308,S473 variant using PRM-MS/MS (Figure S2.2). In the MS/MS analysis, we 
achieved up to 90% coverage of the full length Akt1 (Figure S2.2D), and we were 
unable to identify significant peptides with modifications other than the 
anticipated and programmed phosphorylations. The data indicate that both 
genetic code expansion and PDK1 phosphorylation are highly site-specific, and 
that endogenous modification or de-phosphorylation by E. coli enzymes is absent 
or minimal. 
We first measured the activity of Akt phosphorylated at both positions 
(ppAkt1T308/S473). Doubly phosphorylated Akt1 (Figure S2.4) had an apparent 
reaction rate of 44 ± 6 fmol/min/pmol of enzyme (Figure 2.1, Table 2.1, Figure S2.5, 
S2.6). We performed these kinase assays in conditions of sub-saturating ATP. We 
chose these conditions so that Akt1 protein variants with a wide range of 
activities could be assayed using the same experimental conditions. In order to 
compare the relative activities of Akt1 and pAkt1 variants, we determined an 
apparent catalytic rate (kapp = vo/[Akt1]) based on the initial velocity (vo) observed 
in the kinase assays. Under sub-saturating ATP, our reaction velocities are far 
below Vmax for Akt and related kinases (24,39); kapp is not intended to estimate kcat. 
Interestingly, the bacterially expressed ppAkt1 construct consistently migrated 
slightly faster than the other pAkt1 variants and Akt1 mutants on sodium 
dodecyl sulphate (SDS)-PAGE (Figure S2.1, Figure S2.2A). We determined that 
this was not a result of premature termination of the translation product because 
PRM-MS/MS unambiguously identified intact full length and doubly 
phosphorylated ppAktT308, S473 (Figure S2.2B-D). We found no evidence of 
truncation or stopping at the UAG473 codon, or de-phosphorylation according to 
mass spectrometry. Phosphorylation at Thr450 is known to specifically decrease 
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the electrophoretic mobility of Akt1 expressed in mammalian cells (40). Our 
bacterially expressed pAkt1 variants show no evidence of phosphorylation at 
Thr450. These observations together suggest that phosphorylation status impacts 
the mobility of Akt1 on SDS-PAGE.  
Akt1 variants that contain pThr308 were so highly active under the conditions 
of our assays that we reduced the Akt1 concentration 10-fold in order to establish 
a linear range of activity to determine vo (Figure S2.5). Un-phosphorylated Akt1 
was essentially inactive, showing a low basal activity of 0.03 ± 0.01 
fmol/min/pmol of enzyme (Table 2.1). Thus, in comparison to un-phosphorylated 
enzyme, phosphorylation at both activating sites increased the catalytic rate of 
Akt1 by 1500-fold. We note this is the first time that the activity of Akt1 has been 
definitively measured and reported for homogenously pure variants with site-
specifically programmed phosphorylation at both key regulatory sites and 
without phosphate occupancy at other sites (e.g., pThr450).  
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Table 2.1 Specific activity of Akt1 variants 
 
Initial velocities (v0) and apparent catalytic rates (v0/[Akt1]) of each enzyme 
variant were calculated using linear regression analysis of the activity plots.  
*In order to measure the initial velocity accurately, the most active variants were 
assayed at a 10-fold reduced enzyme concentration (Figure S2.5). 
 
 
 
Akt1 variant 
 Akt1 
amount 
(pmol) 
Initial 
velocity (vo)  
(fmol/min) 
Apparent catalytic rate, 
kapp 
(fmol/min/pmol Akt1) 
Activation 
(fold increase)  
     
Akt1 (unphosphorylated)  18 0.6 ± 0.2 
 
0.03 ± 0.01 1 
pAkt1     
pS473 18 46 ± 5 2.5 ± 0.3 83 
pS308 6 2.9 ± 0.2 0.48 ± 0.03 16 
pT308* 
 
ppAkt1 (pT308, pS473)* 
1.8 
 
1.8 
22 ± 4 
 
 79 ± 11 
12 ± 2 
 
44 ± 6 
400 
 
1467 
 
Phosphomimetics 
    
E473 18 1.5 ± 0.1 0.083 ± 0.006 2.7 
E308 18 1.0 ± 0.1 0.056 ± 0.006 1.9 
D473 18 0.40 ± 0.03 0.022 ± 0.002 0.7 
D308 
 
pAkt1S473 mutants 
                 D308 
                 A308 
        
pAkt1T308 mutants 
                D473 
                E473 
                A473 
18 
 
 
18 
18 
 
 
18 
18 
18 
2.6 ± 0.1 
 
 
83 ± 1 
5.4 ± 0.3 
 
 
188 ± 11 
120 ± 16 
74 ± 3 
0.14 ± 0.01 
 
 
4.6 ± 0.1 
0.30 ± 0.02 
 
 
10.4 ± 0.6 
6.6 ± 0.8 
4.1 ± 0.2 
5 
 
 
153 
10 
 
 
348 
222 
137 
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2.4.2 Phosphorylation of Thr308 is necessary and sufficient for Akt1 activation. 
We next examined the contribution of phosphate at each site individually to the 
maximal activity of Akt1. Based on measurements of the initial velocity, the 
activity of mono-phosphorylated pAkt1T308 corresponded to ~27% that of the 
doubly-phosphorylated species (Figure 2.1, Table 2.1). Thus, phosphorylation at 
the PDK-1 site alone results in an over 400-fold increase in activity compared to 
the un-phosphorylated enzyme. These data establish that phosphorylation at 
Thr308 alone is sufficient for robust activation of Akt. Purified, mono-
phosphorylated pAkt1S473 was considerably less active than protein with 
phosphate at Thr308 (Figure 2.1). pAkt1S473 had activity that corresponded to 
about 5% of the activity of the doubly-phosphorylated species (Table 2.1). 
Although significantly reduced relative to that of the doubly-phosphorylated 
species, activity from pAkt1S473 still represents an 80-fold increase over the un-
phosphorylated Akt1 enzyme. Thus, genetic code expansion with pSer enables 
production of active Akt1 without the need to purify and activate upstream Akt1 
kinases (24). In the absence of substrate peptide, we were able to detect low, but 
above background, phosphorylation that may be attributed to auto-
phosphorylation by pAkt1S473 (Figure 2.2). 
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Figure 2.2 Activity of singly phosphorylated Akt1 variants with regulatory site 
mutations. (A) Akt1 enzyme activity is shown for variants with S473 
phosphorylated and T308 un-phosphorylated (brown diamond), or mutated: 
T308D (purple triangles), T308A (orange squares). Controls include 
unphosphorylated Akt1 (gray circles), and pAkt1S473 in the absence of substrate 
peptide (-peptide, green crosses). (B) In comparison to pAkt1T308 activity (black 
crosses) and in the context of Akt1 phosphorylated at T308, mutations S473D 
(blue triangles), S473E (magenta crosses) or S473A (cyan squares) resulted in 
marginally reduced activity. All reported values represent the mean of triplicate 
experiments with error bars indicating 1 standard deviation. 
 
Genetic code expansion was also used to produce pAkt1S308.  The Akt enzyme 
containing pSer308 had above background but low activity (Figure 3A). Western 
blot analysis revealed a band co-migrating with full-length Akt but also a species 
with an apparent MW of ~35 kDa (Figure S2.7).  This could result either from 
	 46	
degradation or premature truncation from stopping at UAG308, which would 
produce a protein of 37.6 kDa. We adjusted our estimated rate for this enzyme by 
accounting for the fraction of full-length pAkt1S308 in our preparation. Although it 
is possible we underestimated the activity Akt1 with pS308 (Figure 2.3A), the 
data show that pSer cannot substitute for pThr308 to produce optimally active 
Akt1. 
  
 
Figure 2.3 Activity of T308S and phosphomimetic Akt1 variants. (A) In 
comparison to pAkt1T308 activity (black crosses), mutations of T308 to either D 
(pink squares), E (green triangles), or pS (red diamonds) resulted in low but 
above background kinase activity (inset). (B) Kinase activity was also measured 
in the context of an unphosphorylated Akt1 (gray circles) with phosphomimetic 
mutations S473D (green squares) and S473E (peach squares). All reported values 
represent the mean of triplicate experiments with error bars indicating 1 standard 
deviation. 
2.4.3 Enzymatic activity of phosphomimetic Akt1 variants. We next tested the 
activity of purified phosphomimetic Akt1 mutants (Figure S2.6). In these 
	 47	
experiments, we programmed either Ser473 phosphorylation (Figure 2.2A) or un-
phosphorylated Ser473 (Figure 2.3A) and examined the effect of residue 
substitutions at position 308. Replacement of Thr308 with Asp increased the 
activity of pAkt1S473 by a modest 2-fold (from 2.5 to 4.6 fmol/min/pmol Akt), 
resulting in enzyme that displayed only 10% of the activity of doubly-
phosphorylated enzyme (Figure 2.2A, S2.6, Table 2.1). Surprisingly, replacing the 
Thr308 with an Ala eliminated the activity of the mono-phosphorylated pAkt1S473 
(Figure 2.2A), demonstrating that Ala308 is not an appropriate substitute for un-
phosphorylated Thr.  
In the context of Akt1 that was not phosphorylated at Ser473 (Figure 2.3B), 
Akt1D308 demonstrated 5-fold higher enzyme activity in comparison to un-
phosphorylated Akt1, but this was still ~100-times lower than that of pAkt1T308 
(Figure 2.3A, S2.6, Table 2.1). Akt1E308 was >200-fold less active than pAkt1T308 
(Figure 2.3A, S2.6). Interestingly, production of pAkt1S308 by our genetic code 
expansion approach resulted in an enzyme with only 3-fold more activity than 
Akt1D308 (Figure 2.3A), suggesting that Asp308 may, to some extent, mimic 
pSer308, but not the natural pThr308 residue in Akt1.  
Phosphomimetic substitution at Ser473 also failed to activate Akt1. We tested 
Ser473 mutations in the context of un-phosphorylated Akt1 (Figure 2.3B, S2.6) 
and in Akt1 variants phosphorylated at Thr308 (Figure 2.2B). For un-
phosphorylated Akt1, we examined the effect of Asp and Glu substitutions at 
position 473 (Figure S2.6). Substitution with Asp at position 473 lead to 
essentially inactive enzyme (Figure 2.3B, S2.6, Table 2.1). Replacement of Ser473 
with Glu resulted in an insignificant increase above the activity of un-
phosphorylated Akt1 enzyme (Figure 2.2C, S2.6, Table 2.1). In the context of 
pAkt1T308 (Figure 2.2B), phosphomimetic mutations (D and E) failed to stimulate 
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activity above pAkt1T308 with S473. Indeed, all S473 variants reduced pAkt1T308 
activity with S473A showing the most significant reduction (Tables 2.1, 2.2). 
 
2.4.4 Akt1 mutant activity in live cells. Having assessed the Akt mutants in vitro, 
we examined the activity of Akt1 phosphorylation site mutants in live cells. To 
this end, we utilized our quantitative FRET-based kinase activity reporter, BKAR, 
and examined Akt signaling (36). Co-expression of kinase constructs with FRET-
based activity sensors affords a sensitive assay for examining agonist-evoked 
signalling in a cellular context (41). As the response to endogenous Akt activity is 
so low, it provides an ideal system to evaluate signaling by introduced Akt 
variants as a significant response can be observed from the overexpressed kinase.    
Serum-starved COS-7 cells expressing BKAR and mCherry-tagged Akt 
variants were stimulated with epidermal growth factor (EGF) followed by Akt 
inhibition with GDC 0068. In real time, we monitored resulting changes in the 
BKAR FRET ratio (CFP/FRET) that are reflective of cellular Akt activity (Figure 
2.4A). For these experiments, cells selected for analysis had comparable levels of 
Akt1 expression as assessed by quantifying mCherry levels; thus, in this system, 
one can clearly compare the relative signaling competence between wild type 
and mutant Akt. We have documented previously that the mCherry tag does not 
significantly impact Akt1 activity (41).  
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Figure 2.4 Cellular activity of Akt1 variants. (A) Serum-starved COS-7 cells 
expressing BKAR alone (gray) or BKAR with Cherry-tagged Akt WT (blue), 
T308A (orange), T308D (purple), S473A (green), S473D (red), or T308D, S473D 
(DD, yellow) were imaged, stimulated with EGF, and then treated with the Akt 
inhibitor GDC 0068. Multiple cells were included from at least two independent 
experiments for analysis. FRET ratios from each cell were normalized and their 
average plotted over time. Error bars represent SEM. (B) Following a 10-minute 
treatment with EGF, lysates from serum-starved COS-7 cells expressing the 
indicated Cherry-tagged Akt were analyzed by Western blotting for Akt 
activation using phospho-specific antibodies toward the activation loop (α-p308) 
and hydrophobic motif (α-p473). The asterisk (*) marks migration of Cherry-Akt 
and the hyphen (-) marks endogenous Akt. (Experiment by Maya Kunkel) 
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9 
Overexpression of wild type (WT) Akt1 resulted in a significant BKAR 
response to EGF treatment compared to the response observed from endogenous 
Akt (Figure 2.4A, blue vs. grey trace). Interestingly, despite the level of 
overexpressed Akt in these experiments being in vast excess compared to 
endogenous Akt, substitution of either the non-phosphorylatable Ala or the 
‘phosphomimetic’ Asp or Glu at the Thr308 site yielded an Akt1 enzyme that 
displayed no signaling in the cell (Figure 2.4A, orange and purple traces, Figure 
S2.8). These data establish the requirement of pThr308 for detectable Akt1 
activation in cells and show that T308D is not a constitutively active Akt1 variant.  
In contrast to the strict requirement for phosphorylation at Thr308, either Ala, 
Asp or Glu substitution at the Ser473 site were tolerated without detrimental 
effects on cellular Akt activity as assessed using BKAR (Figure 2.4A, green and 
red trace, Figure S2.8). Importantly, a double mutation of both 308 and 473 to Asp 
resulted in an inactive enzyme. Thus, the activity of Akt mono-phosphorylated at 
Thr308 is necessary and sufficient for maximal signaling in the context of cells. 
 
2.4.5 Mutant Akt1 kinases are phosphorylated following EGF stimulation. We 
next examined the phosphorylation state of Thr308 and Ser473 of the mutant Akt 
kinases in our cell-based assay (Figure 2.4B). In experiments in Figure 2.5, we 
reduced the expression of the tagged Akt variants to be equivalent to the 
endogenous Akt expression level as determined by Western blot. EGF 
stimulation (all even numbered lanes) induced phosphorylation of both 
endogenous and wild-type Akt1 (lane 4) as assessed by Western blot (Figure 2.5). 
Importantly, phosphorylation of Thr308 in the Ser473 mutants (lanes 10 and 12) 
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was at the same level as the WT Akt1 (lane 4) demonstrating that PDK1 
phosphorylation downstream of PI3K signaling was intact. Analysis of Ser473 
phosphorylation revealed that, while this site was phosphorylated downstream 
of PI3K signaling, the level of phosphorylation at Ser473 was reduced in the 
T308A and T308D mutants (lanes 6 and 8) compared to WT Akt1 (lane 4). This 
suggests that lack of phosphate on Thr308 impairs phosphorylation of Ser473. 
Even though the level of Ser473 phosphorylation was reduced in these mutants, 
the level of total overexpressed Akt protein was saturating in Figure 2.4A. Given 
the excessive amount of Akt overexpressed in the experiments in Figure 2.4A, 
this lack of activity observed using BKAR indicates that T308A, T308D and T308E 
(Figure S2.8) are clearly not able to signal, and any catalytic activity observed in 
these variants is below the threshold to result in detectable cellular activity. 
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Figure 2.5 Reduced, but active, signaling from Akt T308S. (A) Serum-starved 
COS-7 cells expressing BKAR with or without minimally detectable levels of 
Cherry-tagged Akt were imaged during stimulation with EGF followed by 
treatment with the Akt inhibitor GDC 0068. Normalized average FRET ratios for 
WT (blue), T308S (red) and T308S, S473A (green) in comparison to BKAR alone 
(gray) are shown. Data were analyzed from cells expressing equal low levels of 
Cherry-Akt. Multiple cells were included from at least two independent 
experiments. FRET ratios from each cell were normalized and their average 
plotted over time. Error bars represent SEM. (B) Following a 10-minute treatment 
with EGF, lysates from serum-starved COS-7 cells expressing the indicated 
Cherry-tagged Akt were analyzed by Western blotting for Akt activation using 
phospho-specific antibodies toward the activation loop (α-p308) and 
hydrophobic motif (α-p473). The asterisk (*) marks migration of Cherry-Akt and 
the hyphen (-) marks endogenous Akt. (Experiment by Maya Kunkel) 
	 53	
2.4.6 Impact of Ser substitution at Thr308 in cells. As the recombinant Akt1D308 
had similar activity as the pAkt1S308 protein in vitro, we were interested to 
examine the impact of Ser at 308 in the overexpressed mCherry-Akt system using 
BKAR. Overexpression of mCherry-Akt-T308S resulted in a similar BKAR 
response to that of WT Akt1 (data not shown). As this imaging system is 
monitoring an excess of the overexpressed mutant Akt, we attempted to express 
reduced levels of the kinase in order to discern whether there was a difference in 
cellular activity between WT Akt1 and Akt1 with Ser at position 308. Indeed, 
titrating down the expression levels and selecting for the lowest expressing cells 
based on mCherry intensity, we observed a reduction in Akt1 signaling output 
from the Ser308 enzyme compared to the WT enzyme with Thr308 (Figure 2.5A, 
blue and red traces). In the impaired kinase (Akt1S308), we then substituted the 473 
site with Ala (Ser308, Ala473), however, even in the context of an impaired Akt 
kinase, mutation of the 473 site did not influence Akt signaling (Figure 2.5A, 
green trace). Under the same conditions noted here to analyze minimal levels of 
overexpressed kinase, we were unable to detect a reduced level in signaling from 
the S473A mutant compared to WT Akt1.  This result is in agreement with our 
observations that mutation of Ser473 to Ala in the context of Akt1 
phosphorylated at residue 308 either on Thr (Figure 2.4, green trace) or Ser 
(Figure 2.5, green trace) does not impact signaling in cells. Furthermore, the data 
indicate that the ability of pAkt1T308 S473A to signal is greater than that of Akt1 
T308S. 
Western blot analysis confirmed that phosphorylation of the 308 site (even 
with a Ser substitution) was intact following EGF stimulation (Figure 5B). Our 
data in live cells indicate that phosphate, specifically, not an acidic residue, at 
position 308 is the most critical component to induce Akt activity. In the cell, as 
	 54	
we found in vitro, phosphomimetic substitutions of Asp or Glu at the 308 site are 
unable to propagate Akt signaling, and, in agreement with our enzymatic data, 
substitution of Thr308 to Ser leads to reduced Akt activity and signaling. 
 
2.5 Discussion 
Using genetic code expansion and enzymatic phosphorylation, we 
produced fully active Akt1 directly from E. coli for the first time. We validated 
our biochemical findings in cells using a genetically-encoded reporter for Akt 
signaling. This allowed us to 1) measure the specific activity of Akt1 site-
specifically and exclusively phosphorylated at either or both regulatory sites, 
Thr308 and Ser473, 2) systematically examine the role of phosphate at each site in 
modulating the intrinsic catalytic activity of the pure enzyme, and 3) examine the 
effectiveness of amino acid substitutions to mimic phosphorylated or un-
phosphorylated residues in cells.  
 
2.5.1 Generation of active Akt1. We demonstrated the compatibility of 
enzymatic phosphorylation with genetically-encoded phosphoserine 
incorporation by producing site-specific and doubly-phosphorylated Akt1 
(Figure 2.1A). This was achieved by co-expressing the upstream kinase PDK1, to 
induce Thr308 phosphorylation, and simultaneously genetically encoded pSer473 
in Akt1. To our knowledge, this is the first demonstration of protein production 
in E. coli with programmed pSer and pThr residues in the same protein. 
Consistent with numerous studies (24), our in vitro kinase assays revealed robust 
activity of ppAkt1 activity in the absence of PIP3, suggesting PIP3 is not required 
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for Akt1 activity per se. This contradicts a recent study proposing that PIP3 
binding may be essential for both Akt1 activation and activity in cells (42). As 
noted above, producing site-specifically and doubly phosphorylated, and thus 
fully-activated Akt1 has previously not been achieved via recombinant 
expression in vivo in E. coli given the complicated nature of Akt activation by 
multiple kinases, chaperones, and lipid second messengers (24). Our experiments 
demonstrate a novel approach, taking advantage of genetic code expansion and 
enzymatic phosphorylation, that overcomes the existing limitations in both 
methods to produce fully-active human kinases. 
 
2.5.2 Role of phosphorylation in activating Akt1. The kinetic mechanisms of Akt 
activation by phosphorylation are less well characterized relative to other kinases 
such as PKA (43) and PKC (44), stemming in part from the difficulty in obtaining 
Akt in specifically phosphorylated forms. Most studies relied on 
immunoprecipitating Akt from unstimulated and growth factor-stimulated cells. 
Akt1 activity is then determined using a kinase activity assay in the 
immunoprecipitates. Such studies typically report a 10–50-fold stimulation of the 
activity of Akt immunoprecipitated from growth factor-treated compared to 
unstimulated cells, e.g., (45-49). Alessi and co-workers showed that Akt1 had 45-
fold higher activity when immunoprecipitated from cells treated with IGF-1 
compared to untreated cells (6). In the context of an Akt1 mutant with Ala 
present at position 473, the increase was only 5-fold, and if Ala was present at 
position 308, there was essentially no stimulated activity. Similar results were 
reported by Hemmings and coworkers for Akt3 (50). These data are qualitatively 
similar to the results from our study, yet our quantitative analysis defines Thr308 
as the critical regulator of Akt activity and its phosphorylation alone increases 
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activity to approximately one-third that of the doubly-phosphorylated enzyme. 
Our unique ability to produce recombinant fully-phosphorylated Akt1 from 
bacteria has revealed that specific phosphorylation at both regulatory sites 
increases the intrinsic catalytic activity by over three orders of magnitude, 
defining the stringency with which Akt signaling is ‘silent’ in the absence of 
agonist stimulation and the resulting phosphorylation of Akt.  
Several lines of evidence support our finding that phosphorylation of Thr308, 
but not Ser473, is necessary and sufficient for the activation of the intrinsic 
catalytic activity of Akt. First, Vogt and colleagues concluded that 
phosphorylation of this site, but not Ser473, was sufficient for the oncogenic 
potential of Akt (26). Specifically, they showed that mutating Thr308 prevented 
the phosphorylation of Akt substrates and transformation of chicken embryonic 
fibroblasts. Secondly, Jacinto and coworkers showed that in cells lacking 
mTORC2, Akt was not phosphorylated on Ser473, yet retained the ability to 
phosphorylate a subset of Akt substrates (14). Based on this and other reports 
from the literature, phosphorylation of Ser473 was suggested to determine 
substrate specificity of Akt.  Supporting a role of Ser473 in the cellular function of 
Akt, loss of phosphorylation of this site by overexpressing the PH domain 
Leucine-rich repeat Protein Phosphatase (PHLPP) (which dephosphorylates 
Ser473) results in increased apoptosis (51) and, conversely, enhancing 
phosphorylation at Ser473 by depletion of PHLPP results in suppression of 
tumors in a xenograft model. Although these effects on apoptosis may arise from 
non-Akt functions of PHLPP (52), they support a role of Ser473 phosphorylation 
in Akt biology. Phosphorylation at Ser473 may function to tune rather than 
activate Akt signaling. However, our results establish that the phosphorylation 
state of Thr308 is a superior read-out for the activation state of Akt. Whereas 
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phosphorylation at Thr308 alone is able to activate Akt1, phosphorylation of 
Ser473 alone leads to relatively weak activity in vitro, and no detectable activity in 
the cell. Neither the Asp308 nor Glu308 Akt1 mutants had EGF-stimulated 
activity in cells. Although the pAkt1S473 Thr308Asp mutant had 10% of the 
activity of the doubly-phosphorylated Akt1 in vitro (Table 2.2), we observed no 
cellular Akt1 activity and impaired Ser473 phosphorylation in Akt1 variants with 
Asp, Glu or Ala mutations at position 308. Even if these variants are active in the 
cell, the low intrinsic activity of the Asp308 mutant, for example, may be too low 
to overcome the opposing de-phosphorylation reaction catalyzed by cellular 
phosphatases acting on Akt substrates, including the BKAR reporter. Akt1 
Thr308Asp mutants can no longer be regarded as constitutively active Akt1 
variants (30-32). 
The phosphorylation status of Akt1 is indeed clinically relevant. Whereas 
pSer473 is the most commonly used biomarker (53,54), pThr308 was identified as 
a better prognostic biomarker in human non-small cell lung cancer (55) and acute 
myeloid leukemia (56). Our study underscores the relevance of examining the 
phosphorylation state of Thr308 as a general marker for the activation state of 
Akt in basic research and clinical settings. 
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Table 2.2 Akt enzyme activity comparison in vitro and in COS7 cells 
 
Enzyme activity determined biochemically is given as a percentage of the 
maximally active ppAkt1. Agonist-evoked enzyme activity in cells is denoted by 
a plus (+) sign. No detectible activity is denoted by zero (0). N.D. Not determined. 
*Observed a reduced response compared to WT when the Akt1 mutant indicated 
was expressed at a reduced level, similar to the level of endogenous Akt (Figure 
3B). 
 
 
 
            Akt1 sites             Akt1 activity 
308 473 in vitro (%) in cell 
pThr pSer   100 + 
Thr Ser     <1 N.D. 
pThr Ser     27 N.D. 
pThr Asp     24 + 
pThr Glu     15 + 
pThr Ala       9 + 
Thr pSer       5 N.D. 
Asp pSer     10 0 
Glu pSer N.D. 0 
Ala pSer   <0.001 0 
pSer pSer N.D. +* 
pSer Ser       1 N.D. 
pSer Ala N.D. +* 
Thr Asp     <1 N.D. 
Thr Glu     <1 N.D. 
Asp Ser     <1 N.D. 
Glu Ser     <1 N.D. 	
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2.5.3 Acidic residues do not function as phosphomimetics in Akt1. Koshland 
and colleagues first introduced the use of acidic amino acids to mimic phosphate, 
showing that an Asp mimicked the functional effect of phosphate to inactivate 
isocitrate dehydrogenase (57). There are other examples where the negative 
charge of the amino acid effectively mimics that of phosphate and, indeed, nature 
has used the trick in reverse: it is estimated that 5% of pSer sites may have 
evolved from an ancestor with Glu or Asp at the homologous position (34). 
However, acidic residues are not necessarily ‘phosphomimetics’: their negative 
charge, hydration sphere, and size are considerably different from a 
phosphorylated Ser or Thr residue. Acidic amino acids have a net negative 
charge of 1 compared to 2 for phosphate at neutral pH, the hydration sphere is 4 
waters compared to 14 for phosphate, and their volume is considerably smaller 
than the phospho-amino acids they replace. 
Because kinases are often activated by phosphorylation, Glu and Asp 
mutations are routinely used to mimic the function of phosphorylated serine or 
threonine residues in many kinases (33), including Akt1 (26,29). Our current 
study reveals that acidic residues do not mimic phosphorylation in Akt1. This is 
an important finding given the widespread and continued use of 
phosphomimetics in interrogating Akt signaling, and kinase signaling generally, 
in cells. The phosphomimetic variants that were active in our assays are 30 to 
210-fold less active than their monophosphorylated counterparts. Based on our 
data in live cells, Thr308 phosphomimetic variants fail to activate Akt signaling 
(Figure 2.4A). Although, Akt1 Thr308Asp was the most active of the 
phosphomimetic mutants in vitro, this level of activity is insufficient to produce a 
cellular response. This result is consistent with a study from Vogt and colleagues 
who reported that Thr308Asp was an ‘unsuitable’ substitution for pThr308 
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(26,29). Their data showed that Akt Thr308Asp did not cause the 
phosphorylation of cellular Akt substrates such as GSK-3β nor did it induce 
oncogenic transformation, functions that were robustly mediated by wild-type 
Akt. Nonetheless, phosphomimetics constructs of Akt pervade the literature on 
Akt signaling mechanisms. Because phosphomimetics do not result in 
physiologically relevant activation of the kinase activity of Akt, it is possible that 
any biological effects of such mutations may arise from scaffolding functions or 
non-catalytic mechanisms, as increasingly described for protein kinase family 
members (58).  
An interesting finding from our study is that pSer is not well tolerated at 
position 308. According to the in vitro kinase assays, pAkt1S308 is more active than 
phosphomimetic 308 mutants, yet pAkt1T308 is ~25-fold more active than pAkt1S308. 
Furthermore, when phosphorylated post-translationally in the cell, pAkt1S308 also 
showed reduced activity compared to that of pAkt1T308. To the best of our 
understanding, there is no literature-based evidence on the effect of pS308 on the 
activation of Akt1 in vivo or in vitro. Our results indicate that the γ-methyl group 
of Thr308 optimally positions the phosphate to create the ordered hydrogen-
bonding network between the phosphate of pThr308, His194 and Arg273, which 
facilitates the binding to ATP and substrate at the Akt1 active site (26). Indeed, 
this observation is supported by crystallographic structures of Akt in partially 
active form and in complex with substrate peptide and an ATP analog (59,60). 
The structure shows pThr308 is involved in salt bridge interactions with Arg273 
and Lys297, and a water-mediated hydrogen bond with His194 is also evident 
(Figure 2.6). In the structure, steric complementarity can be seen between the γ-
methyl of pThr308 and Cys310 (Figure 2.6B). In agreement with our cell-based 
and biochemical data, the structure suggests the interaction between the γ-
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methyl of pThr308 and Cys310 optimally orients the phosphate for interaction 
with is positively charged counterparts in the salt bridges. We hypothesize that 
pS308, which lacks this methyl group, will rotate more freely in the active site, 
perhaps shifting the enzyme in and out of its active confirmation.   
Our study also revealed that Ala is not a mimic of un-phosphorylated Thr308. 
Ala at position 308 resulted in a 10-fold reduction in the basal activity of Akt1 
mono-phosphorylated at Ser473. Taylor and colleagues also found that Ala at the 
activation loop of protein kinase A (PKA) results in a more severe kinetic defect 
compared to having an un-phosphorylated Thr at the activation loop (61,62). The 
detrimental effect of Ala may arise from a loss of hydrogen bonding ability. The 
Ala mutation favors a helical conformation of the activation loop that may also 
drive structural ensembles away from the active conformation or it may favor an 
inhibited conformation due to interactions with other domains or proteins (A. 
Kornev and S. Taylor, personal communication).  
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Figure 2.6 Structure of human Akt in complex with GSK-3β substrate peptide. 
(A) Structure of the active human pAktT308 (S473D) kinase domain (gray, cartoon) 
shown in complex with GSK-3β peptide (purple) and a non-hydrolyzable ATP 
analog (ATP’ = AMP-PNP). The target of Akt1 phosphorylation on the GSK-3β 
substrate peptide is indicated (*). Key residues are labeled and in addition to the 
regulatory phosphorylation sites (pThr308, and phosphomimetic mutation 
S473D), other Ser/Thr phosphorylation sites are highlighted (yellow). (B) A 90° 
rotated and close up view of the Akt1 active site, focused on the position of 
pThr308. The phosphate at position 308 makes extensive salt bridge interactions 
with Arg273 and Lys297; pThr308 also participates in a water mediated hydrogen 
bond network with His194. The Cγ methyl group on pThr308 forms a 
hydrophobic interaction with Cys310 as indicated in the van der Waals surface 
representation (transparent). The figure includes structural data from PDB codes 
3CQU (59) and 1O6K (60). 
 
2.5.4 Akt1 activation threshold in cells. Live cell imaging experiments revealed 
that all forms of Akt1 that had phosphorylation of Thr at position 308 had 
maximal signaling output following EGF stimulation of cells, regardless of the 
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amino acid at position 473 (Table 2.2). In contrast, no activity was observed if the 
residue at position 308 was not phosphorylated, regardless of the amino acid at 
position 473 (Table 2.2). Based on in vitro data, we can estimate a threshold to 
observe Akt activity in cells: our in vitro studies reveal that phosphorylation of 
Ser473 alone stimulated Akt1 activity 80-fold over the un-phosphorylated 
enzyme, yet this level of Akt1 activity is apparently below the threshold required 
to elicit Akt1 signaling in the cell. In vitro, the activity of mono-phosphorylated 
Akt1 at Thr308 was reduced by less than 3-fold compared to the maximally-
active and doubly-phosphorylated enzyme, and this level of activity is sufficient 
for maximal signaling output in cells. In addition, pAkt1T308 S473A was 10-fold 
less active than the doubly phosphorylated enzyme, yet this enzyme was 
sufficient for robust Akt1 signaling in the cell. Taken together, our data suggest 
that Akt1 variants whose intrinsic catalytic activity is greater than ~10% that of 
doubly phosphorylated enzyme are robustly active in cells. This novel finding 
further suggests that in cells only a fraction of Akt needs to be activated by 
phosphorylation for full Akt-dependent signaling.  
Although previous reports have identified a 10-fold activity increase 
associated with Ser473 phosphorylation in immuno-precipitates, the 
stoichiometry of phosphorylation was unknown (6). Furthermore, the 
phosphorylation state of Akt1 may differentially impact substrates based on the 
local concentration or abundance of the substrate. For example, if Akt1 is poised 
on a scaffold and co-localized with substrate, a lack of Ser473 phosphorylation 
may be irrelevant as the local concentration of substrate is high. For 
phosphorylation of an untethered or low abundant substrate, that 3-fold 
difference in activity may reduce or eliminate Akt1 signaling in a substrate-
specific manner. Indeed, previous work suggested that phosphorylation at Ser473 
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may increase the activity of Akt1 for particular substrates, e.g., FoxO1/3a (14), yet 
significant future efforts are required to define the impact of Akt1 
phosphorylation status on substrate selectivity. 
Mutation and phosphorylation state can impact Akt1 activity directly, but 
also indirectly by altering the accessibility of phosphatases. For example, 
previous studies showed that Ala substitution in PKC at the hydrophobic motif 
increased phosphatase sensitivity of PKC at additional sites (63). Our finding that 
Akt1 mutants with very low activity did not signal in cells suggests that localized 
activation needs to exceed a threshold to outcompete phosphatases in the cellular 
environment. Thus, the dynamic range of Akt signaling in a cell is such that 
sufficient Akt needs to be activated to overcome phosphatase suppression, but 
additional changes in phosphorylation site occupancy may or may not be needed 
for maximal signaling, particularly if localized to protein scaffolds and 
microdomains (64). 
 
2.6 Conclusion 
We established a robust protocol to generate and characterize fully active and 
differentially active Akt1 variants. These Akt1 variants will next be employed as 
a unique set of tools to investigate Akt1 substrate specificity and to screen for 
potential drug candidates against the most potent and active forms of the 
oncogenic kinase. The ability to produce optimally active Akt1 will have broad 
implications for drug discovery efforts, as we hypothesize that drug screening 
against a fully active Akt1 enzyme will more likely produce a potent and 
selective inhibitor. 
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We presented a systematic study of the impact of phosphorylation and 
phosphomimetic substitutions on the activity of Akt1 in the test tube and in 
living cells. Our data suggest that phosphomimetic substitutions should be tested 
for their ability to mimic phosphorylation, and Ala substitutions should also be 
assessed for their ability to act as non-phosphorylatable counterparts. We found 
these common assumptions simply do not hold for Akt1 and complementary 
experiments in vitro and in the cell were invaluable in reaching this conclusion. 
Viewing the cell-based assays in isolation of the kinase activity data may have led 
to the erroneous conclusion that phosphomimetic substitution at 473 supports 
full Akt1 activity. Rather the situation in the cell is more complex. 
Phosphorylation at 308 alone is sufficient to observe maximal Akt1 signaling, and 
mutation of 473 to Ala, Asp or Glu had no apparent impact on Akt1 activity in 
the cell. In the test tube, we determined that phosphomimetics fall far short of 
activating Akt1 to the same extent as true phosphorylation at both regulatory 
sites. Indeed and counter-intuitively, we found that Thr308Asp is a good mimic 
of a lack of phosphorylation at 308, while Thr308Ala is a kinase-dead enzyme that 
is not active in vitro despite phosphorylation at 473. In the cell, only true 
phosphorylation at 308 led to observable activity, suggesting that mimics of pThr 
are particularly inappropriate at this site. Interestingly, pSer308 shows reduced 
activity, which was still sufficient to observed Akt1 signaling in the cell. The data 
demonstrate conclusively that pSer is a far better mimic of pThr than Asp or Glu 
phosphomimetic substitutions.  
The foregoing experiments reveal that phosphorylated Thr308 is necessary, 
sufficient, and irreplaceable for activation of Akt in vitro and in cells. We showed 
that no other residue is tolerated at that site, including acidic amino acids, which 
are frequently used as ‘phosphomimetics’. Our findings also question the 
	 66	
generally assumed validity of using Ala mutation to mimic a non-
phosphorylated form of residues like Ser and Thr. In total, our results beg caution 
in using amino acid substitutions to examine the role of phosphorylation in 
protein function and in the biology of cell signaling.  
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2.8 Supporting information: 
2.8.1 Supporting experimental procedures 
Bacterial strains and plasmids 
The human akt1 gene was purchased from Harvard PlasmidID repository service 
(Boston, MA, USA) and subcloned (NdeI/BamH1) into an IPTG (isopropyl β-D-1-
thiogalactopyranoside) inducible T7 promoter driven expression vector (pDS1) 
(38). In addition, the akt1 gene was subcloned (NcoI/NotI) into T7lac promoter 
preceded pCDFDuet-1 vector. PDPK1 gene, which was also purchased from 
Harvard PlasmidID repository service, was subcloned (KpnI/NdeI) into the 
second cloning site of pCDFDuet-1. The codons for Ser and Thr residues in akt1 at 
positions Ser473 and Thr308, were mutated to amber (TAG), Asp (GAC) and Glu 
(GAG) codons using site-directed mutagenesis according to previously described 
methods(65). Successful cloning was verified by DNA sequencing (London 
Regional Genomics Centre, London, ON, Canada and Genewiz, Cambridge, MA, 
USA).  
 
Protein and phosphoprotein production. Recombinant proteins were expressed 
in BL21(DE3) (Invitrogen). Phosphoproteins were produced using 2nd generation 
mutants of the pSer incorporation system (SepRS9, EFSep21) (66). The system is 
encoded on the pDS-pSer2 plasmid (described previously (38)), which contains 5 
copies of tRNASep, SepRS9 and EFSep21. pDS1 and pDS-pSer2 plasmids for 
phosphoprotein expression were co-transformed into E. coli Bl21(DE3) and plated 
on LB-agar plates with 25 µg/ml kanamycin and 100 µg/ml ampicillin. A single 
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colony was used to inoculate 70 ml of LB (with ampicillin 100 µg/ml, kanamycin 
25 µg/ml), which was grown, shaking, overnight at 37°C. From this starter 
culture, a 10 ml inoculum was added to 1 l of LB medium with antibiotics (as 
above) and O-phospho-L-serine (pSer, 2.5 mM final concentration, Sigma Aldrich). 
These cultures were grown at 37°C until OD600 = 0.6 at which point 2.5 mM of 
additional pSer was added to the culture. Protein expression was induced by 
adding 300 µM of IPTG at OD600 = 0.8. Cultures were further incubated at 16°C 
for 18 h. The same protocol was used in producing pAkt1 variants from 
pCDFDuet-1 construct, except that here streptomycin (50 µg/ml) was used as the 
antibiotic to maintain pCDF. In expressing phosphomimetic proteins, ampicillin 
at a concentration of 100 µg/ml was used and no pSer was added to the cultures.  
 
Affinity column chromatography. The His-tagged proteins were purified using 
Ni affinity column chromatography. 0.5 ml of Ni-NTA resin (Thermo-Fisher 
Scientific) was used for 1 l of E. coli culture. The cell lysates (see Methods) were 
loaded into the column and washed extensively with wash buffer A (20 mM 
Hepes, 150 mM NaCl, 3 mM β-mercaptoethanol, 3mM Dithiothreitol, 1 mM 
Na3VO4 and 5 mM NaF, 15 mM Imidazole) followed by wash buffer B (20 mM 
Hepes, 150 mM NaCl, 3 mM β-mercaptoethanol, 3mM DTT, 1 mM Na3VO4 and 5 
mM NaF, 20 mM Imidazole). Protein was eluted using an elution buffer (20 mM 
Hepes, 150 mM NaCl, 3 mM β-mercaptoethanol, 3mM dithiothreitol, 1 mM 
Na3VO4 and 5 mM NaF) with 75 mM Imidazole. The same protocol was used for 
Akt1 variants with phosphomimetic mutations except: 1) phosphatase inhibitors 
were excluded from the buffers, 2) the imidazole concentrations of the wash 
buffers were 20 - 50 mM, and 3) the imidazole concentration of the elution buffer 
was 200 mM. Fractions were run on 10% SDS (sodium dodecyl sulfate) poly-
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acrylamide gels. Akt1 variants were further purified by size exclusion 
chromatography. 
 
Size exclusion chromatography. Purification was performed in AKTA Pure L1 
FPLC system (GE Healthcare, Little Chalfont, UK) using Superdex200 (GE 
Healthcare Uppsala, Sweden) gel filtration column equilibrated with buffer (25 
mM HEPES pH 7.0, 100 mM NaCl, 0.25 mM Tris(2-carboxyethyl)phosphine 
(TCEP)). The flow rate was maintained at 0.1 ml/min and 1 ml fractions were 
collected. Fractions were run on 10% SDS-PAGE and pure fractions were pooled 
and concentrated using Vivaspin 6 (6 ml, 10 kDa, GE Health Care, 
Buckinghamshire, UK) or Amicon ultra (0.5 ml, 3 kDa, Merk Millipore Ltd., Cork, 
Ireland) concentration units. Protein concentrations were determined using 
Bradford assay and samples were stored in aliquots at -80°C in storage buffer (20 
mM HEPES pH 7.0, 150 mM NaCl, 3 mM β-mercaptoethanol, 3mM DTT) 
containing 50% glycerol until further analysis. 
 
Western blotting. The purified proteins were denatured using standard SDS 
sample buffer and run on a 10% SDS gel. The gel was blotted onto a 
nitrocellulose membrane using Turbo-Blot Turbo transfer system (Bio-Rad). The 
membrane was immunoblotted with mouse anti-histidine primary antibody (GE 
Health Care Life Sciences) followed by anti-mouse horseradish peroxidase linked 
secondary antibody (GE Health Care Life Sciences). Bands were visualized by 
chemiluminescence and detected with Gel Doc XR plus (Bio-Rad). 
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Multiple Reaction Monitoring (MRM) of pAkt1S473. Following protein 
purification, phosphorylated Akt protein was re-suspended in trypsin digestion 
buffer (100 mM Tris pH 8.5, 1 mM CaCl2) and digested at a ratio of 20:1 w/w with 
sequencing grade trypsin (Roche Diagnostics) overnight at 37°C. The digest was 
then analyzed by positive electrospray ionization LC-MS/MS on a triple 
quadruple mass spectrometer (4000 QTRAP AB Sciex, Concord, ON, Canada) 
with Q3 used as a linear ion trap. A NanoAcquity UPLC system (Waters, Milford, 
MA, USA) equipped with a C18 analytical column (1.7 µm, 75 µm × 200 mm) was 
used to separate the peptides at the flow rate of 300 µl/min and operating 
pressure of 8000 psi. Peptides were eluted using a 62 min gradient from 95% 
solvent A (H2O, 0.1% formic acid) and 5% B (acetonitrile, 0.1% formic acid) to 
50% B in 41 min, 6 min at 90% B, and back to 5% for 10 min. Eluted peptides were 
directly electrosprayed (Nanosource, ESI voltage +2000V) into the mass 
spectrometer. The instrument was set to monitor 49 transitions in each sample 
with a dwelling time of 100 msec/transition. The in silico protease digest patterns 
and the corresponding MRM-MS transitions were compiled with Skyline 
software. Transitions that were larger than the precursor ion were selected on the 
basis of the Skyline predictions and the specific b/y ions that allow unambiguous 
identification of the selected phosphorylated Akt serine residues (Ser473) were 
included. Akt peptides were monitored for serine phosphorylation, non-
phosphorylated serine, as well as a serine deletion or mistranslation with 
glutamine. 
 
Parallel-Reaction Monitoring (PRM) of pAkt1T308. Following protein purification, 
the Akt protein was precipitated in ice-cold acetone/ethanol/acetic acid (50/50/0.1, 
vol/vol/vol). The protein precipitate was re-suspended in 8 M Urea, then reduced 
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in 5mM dithiothreitol (DTT) at 37°C for 1h and alkylated in 14 mM 
iodoacetamide (IAA) in darkness at room temperature for 1h. Unreacted IAA 
was neutralized by adding 5 mM DTT in the suspension. The final protein 
concentration was determined by Bradford assay. Glu-C digestion was 
performed at 37°C overnight with a protein:Glu-C ratio of 20:1 w/w. The digest 
was desalted in C18 column (Phenomenex) according to the manufacture’s 
protocol and re-suspended in MS-grade water. A Q Exactive Hybrid Quadrupole 
Orbitrap MS (Thermo Fisher Scientific) was used to analyze the peptides. Data 
were analyzed using Skyline software. 
 
2.8.2 Supporting References 
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2.8.3 Supporting Figures 
 
Figure S2.1 Production of purified full-length Akt1 and pAkt1 variants. 
Following affinity chromatography, purified fractions from size exclusion 
chromatography are visualized on SDS-PAGE. The Coomassie stained gel shows 
successful purification of full-length Akt1 variants: un-phosphorylated Akt (lane 
1), pAktT308 (lane 2), ppAktT308, S473 (lane 3), AktT308D (lane 4), pAktS473 (lane 5), 
pAktS473 T308A (lane 6), pAktS473 T308D (lane 7), AktS473D (lane 8). The ppAkt1 
variant, likely due to its double negative charge, consistently runs slightly faster 
than anticipated. We found this to be reproducible from 3 independent 
preparations. MS/MS analysis confirmed the full-length ppAkt1 protein with the 
expected protein sequence (Figure S2.2). 
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Figure S2.2 Physical characterization of ppAkt1T308, S473. (A) Western blots of 
His6-tagged un-phosphorylated Akt1 (lane 1), pAkt1T308 (lane 2), pAkt1S473 (lane 3), 
and ppAktT308, S473 (lane 4) with anti-his antibody. Mass spectra confirming 
enzymatically phosphorylated ppAkt1T308,S473. PRM-MS/MS was used to identify 
peptides with pT308 (B) and pS473 (C) in tryptic or GluC-digested samples of 
ppAkt1T308, S473, we were unable to identify peaks corresponding to de-
phosphorylation or truncation of the ppAkt1. (D) Coverage map shows the 
locations in the protein sequence where one or more significant tryptic or GluC 
peptides were identified (blue line) by PRM-MS/MS in the ppAkt1T308, S473 sample. 
Identified phosphorylation sites are indicated (P). 
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Figure S2.3 Mass spectra confirming quantitative, genetically encoded pS473 in 
Akt1. MRM-MS/MS was used to identify pS473 (A) but not Ser473 in a tryptic 
digested sample of pure pAkt1S473 (A, B). MRM-MS/MS also identified a peptide 
containing S473 (D) but not pS473 (C) in samples of purified and un-
phosphorylated Akt1 (C, D). 
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Figure S2.4 Physical characterization of pAkt1T308. Mass spectra (A) confirming 
enzymatically phosphorylated pAkt1T308. PRM-MS/MS was used to identify 
peptides in tryptic digested samples of pAkt1T308.  Abundant occurrence of 
peptide containing pThr308 (A) and relatively very low levels of 
unphosphorylated form of peptide containing T308 (B) were identified. 
 
 
 
 
 
 
 
 
Figure	S3. Physical	characterization	of	pAkt1T308. Mass	spectra	(A)	confirming	enzymatically	
phosphorylated	pAkt1T308. MRM-MS	was	used	to	identify	peptides	in	tryptic digested	samples	
of	pAkt1T308.	 Abundant	occurrence	of	peptide	containing	pThr308	(A)	and	relatively	very	low	
levels	of	unphosphorylated form	of	peptide	containing	T308	(B)	were	identified.
A B
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Figure S2.5 Activity of pAkt1T308 variants at reduced enzyme concentrations. A) 
ppAkt1 and B) pAkt1T308 enzyme concentrations were reduced by 10-fold in order 
to provide a sufficient linear phase to measure the reaction velocity accurately. 
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Figure S2.6 Autoradiographs of γ-[32P]-ATP kinase assays with pAkt1 variants. 
Time courses are shown for reactions catalyzed by (A) unmodified Akt1, (B) 
ppAkt1T308,S473, (C) pAkt1T308 (D) pAkt1S473 (E) pAkt1S473 D308 (F) pAkt1S473 A308 (G) 
pAkt1S308 (H) Akt1D308 (I) Akt1E308 (J) Akt1E473 (K) Akt1D473. Assays were performed 
in triplicate (as indicated by R1-R3). Controls include: C1 without substrate 
peptide, C2 without enzyme, C3 only kinase assay buffer. 
Figure S6. Autoradiographs of γ-[32P]-ATP kinase assays with pAkt1 variants. Time 
courses are shown for reactions catalyzed by (A) unphosphorylated Akt1, (B) ppAkt1T308,S473, 
(C) pAkt1T308 (D) pAkt1S473 (E) pAkt1S473 D308 (F) pAkt1S473 A308 (G) pAkt1S308 (H) Akt1D308 (I) 
Akt1E308 (J) Akt1E473 (K) Akt1D473. Assays were performed in triplicate (as indicated by R1-R3). 
Controls include: C1 without substrate peptide, C2 without enzyme, C3 only kinase assay 
buffer.
B ppAkt1T308,S473
R1    R2    R3  
C1   
C2  
C3
5
15
30
A unphosphorylated Akt1
2
5
10
15
30
R1      R2      R3 C1   C2  C3 
C   pAkt1T308
R1  R2   R3 C3  C2   C1
2
5
10
15
30
R1  R2  R3  
C1   
C2  
C3
5
10 
30
D pAkt1S473 E pAkt1S473 D308
2
5
10
15
30
R1      R2       R3     C1   C2   C3   
F pAkt1S473 A308
R1  R2   R3    C1  C2   C3   
2
5
10
15
30
G pAkt1S308
R1     R2    R3  
C1   
C2 
C3
2 
5
15
30
H Akt1 D308
R1  R2     R3       C1      C2     C3
2
5
10
15
30
I Akt1 E308
5
10
30
R1     R2    R3  
C1   
C2 
C3
J Akt1 E473
5
15
30
R1     R2    R3  
C1  
C2  
C3
K Akt1 D473
R1     R2    R3  C1     C2     C3Time 
(min)
Time 
(min)
2
5
10
15
30
Time 
(min)
Time 
(min)
Time 
(min)
Time 
(min)
Time 
(min)
Time 
(min)
Time 
(min)
Time 
(min)
Time 
(min)
	 85	
 
Figure S2.7 Production of pAkt1S308. Fractions from affinity chromatography are 
visualized on SDS-PAGE by anti-His immunoblot. Elution gradient of pAkt1S308 
(lanes 1-5) with increasing imidazole concentrations. 
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Figure S2.8 Cellular activity of Akt1 variants with glutamate substitutions. 
COS-7 cells co-expressing BKAR and equal levels of the indicated Cherry-tagged 
Akt were imaged and the CFP/FRET ratio examined following EGF stimulation 
and Akt inhibition with GDC 0068 (GDC).  Mutation of Thr308 to Glu resulted in 
an inactive kinase (middle plot), whereas mutation of Ser473 to Glu did not 
impair its activity (bottom plot).  Data were normalized to the first 4 minutes and 
plotted.  Graphs are representative of three independent experiments. 
(Experiment by Maya Kunkel) 
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Figure	S7. COS-7	cells	co-expressing	BKAR	and	equal	levels	of	Cherry-tagged	Akt's were	imaged	
and	the	CFP/FRET	ratio	examined	following	EGF	stimulation	and	Akt	inhibition	with	GDC	0068	
(GDC).		Mutation	of	Thr308	to	Glu resulted	in	an	inactive	kinase	(middle	plot),	whereas	
mutation	of	Ser473	to	Glu did	not	impair	its	activity	(bottom	plot).		Data	were	normalized	to	the	
first	4	minutes	and	plotted.		Graphs	are	representative	of	three	independent	experiments.
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Figure S2.9 Cellular activity of phospho-ablated Akt1 variant S473A. Serum-
starved COS7 cells expressing BKAR with minimally detectable levels of Cherry-
tagged Akt were imaged during stimulation with EGF followed by treatment 
with the Akt inhibitor GDC 0068. The average FRET ratios for WT (blue) and 
S473A (yellow) are shown. Data were analyzed from cells expressing equal low 
levels of Cherry-Akt (n=12 for WT and n=8 for S473A) from three independent 
experiments. FRET ratios from each cell were normalized and their average 
plotted over time. Error bars represent SEM. (Experiment by Maya Kunkel) 
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Chapter 3 
 
3 Phosphorylation-dependent chemical and auto-
inhibition of Akt1 
 
3.1 Abstract 
Akt1 is a proto-oncogene that is over active in most cancers. Akt1 activation 
requires phosphorylation at Thr308; phosphorylation at Ser473 further enhances 
catalytic activity. Akt1 activity is also regulated via interactions between the 
kinase domain and the N-terminal auto-inhibitory pleckstrin homology (PH) 
domain. As it was previously difficult to produce Akt1 in site-specifically 
phosphorylated forms, the contribution of each activating phosphorylation site to 
auto-inhibition was unknown. Using a combination of genetic code expansion 
and in vivo enzymatic phosphorylation, we produced Akt1 variants containing 
programmed phosphorylation to probe the interplay between Akt1 
phosphorylation status and the auto-inhibitory function of the PH domain. 
Deletion of the PH domain increased the enzyme activity for all three 
phosphorylated Akt1 variants. For the doubly phosphorylated enzyme, deletion 
of the PH domain relieved auto-inhibition by 295-fold. We next found that 
phosphorylation at Ser473 provided resistance to chemical inhibition by Akti-1/2 
inhibitor VIII. The Akti-1/2 inhibitor was most effective against pAkt1T308 and 
showed 4-fold decreased potency with Akt1 variants phosphorylated at Ser473. 
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The data highlight the need to design more potent Akt1 inhibitors that are 
effective against the doubly phosphorylated and most pathogenic form of Akt1. 
 
3.2 Introduction 
Protein kinase B (Akt) is a human serine-threonine kinase and a member of 
the AGC family of protein kinases (1,2). The pathway regulated by Akt is the 
most commonly activated signaling pathway in human cancers (3). Given that 
more than 50% of human tumors contain hyper-activated Akt (2), effective 
inhibition of active Akt has the potential to treat several distinct cancers. There 
are three Akt genes in humans, encoding the isozymes Akt1, Akt2, and Akt3. The 
Akt1 isozyme has well established roles in many human cancers. Over-active 
Akt1 is a hallmark of diverse human malignancies (3,4) and linked to reduced 
survival outcomes (5,6). Indeed, Akt1 is a leading drug target in cancer (7,8). 
Over 300 clinical trials are completed or underway that involve targeting the 
Akt1 signaling pathway. 
Akt1 is a key regulator of the phosphoinositide 3-kinase (PI3K)/Akt1 
signaling cascade that controls cell growth and survival (1). In human cells, the 
activation of Akt1 occurs in response to growth factor stimulation (Figure 3.1). 
Following activation by a receptor tyrosine kinase at the plasma membrane, 
phosphoinositide-3-phosphate kinase (PI3K) phosphorylates its immediate 
downstream target, a lipid second messenger called phosphatidylinositol-4, 5-
bisphosphate (PIP2), converting PIP2 into phosphatidylinositol-3, 4, 5-
triphosphate (PIP3) (2). Membrane anchored PIP3 is a binding site for pleckstrin 
homology (PH) domain-containing proteins such as Akt1 and one of the 
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upstream kinases that activates Akt1, phosphoinositide dependent kinase 1 
(PDK1) (9). Co-localization of Akt1 with PDK1 leads to partial activation of Akt1 
by PDK1-mediated phosphorylation of Thr308 in the kinase domain of Akt1. Full 
activation of Akt1 results from a second phosphorylation event at Ser473 in the 
regulatory domain of Akt1 by mechanistic target of rapamycin complex 2 
(mTORC2) (Figure 3.1).  
 
 
Figure 3.1 Simplified schematic of Akt1 activation via phosphorylation of sites 
Thr308 and Ser473. The transition from Akt1’s inactive state (PH-in) to its fully 
active state (ppAkt1T308/S473) requires the release of PH domain mediated auto-
inhibition. This release occurs when Akt1’s PH domain interacts with PIP 3 (PH-
out). In the PH-out conformation, Akt1 is more susceptible to phosphorylation at 
Thr308 and Ser473 by PDK1 and mTORC2 respectively. Upon release from PIP3, 
Akt1 distributes rapidly in the cytosol and translocates to the nucleus to 
phosphorylate >100 cellular proteins(2,10).  
Leveraging our ability to produce Akt1 protein in specifically 
phosphorylated forms (Figure 3.2), we recently quantified the precise 
contribution of pThr308 and pSer473 to Akt1 activity in vitro and in mammalian 
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cells (11). In studies with purified full length Akt1, we found that pAkt1T308 
achieves 30% of the activity of the doubly phosphorylated kinase. We also 
observed in COS-7 cells that pSer473 is dispensable for Akt1 signaling and 
phosphorylation of Thr308 alone was sufficient for maximal Akt1 signal 
propogation. These results indicated Thr308 phosphorylation status is a superior 
biomarker for Akt1 activity (11) and called into question the frequent use of 
Ser473 phosphorylation as a diagnostic marker for Akt1 activity in cancer 
patients (12-15). 
 
Figure 3.2 Production of Akt1 variants with programmed phosphorylation. To 
produce pAkt1T308, PDK1 (Akt1’s natural upstream kinase) was co-expressed 
along with Akt1. To produce pAkt1S473, the phosphoserine orthogonal translation 
system was used to genetically incorporate phosphoserine at position 473 in 
response to an amber (UAG) codon. The ppAkt1T308,S473 variant was produced by 
combining both methods.  
The N-terminal PH domain is auto-inhibitory to Akt1 activity. Due to 
previous roadblocks in preparing Akt1 with programmed phosphorylation(s), 
there are no reports that measure the contribution of a phosphate at each key 
regulatory site to the auto-inhibition of Akt1 by the PH domain. In the current 
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Figure 2: Production of differentially phosphorylated Akt1 variants. Four 
differentially phosphorylated variants of Akt1 were produced in E. coli; 
(unphosphorylated) WT Akt1, (mono-phosphorylated) pAkt1T308, pAkt1S473, and (dual-
phosphorylated) ppAkt1T308/S473. To create pAkt1T308, PDK1 (Akt1’s natural upstream 
kinase) was co-expressed along with Akt1. To create pAkt1S473, the phosphoserine 
orthogonal translation system was used to genetically incorporate phosphoserine at 
position 473. ppAkt1T308/S473 was created by combining both methods and the WT Akt1 
by omitting both methods. For the production of pAkt1S473 and ppAkt1T308/S473, E. coli 
were supplemented with chemically synthesized phosphoserine (pSer) [should we 
include the product number?].
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model, Akt1 exists in an auto-inhibited (PH-in) and activated confirmation (PH-
out). In its auto-inhibited conformation (PH-in), the PH domain binds between 
the N- and C-terminal lobes of the un-phosphorylated Akt1 kinase domain. 
During growth factor-mediated activation of Akt1, the PH domain forms a new 
interaction with PIP3 causing it to move outward from the now more accessible 
kinase domain. This PH-out conformation is readily activated via 
phosphorylation at Thr308 by PDK1 and Ser473 by mTORC2. Disruption of the 
PH and kinase domain interaction was identified as a plausible cause of 
increased Akt1 phosphorylation and subsequent activity in cancer (16).  
Here we quantified the ability of the PH domain to auto-inhibit Akt1 variants 
phosphorylated at either or both key regulatory sites Thr308 and Ser473. We 
produced novel recombinant Akt1 variants lacking the PH domain (ΔPH-Akt1) 
that also contained programmed phosphorylation at each site separately or with 
both sites phosphorylated. In the context of full length phosphorylated Akt1 
variants, we quantified the contribution of both regulatory phosphorylation sites 
to chemical inhibition with the PH domain dependent allosteric inhibitor Akti-
1/2. 
 
3.3 Materials and Methods 
3.3.1 Bacterial strains and plasmids. We designed a codon optimized PH domain 
deficient (ΔPH) human akt1 gene (residues 109-480), which was synthesized by 
ATUM (Newark, California, USA). The ΔPH-akt1 gene was sub-cloned 
(NcoI/NotI) into an isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible T7lac 
promoter driven pCDF-Duet1 vector with CloDF13-derived CDF replicon and 
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streptomycin/spectinomycin resistance (pCDF-Duet1-ΔPHAkt1). The PDPK1 
gene was purchased from Harvard PlasmidID repository service (plasmid ID: 
HsCD00001584, Boston, MA, USA) and sub-cloned (KpnI/NdeI) into the second 
multi-cloning site (MCS) of pCDF-Duet-1. Full length pAkt1 variants were 
produced from pCDF-Duet1 plasmids as described previously (11). The genetic 
code expansion system for phosphoserine (pSer) is encoded on the pDS-pSer2 
plasmid (11,17,18), which contains 5 copies of tRNASep (19), phosphoseryl-tRNA 
synthetase (SepRS9), and elongation factor Tu mutant (EFSep21) (20). 
Incorporation of pSer also required site-directed mutagenesis of the Ser473 codon 
to TAG in the ΔPH-akt1 constructs. Successful cloning was verified by DNA 
sequencing at the London Regional Genomics Centre (London, ON, Canada) and 
Genewiz (Cambridge, MA, USA). 
 
3.3.2 Protein and phosphoprotein production. Recombinant Akt1 protein 
variants were expressed in BL21(DE3) (Invitrogen) (Figure 3.2). The pDS-pSer2 
plasmid (18) was used as before (11) to incorporate pSer in response to a UAG 
codon at position 473 in ΔPHAkt1 and full length Akt1 variants. To produce both 
full length and PH domain deficient Akt1 variants containing pSer473 (Table 
S3.1), the pCDFDuet-1 Akt1 bearing plasmid was co-transformed with pDS-pSer2 
into E. coli Bl21(DE3) and plated on LB agar plates with 25 µg/ml kanamycin and 
50 µg/ml streptomycin. To produce pAkt1T308 variants, a pCDF-Duet1 plasmid 
containing both the Akt1 variant (multiple cloning site 2 (MSC 2)) and PDK1 
(multiple cloning site 1 (MSC 1)) was transformed into E. coli BL21(DE3) and 
plated on LB agar plates with 50 µg/ml streptomycin. To produce ppAkt1T308,S473 
variants, a pCDF-Duet1 plasmid containing both the Akt1 variant (MSC 2) with a 
TAG codon at position 473 and PDK1 (MSC 1) (11) was co-transformed with 
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pDS-pSer2 into E. coli Bl21(DE3) and plated on LB-agar plates with 25 µg/ml 
kanamycin and 50 µg/ml streptomycin.                                 
In all cases, a single colony was used to inoculate 70 ml of LB (with 
streptomycin 50 µg/ml and, if needed, kanamycin 25 µg/ml), which was grown, 
shaking, overnight at 37 °C. From this starter culture, a 10 ml inoculum was 
added to 1 L of LB with antibiotics (as above) and, for pSer473 containing 
variants only, O-phospho-L-serine (Sigma Aldrich, Oakville, Ontario) was added 
to a final concentration of 2.5 mM. The cultures were grown at 37 °C until OD600 = 
0.6 at which point, for pSer473 containing variants only, 2.5 mM of additional 
pSer was added to the culture. Protein expression was induced by adding 300 
µM of IPTG at OD600 = 0.8. Cultures were then incubated at 16°C for 18 h. Cells 
were grown and pelleted at 5000 × g and stored at -80°C until further analysis. 
Akt1 protein variants were purified from the cell pellets using Ni-Nitrilotriacetic 
acid affinity column chromatography (see Supplementary Methods). 
 
3.3.3 Parallel-Reaction Monitoring Mass Spectrometry (PRM-MS) of ppAkt1. 
The ppAkt1 protein produced as noted above and the commercially available 
active Akt1 (Abcam, lot 1) were precipitated in ice-cold acetone/ethanol/acetic 
acid (50/50/0.1, vol/vol/vol). The protein precipitate was re-suspended in 8 M 
urea, then reduced in 5 mM dithiothreitol (DTT) at 37°C for 1 h and alkylated in 
14 mM iodoacetamide (IAA) in darkness at room temperature for 1 h. Unreacted 
IAA was neutralized by adding 5 mM DTT. The final protein concentration was 
determined by Bradford assay. Glu-C digestion was performed at 37 °C 
overnight with a Glu-C to-protein ratio of 1/20 (w/w). The digest was desalted in 
C18 column (Phenomenex) according to the manufacture’s protocol and re-
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suspended in MS-grade water. A Q Exactive Hybrid Quadrupole Orbitrap MS 
(Thermo Fisher Scientific) was used to analyze the peptides. Data were analyzed 
using Skyline software. 
 
3.3.4 MALDI-TOF/TOF Mass Spec Analysis. In-gel digestion was performed 
using a MassPREP automated digester station (PerkinElmer). Gel pieces were de-
stained using 50mM ammonium bicarbonate and 50% acetonitrile, which was 
followed by protein reduction using 10 mM dithiotreitol (DTT), alkylation using 
55 mM IAA, and tryptic digestion in 50 mM ammonium bicarbonate, pH 8. 
Peptides were extracted using a solution of 1% formic acid and 2% acetonitrile 
and lyophilized. Prior to mass spectrometric analysis, dried peptide samples 
were re-dissolved in a 10% acetonitrile and 0.1 % trifluoroacetic acid solution. 
MALDI matrix, a–cyano–4–hydroxycinnamic acid, was prepared as 5 mg/ml in 6 
mM ammonium phosphate monobasic, 50% acetonitrile, 0.1 % trifluoroacetic acid 
and mixed with the sample at 1:1 ratio (v/v). Mass Spectrometry data (Figure 
S3.1) were obtained using an AB Sciex 5800 MALDI TOF/TOF System 
(Framingham, MA, USA). Data acquisition and data processing were done using 
a TOF TOF Series Explorer and Data Explorer (both from AB Sciex), respectively. 
The instrument is equipped with a 349 nm Nd:YLF OptiBeam On-Axis laser. The 
laser pulse rate is 400 Hz. Reflectron positive mode was used. Reflectron mode 
was externally calibrated at 50 ppm mass tolerance and internally at 10 ppm. 
Each mass spectrum was collected as a sum of 500 shots. 
 
3.3.5 Akt1 kinase activity assay. The activity of each Akt1 variant was 
characterized by performing kinase assays in the presence of 200 µM substrate 
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peptide CKRPRAASFAE (SignalChem, Vancouver, BC, Canada) derived from 
the natural Akt1 substrate, glycogen synthase kinase (GSK-3β). Assays were 
performed in 3-(N-morpholino)propanesulfonic acid (MOPS, 25 mM, pH 7.0), β-
glycerolphosphate (12.5 mM), MgCl2 (25 mM), ethylene glycol-bis(β-aminoethyl 
ether)-N,N,N',N'-tetraacetic acid (EGTA, 5 mM, pH 8.0), EDTA (2 mM), ATP 
(0.02 mM) and 0.4 µCi (0.033 µM) γ-[32P]-ATP in a 30 µl reaction volume. 
Reactions were incubated at 37 °C and time points were taken over 30 min time 
courses. As previously (11), reactions were initiated by the addition of 18 pmol of 
the indicated Akt1 variant to yield a final enzyme concentration of 600 nM and 
quenched by spotting on P81 paper (21). For highly active Akt1 variants, the level 
of Akt1 was titrated to identify a linear range to accurately determine initial 
velocity (vo) (Figure S3.2). For this reason, Akt1 activity is compared based on kapp 
= vo/[Akt1]. Samples from each reaction (5 µl) were spotted on P81 paper at 
specified time points. Following washes with 1% phosphoric acid (3 × 10 min) 
and 95% ethanol (1 × 5 min), the P81 paper was air-dried. Incorporation of 32P 
into the substrate peptide was detected by exposing the P81 paper to a phosphor-
imaging screen. The 32P-peptide products were imaged and quantitated using a 
Storm 860 Molecular Imager and ImageQuant TL software (GE Healthcare). 
 
3.3.6 Kinase inhibition assay. A concentration gradient (0.001, 0.05, 0.5, 1, 5, 10 
µM) of Akti-1/2 inhibitor VIII (Sellekchem, Houston, TX, USA) (22) was selected 
to determine the concentration dependence of Akt1 inhibition. Kinase inhibition 
assays were performed exactly as described above (section 3.3.5) and with the 
addition of dimethyl sulfoxide at 10% (v/v) (control) or with the indicated 
concentration of Akti-1/2 inhibitor. For each condition, initial velocity was 
determined over a time course of 10 minutes with time points at 0, 2, 5 and 10 
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min (Figure S3.3). In the inhibition assays, following established protocols (16), 
the inhibitor was pre-incubated with the enzyme for 5 min at 37°C before 
addition of ATP and Akt1 substrate peptide to start the reaction. The time 
courses were used to determine the initial velocities of each reaction. The fraction 
of enzyme inhibition was measured based on initial velocities of uninhibited and 
inhibited reactions. From these data, half maximal inhibitory concentration (IC50) 
values were calculated using Sigma Plot (Systat Software, Inc, San Jose, CA). 
 
3.4 Results 
3.4.1 Production of recombinant Akt1 variants. We recently established a 
method to produce full length Akt1 variants with programmed phosphorylations 
(11). Here we applied this method to produce site-specifically phosphorylated 
Akt1 variants lacking the auto-inhibitory PH domain (ΔPH-Akt1). The approach 
combines in vivo enzymatic phosphorylation with genetic code expansion to 
produce Akt1 variants containing either or both pThr308 and pSer473 (Figure 
3.2).  
Using genetic code expansion (11,18), we incorporated pSer in response to 
a UAG stop codon at position 473 in the relevant Akt1 constructs. Thr308 was 
site-specifically phosphorylated by the co-expression of the upstream kinase 
PDK1 in E. coli. We (11) and others (23) have demonstrated that PDK1 is strictly 
specific in phosphorylating only the 308 site in Akt1. We used these methods in 
isolation or in combination to produce the three physiologically relevant Akt1 
variants pAkt1S473, pAkt1T308, and ppAkt1T308,S473 (Figure 3.2). We observed that the 
ΔPH-Akt1 variants were all more soluble and were produced at 1.5 to 7-fold 
greater yield per liter of E. coli culture than the corresponding full length Akt1 
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variants (Table 3.1). As previously (11), we confirmed phosphorylation of the 
Thr308 site (Figure 3.3C) and the Ser473 site (Figure S3.1) by mass spectrometry. 
 
Table 3.1 Protein yields for Akt1 variants. 
 
3.4.2 Recombinant Akt1 produced in E. coli versus Sf9 cells. Earlier work 
established production of partially active and truncated Akt1 in E. coli, which 
was unsuccessful in producing a sufficient amount of full length Akt1 to 
determine activity (24). Although we recently overcame these difficulties and 
developed a robust protocol to produce full length Akt1 from E. coli with 
programmed phosphorylation, studies in the intervening period relied on insect 
Sf9 cell culture to produce recombinant Akt1 (25). The ability to generate ppAkt1 
from insect cells, however, requires a complex and low yield in vitro procedure 
to phosphorylate Akt with 2 additional purified upstream kinases in the presence 
of lipid vesicles (25). Protein production in Sf9 cells fails to produce Akt1 with 
site-specific or programmed phosphorylation. The resulting protein is a mixture 
of singly and doubly phosphorylated species (26).  
In order to benchmark the activity of the recombinant phosphorylated 
Akt1 protein we produce in E. coli, we compared the activity of full length 
ppAkt1 to active Akt1 purchased from Abcam. The commercially available full-
 Protein Yields 
(µg/L E. coli culture) 
Akt1 variant full length ΔPH Akt1 
Akt1 (unphosphorylated)  46 330 
pAkt1S473 100 150 
pAkt1T308 
ppAkt1T308,S473 
37 
45 
235 
224 
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length Akt1 is made by a protocol similar to that established previously (25) in 
which Akt1 protein production in Sf9 cells followed by in vitro phosphorylation 
of the purified Akt1 with purified PDK1. In testing an initial lot of active Akt1 
(lot 1), we found that the commercially available Akt1 enzyme was catalytically 
deficient by a factor of 8-fold (Table 3.2) compared to the full length ppAkt1 we 
produced (Figure 3.3A).  
 
Table 3.2 Activity of Akt1 variants 
 
 
 
 
 
 
Akt1 variant 
Akt1 
amount 
(pmol) 
Initial velocity 
vo 
(fmol/min) 
Apparent  
catalytic rate kapp 
(fmol/min/pmol 
Akt1) 
 
Activation 
(fold increase) 
 
Reference 
      
Akt1 (un-
phosphorylated)  
18   0.6 ± 0.2   0.03 ± 0.01   1.0 ± 0.3 [10] 
pAkt1S473 18 46 ± 5   2.6 ± 0.3 85 ± 9 [10] 
pAkt1T308 
ppAkt1T308,S473 
1.8 
1.8 
22 ± 4 
  79 ± 11 
12 ± 2 
44 ± 6 
400 ± 70 
1500 ± 200 
[10] 
[10] 
 
ΔPHAkt1 (un-
phosphorylated) 
ΔPH pAkt1S473 
ΔPH pAkt1T308 
ΔPH ppAkt1T308,S473 
 
18 
18 
0.18 
0.18 
 
  1.4 ± 0.1 
210 ± 20 
  370 ± 100 
2300 ± 600 
 
  0.079 ± 0.006 
12 ± 1 
2100 ± 600 
(13 ± 3) x 103 
 
  2.7 ± 0.2 
390 ± 40 
 6900 ± 1800 
(4 ± 1) x 105 
 
this study 
this study 
this study 
this study 
      
Commercial Akt1 
(abcam) 
Lot 1 
 
18 
 
100 ± 20 
 
  6 ± 1 
 
200 ± 30 
 
this study 
Lot 2 18 2200 ± 700 120 ± 40   4000 ± 1000 this study 
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PRM-MS/MS was used to determine the identity of the residue at position 
308 and the level of phosphorylation in ppAkt1 we produced and in the 
purchased protein. Mass spectrometry revealed that the low activity of lot 1 
enzyme was attributable to the low level of phosphorylation at position 308 (peak 
intensity 1.3 × 101) and a relatively high level of un-phosphorylated Thr at 
position 308 (Figure 3.3B). In contrast, ppAkt1T308,S473 that we produced showed a 
high level (peak intensity 1.6 × 106) of Thr308 phosphorylation and un-
phosphorylated Thr308 was not detected (Figure 3.3C). We then purchased a 
second lot of Akt1 enzyme (lot 2), and this enzyme displayed significantly more 
but highly variable activity compared to lot 1 (Table 3.2). Presumably, the second 
lot was quantitatively phosphorylated during production. In contrast to the 
method we developed for pAkt1 production in E. coli (Figure 3.2), the protocol to 
generate active Akt1 relying on Sf9 cells and subsequent in vitro phosphorylation 
appears to lead to a variable level of phosphorylation and activity in the resulting 
Akt1 preparations.  
 
 
 
 
 
 
 
 101 
 
Figure 3.3 Activity of full length ppAkt1 and commercially available active 
Akt1. (A) Kinase activity assays over a 30-minute time course show substantially 
reduced activity of commercial Akt1 (lot 1, green squares) compared to full 
length ppAkt1 (blue diamonds) produced in E. coli. Commercial Akt1 lot 2 (red 
circles) showed highly variable but similar activity to full length ppAkt1. (B) 
Tryptic peptides from commercial Akt1 and ppAkt1 were analyzed by PRM-MS 
analysis. The purchased ‘active’ Akt1 (lot 1) showed a low intensity peak for 
phosphorylation at Thr308 (green peak at a retention time of ~40 min) and high 
intensity peak for non-phosphorylated Thr308 (cyan peak, retention time of ~37 
min). (C) PRM-MS analysis of ppAkt1T308,S473 showed a high intensity peak for 
phosphorylation at Thr308 (green peak at a retention time of 40) and the non-
phosphorylated Thr308 was undetectable. 
 
3.4.3 Impact of PH domain deletion on differentially phosphorylated Akt1. In 
order to determine the impact of the PH domain on each phospho-form of Akt1, 
we next assayed the activity of specifically phosphorylated ΔPH-Akt1 variants 
using γ-[32P]-ATP and a substrate peptide for Akt1 (CKRPRAASFAE) that was 
derived from GSK-3β, a well-established Akt1 substrate (11,27). In kinase assay 
conditions that we previously optimized (11) to measure a wide range of Akt1 
activity, we determined the apparent catalytic rate of each ΔPH-Akt1 variant (un-
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phosphorylated, pAkt1S473, pAkt1T308, ppAkt1T308,S473). We then compared the 
apparent catalytic rates to the measurements we had made previously with full-
length Akt1 and pAkt1 variants to ascertain the relative impact of each 
phosphorylation state on the auto-inhibition by the PH domain. 
As anticipated, all Akt1 variants lacking the PH domain were significantly 
more active than their full-length counterparts (Table 3.1). Doubly 
phosphorylated ΔPH-Akt1 (ppAktT308,S473) showed the highest activity among all 
three variants (Figure 3.3). The un-phosphorylated ΔPH-Akt1 showed a basal 
level of activity that was significantly higher (2.7 ± 0.3 -fold) than the background 
activity we recorded for full length un-phosphorylated Akt1 (Table 3.3). 
Although both un-phosphorylated Akt1s would not be of sufficient activity to 
induce Akt1-dependent signaling in cells (2,11), it is interesting to note that the 
auto-inhibitory effect of the PH domain is indeed measurable in the increased 
minimal activity of un-phosphorylated ΔPH-Akt1 (Figure 3.4B). 
 
Table 3.3 Relative activity of full length versus ΔPH Akt1 variants 
 
 
 
Akt1 variant 
full 
length 
Akt1 
 
ΔPH 
Akt1 
Akt1 (un-phosphorylated)  1.0 ± 0.3   2.7 ± 0.2 
pAkt1S473 1.0 ± 0.1   4.6 ± 0.4 
pAkt1T308 
ppAkt1T308,S473 
1.0 ± 0.2 
1.0 ± 0.1 
175 ± 50 
295 ± 68 
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Figure 3.4 Enzyme activity of ΔPH-Akt1 variants. (A) The activity of 
differentially phosphorylated ΔPH Akt1 variants with the GSK-3β substrate 
peptide was measured over a 30-minute time course. Akt1 phosphorylated at 
both 308 and 473 (ΔPH ppAktS473, T308, blue diamonds) showed maximal activity 
compared to the un-phosphorylated ΔPH-Akt1 (gray circles), and singly 
phosphorylated Akt1 variants: ΔPH pAkt1T308 (black cross) and ΔPH pAkt1S473 
(pink diamonds). (B) The basal activity of un-phosphorylated ΔPH Akt1 (gray 
circles) was compared to full length 
 
Compared to un-phosphorylated ΔPH-Akt1, the most active doubly 
phosphorylated Akt1 variant (ΔPH- ppAktT308,S473) showed 150,000-fold increase 
in relative catalytic rate (Table 3.2, Figure 3.4). Since rapid enzyme kinetics were 
observed with 18 pmol of enzyme with both these variants containing Thr308 
phosphorylation, the enzyme concentrations were subsequently reduced by 10-
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fold and 100-fold to obtain a highly accurate initial velocity with which to 
determine the apparent rate (kapp = vo/[enzyme]) (Figure S3.2). 
Interestingly, dual phosphorylation of ΔPH-Akt1 leads to 100-fold greater 
increases in activity than that observed upon dual phosphorylation of the full-
length enzyme, which is 1500-fold more active that the un-phosphorylated full-
length enzyme. The data indicate the PH domain significantly dampens the 
catalytic activity endowed by phosphorylation at Thr308 and Ser473 (Figure 3.5). 
The ΔPH-Akt1 variant with a single phosphorylation at Thr308 site was robustly 
active, 2500-fold above the unphosphorylated ΔPH-Akt1, yet 60-fold reduced 
activity compared to the doubly phosphorylated enzyme ΔPH-ppAktT308/S473 
(Table 3.2). Phosphorylation at the C-terminal site Ser473 activated the enzyme 
140-fold above the un-phosphorylated control, but to a lesser extent (18-fold) 
than the ΔPH-pAkt1T308. We previously observed a quantitatively similar pattern 
of activity with the full length Akt1 variants (Table 3.2, (11)).  
We found that the PH domain exerts an auto-inhibitory effect, the strength of 
which depends on the phosphorylation status of the Akt1 enzyme. We compared 
the apparent catalytic rates (kapp) (Figure 3.5A) and normalized relative catalytic 
rates (Figure 3.5B) between the full length (11) and PH domain deficient Akt1 
variants. In the context of a single phosphorylation at Ser473, the PH domain is 
associated with a ~5-fold reduction in activity (Table 3.3, Figure 3.5). In the singly 
phosphorylated pAkt1T308 enzyme the auto-inhibition is far stronger (175-fold). 
The two phosphorylations together led to a super-additive inhibitory effect (295-
fold) in the doubly phosphorylated enzyme (Figure 3.5).  
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Figure 3.5 Impact of the PH domain on the activity of differentially 
phosphorylated Akt1. (A) Apparent catalytic rates (kapp) and (B) normalized kapp 
values of full-length Akt1 variants (blue) and ΔPH Akt1 variants (red) are shown. 
Error bars represent 1 standard deviation of triplicate measurements.  
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associated with a ~5-fold reduction in activity (Table 3.3, Figure 3.5). In the singly 
phosphorylated pAkt1T308 enzyme the auto-inhibition is far stronger (175-fold). 
The two phosphorylations together led to a super-additive inhibitory effect (295-
fold) in the doubly phosphorylated enzyme (Figure 3.5).  
 
3.4.4 Chemical inhibition of phosphorylated Akt1 variants. Given the 
differential impact of Akt1 phosphorylation on auto-inhibition, we next 
identified phosphorylation dependence in the interaction between Akt1 and a 
clinically relevant drug scaffold, Akti-1/2 inhibitor VIII. Several classes of 
chemical inhibitors were developed to repress aberrant Akt1 activity in cancer 
cells (28). Early Akt1 inhibitors focused on ATP competitive compounds (29), yet 
these molecules suffered from significant cross reactivity with other AGC family 
kinases (30). For this reason, subsequent efforts focused on allosteric Akt1 
inhibitors. Akti-1/2 is an allosteric inhibitor that binds Akt1 in a cleft between the 
kinase and PH domains, locking the enzyme in a non-catalytic confirmation 
(Figure 3.6). Biochemical data with different Akt1 preparations have provided 
estimates of IC50 of Akt1 for the Akti-1/2 inhibitor ranging from 58 nM to 2.7 µM 
(22,31,32) (Table 3.4). We suspected that this range of values result from 
preparations of Akt1 with various levels of phosphorylation with less active Akt1 
preparations leading to an underestimate of IC50. In addition, previous studies 
were unable to isolate the contribution of each regulatory phosphorylation site to 
inhibition by Akti-1/2. 
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Figure 3.6 Structure of Akt1 in active and inhibitor bound forms. (A) The 
structure of DPH-pAkt1Thr308 Ser473Asp (PDB 1O6K (33)) is shown in complex 
with ATP analog (AMP-PNP) and substrate peptide (purple). (B) Structure of the 
full length Akt1 (un-phosphorylated) is shown in complex with the Akti-1/2 
inhibitor VIII (PDB 1O96 (34)) binding in the cleft between the kinase domain 
(green) and the N-terminal PH domain (red).  
 
Table 3.4 Akti-1/2 inhibitor half maximal inhibitory concentration (IC50) for 
pAkt1 variants 
 
A B
AMP-PNP
GSK-3!
peptide
pT308
S473D
*
Akti-1/2 
inhibitor VIII
kinase domain
PH domain
Akt1 variant inhibitor type IC50 (µM) expression system reference 
ppAkt1T308,S473 Akti-1/2 inhibitor VIII 1.2 ± 0.3 E. coli this study 
pAkt1T308 Akti-1/2 inhibitor VIII 0.3 ± 0.1 E. coli this study 
pAkt1S473 Akti-1/2 inhibitor VIII 1.3 ± 0.1 E. coli this study 
active Akti-1/2 inhibitor VIII 0.058 Drosophila S2 cells [22] 
active Akti-1/2 inhibitor VIII 0.1 HEK 293 cells [31] 
active Akti-1/2 inhibitor  2.7 Drosophila S2 cells [32] 
active Akti-1 inhibitor  4.6 Drosophila S2 cells [32] 
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We conducted Akt1 inhibition assays using Akti-1/2 concentrations 
varying from 0.01 to 10 µM. All three full-length phosphorylated Akt1 variants 
showed concentration responsive enzyme inhibition (Figures 3.7, S3.3-S3.6). Akti-
1/2 was most potent (IC50 = 300 nM) when only the Thr308 site was 
phosphorylated (Table 3.4). Interestingly, at the lower concentrations of Akti-1/2 
(0.001, 0.05, 0.5 µM) the compound was not effective in inhibiting the activity of 
pAkt1S473. Akt1 phosphorylated at the C-terminal Ser473 site was overall more 
resistant to inhibitor VIII inhibition resulting an IC50 value of 1.3 µM. In a 
surprising finding, the doubly phosphorylated enzyme had an indistinguishable 
IC50 from the pAkt1S473 enzyme. Together the data indicate that Ser473 
phosphorylation provides a 4-fold increase in resistance to the Akti-1/2 inhibitor 
even in the presence of phosphorylation at Thr308. This is the first report that 
demonstrating phosphorylation dependence in the interaction between Akt1 and 
an inhibitor.  
 
 
Figure 3.7 Chemical inhibition of full length phosphorylated Akt1 variants. (A) 
Inhibition of (A) pAkt1S473, (B) pAkt1T308, and (C) ppAkt1T308,S473 with varying 
concentrations (0.001, 0.05, 0.5, 1, 5, 10 µM) of Akti-1/2 inhibitor VIII. The 
resulting IC50 values are in Table 3.4. 
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3.5 Discussion 
Akt1 is a prime target for therapeutic intervention due to its involvement in 
regulating a multitude of cellular pathways (35,36). Aberrant Akt function has 
been linked to cancers and a variety of human diseases related to metabolic 
regulation, immune function, and neurological development (2). The broad range 
of cellular processes governed by Akt, therefore, presents an opportunity for 
single-target therapeutic intervention of a variety of conditions. To capitalize on 
this opportunity, compounds that selectively attenuate Akt1 activity rather than 
global kinase inactivation are required. This need is reflected in clinical trials 
which show that non-specific Akt inhibition in cancer therapy, due to inadvertent 
off-targeting of closely related kinases or multiple Akt isozymes, can result in 
detrimental side-effects including liver damage and metabolic disorders (37-40). 
Accordingly, the development of small molecule inhibitors for Akt has reflected 
this sentiment towards engineering greater target specificity (28). From the 
earliest ATP-competitive inhibitors that unintentionally inhibited related AGC 
kinases, to more recent allosteric inhibitors that preferentially target Akt or even 
a subset of Akt isozymes, the continued pursuit for Akt1 inhibitor specificity 
requires an expanded understanding of the molecular basis of Akt1 activation 
and inhibition.  
Previous work was unable to uncover the role of each regulatory site (Thr308 
and Ser473) in the inhibition kinetics of Akt1. Given this critical knowledge gap, 
we investigated the role of Akt1 phosphorylation status on the auto-inhibitory 
effect of the PH-domain and on allosteric inhibition by Akti-1/2.  
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3.5.1 Phosphorylation-Dependent Auto-Inhibition of Akt1. The N-terminal PH 
domain is shared amongst all three Akt isozymes and its direct function is to 
mediate protein-lipid interactions. It is well documented that the PH domain 
binding to a lipid second messenger PIP3 in cell membranes releases the 
inhibitory effect of the PH domain (2). Here, we produced differentially 
phosphorylated Akt1 variants with and without the PH domain in E. coli using 
genetic code expansion to incorporate pSer473 and the upstream Thr308 kinase 
PDK1 was co-expressed in E. coli, leading to quantitative phosphorylation of the 
recombinant Akt1 protein. Compared to un-phosphorylated Akt1, all 
phosphorylated variants showed increased enzyme activity.  
Previously, live cell imaging studies revealed that once phosphorylated, Akt1 
favors a ‘PH-out’ confirmation that increases Akt1 activity in the downstream 
phosphorylation of substrate proteins both in the cytoplasm and nucleus. In 
addition, binding of Akt1 to PIP3 in the plasma membrane further releases the 
auto-inhibitory effect of the PH domain (41,42). Although phosphorylation of the 
kinase domain at Thr308 is known to reduce the PH domain’s affinity towards 
the kinase domain (41), the contribution of Thr308 and Ser473 phosphorylation to 
auto-inhibition by the PH domain was unknown.   
We quantitated the release of PH domain mediated inhibition corresponding 
to each phosphorylation site and both sites in combination. Our data revealed 
that the magnitude of the auto-inhibitory effect of the PH domain was sensitively 
dependent on the phosphorylation status of Akt1. In comparison to the activity of 
full length Akt1 phospho-variants, deletion of the PH domain significantly 
increased activity. In comparison to singly phosphorylated Akt1 variants, the 
auto-inhibitory effect of the PH domain was strongest (295-fold) in the most 
active and doubly phosphorylated Akt1 variant. Interestingly, the doubly 
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phosphorylated Akt1 displayed an increase in activity upon PH domain deletion 
that was greater than the sum of the effects observed for the singly 
phosphorylated Akt1 variants. The data suggest a novel finding that the PH 
domain dampens the activity of Akt1 variants in a phosphorylation-dependent 
manner. 
The combination of phosphorylation and PH domain release regulate the 
kinase activity of Akt1 over a 400,000-fold range. The data indicate the degree to 
which the un-phosphorylated PH-in conformation of Akt1 is suppressed in 
comparison to the PH-out doubly phosphorylated version of the enzyme that 
exists at the plasma membrane in living cells. Recent in vitro biochemical work 
suggested that association with PIP3 containing lipid vesicles stimulated the 
activity of a full length Akt1 protein by 7-fold (42). The authors suggested that 
this may be an underestimate due to low levels of phosphorylation (10% Thr308, 
1% Ser473) in their Akt1 prepared from Sf9 cells. Our data suggest release of the 
PH domain in the context of doubly phosphorylated Akt1 would lead to maximal 
activity increase of 300-fold; a PH domain dependent reduction of less than this 
value would indicate there may be significant interaction between the Akt1 
kinase and PH domains even in the PIP3 bound state at the plasma membrane.   
Indeed a recent debate in the literature (43) is underway to explain how Akt1 
activity can be maintained far from the membrane. Recent findings suggest that 
Akt1 is de-phosphorylated on a time scale of ~10 minutes following dissociation 
from PIP3 on the plasma membrane (44). Multiple nuclear substrates of Akt1 are 
known to be phosphorylated much more rapidly, on a time scale of seconds (45). 
Although the authors suggested that all or perhaps most of the active Akt1 is 
membrane-associated (44), this finding disputes several independent studies 
identifying many cytosolic and nuclear targets of Akt1-dependent 
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phosphorylation. Multiple studies clearly identified both phospho-Akt1, e.g., (45-
47), and directly measured Akt1 activity in the nucleus (10). Using a fluorescent 
reporter that quantifies Akt1 activity in live cells in real time, Kunkel and 
Newton observed Akt1 activity distributed in both the cytoplasm and nucleus on 
a time scale of seconds to minutes following growth factor stimulation. Their 
data further show similar levels of Akt1 activity in the nucleus and cytoplasm, 
with a delay in the peak activity in the nucleus of ~2 minutes. Additional 
experiments confirmed this lag is related to the time it takes for active Akt1 to 
translocate from the plasma membrane to the nucleus (10). In light of our data 
and these findings, the membrane associated Akt1 is likely significantly more 
active than doubly phosphorylated Akt1 found in the nucleus and cytosol. 
Phosphorylated Akt1, nevertheless, does persist away from the membrane, 
retaining significant activity in comparison to the un-phosphorylated Akt1. 
 
3.5.2 Phosphorylation-Dependent Chemical Inhibition of Akt1. Post-
translational-modifications, of which phosphorylation is the most common, are a 
ubiquitous mechanism that cells use to tune the activity of individual proteins 
and increase the functional diversity of the proteome. Phosphorylation can have 
a significant impact on the activity of proteins, kinases are a prime example, and 
phosphorylation status of a protein target can accordingly impact the ability of 
small molecules to inhibit enzyme activity. In the experiments presented here, we 
determined precisely how the phosphorylation-status of Akt1 influences the 
repression of kinase activity by chemical inhibition. We investigated the Akt-
specific allosteric inhibitor Akti-1/2. Based on the results of our assays, the 
phosphorylation status of Akt1 can indeed influence the degree to which Akti-1/2 
is able to act on Akt1. Akti-1/2 was most effective at inhibiting pAkt1T308, whereas 
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phosphorylation at position Ser473 in either pAktS473 or ppAktT308/S473, reduced the 
relative effectiveness of the inhibitor by a factor of 4.  
Ser473 phosphorylation appears to act as a built-in mechanism of drug 
resistance for Akt1. It is well established that hyper-phosphorylation of Akt1 at 
both regulatory sites is linked to poor prognoses and therapeutic resistance (3-
6,48). The accepted model for Akti-1/2 activity suggests that the compound locks 
Akt1 into the auto-inhibited or PH-in confirmation and prevents Akt1 from 
binding PIP3 in the plasma membrane, inhibiting phosphorylation at Thr308 and 
Ser473 (49). Our data also suggest that although limited by Ser473 
phosphorylation, the Akti-1/2 has significant activity in inhibiting the pre-
phosphorylated Akt1 variants that the inhibitor initially encounters in the cell. 
Studies in cell culture and mouse models show that the short-term impact of 
Akti-1/2 treatment is that pThr308 and pSer473 levels are depleted within hours. 
A related allosteric Akt inhibitor, and the most clinically promising (50) 
compound, MK-2206 significantly reduces Ser473 phosphorylation after 10 hours 
in mouse models with patient derived xenografts of endometrial tumors (51).  
Surprisingly, breast cancer cells (BT474) treated with Akti-1/2 (1 µM) showed 
a rebound effect in Akt1 phosphorylation status following Akti-1/2 treatment. 
These cells have amplified HER2 genes and constitutively activate the PI3K/Akt 
signaling cascade. In short term experiments (minutes to hours), Akt1 
phosphorylation reduces in response to inhibitor treatment, but at longer times 
(2-3 days) Akt1 phosphorylation status returns to stimulated levels in these 
cancer cells. In this longer time frame, phosphorylation of downstream Akt1 
target, S6K, was not restored, but PRAS40 phosphorylation was partially restored 
concomitant with increased Akt1 phospho-status. The study provided evidence 
that Akti-1/2 ultimately induces the expression and activation of receptor 
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tyrosine kinases EGFR, HER3, and HER4, which in turn re-activate Akt1 (52). 
Interestingly, in mouse models a similar rebound in Ser473 phosphorylation 
following treatment with MK-2206 was observed on time courses of 5 to 20 days 
(53). In these cases, Ser473 phosphorylation may provide the tumor cell with a 
means to reduce the effectiveness of Akt1 inhibitor. The data suggest the need to 
develop an inhibitor that is more effective towards the most active and doubly 
phosphorylated form of Akt1. 
 
3.5.3 Synthetic Biology Approach to Generate Active Akt1. In our current study, 
and previous work (11,17-19), we demonstrated that genetic code expansion with 
pSer in E. coli provides a simple route to produce designer phosphoproteins. 
Here, we have produced differentially phosphorylated Akt1 variants with and 
without the PH domain in E. coli using genetic code expansion and enzymatic 
phosphorylation in E. coli. We found that the variants lacking the PH domain 
were produced at significantly higher yield compared to the full length Akt1 
protein. The ability to produce recombinant Akt1 protein with programmed 
phosphorylation(s) was essential for our investigations in the role of each 
phospho-site in Akt1 inhibition.  
In comparison with our previous work (11), we found the system we 
developed to produce Akt1 with either or both regulatory phosphorylation sites 
(Figure 3.2) leads to a consistently active Akt1 variant with indistinguishable 
batch to batch variability. This is in contrast to the commercially available Akt1 
produced in using Sf9 cell system followed by in vitro PDK1 phosphorylation of 
Thr308 (25). We observed a vast batch-to-batch variability of enzyme activity in 
the commercially available Akt1, which warrants cautious attention in its 
experimental use. Previous work also established that Akt1 produced in Sf9 cells 
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leads to a mixture of singly and doubly phosphorylated Akt1 variants (26) at 
times leading to a low stoichiometry of phosphorylation (42) (Figure 3.3B). Our 
approach consistently results in site-specifically phosphorylated and active Akt1 
variants that provide a reliable and consistent source of protein that for 
biochemical studies and applications in inhibitor screening. 
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3.7 Supporting information: 
3.7.1 Supporting experimental procedures 
Affinity column chromatography. The His-tagged proteins were purified using 
Ni affinity column chromatography. 0.5 ml of Ni-NTA resin (Thermo-Fisher 
Scientific) was used for 1 l of E. coli culture. The cell lysates (see Methods) were 
loaded into the column (2 ml column volume) and washed with 20 column 
volumes of wash buffer A (20 mM Hepes, 150 mM NaCl, 3 mM β-
mercaptoethanol, 3mM Dithiothreitol, 1 mM Na3VO4 and 5 mM NaF, 15 mM 
imidazole) followed by 10 column volumes of wash buffer B (20 mM Hepes, 150 
mM NaCl, 3 mM β-mercaptoethanol, 3mM DTT, 1 mM Na3VO4 and 5 mM NaF, 
20 mM imidazole). Protein was eluted using an elution buffer (20 mM Hepes, 150 
mM NaCl, 3 mM β-mercaptoethanol, 3mM dithiothreitol, 1 mM Na3VO4 and 5 
mM NaF) with 75 mM Imidazole. The same protocol was used for Akt1 variants 
with phosphomimetic mutations except: 1) phosphatase inhibitors were excluded 
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from the buffers, 2) the imidazole concentrations of the wash buffers were 20 - 50 
mM, and 3) the imidazole concentration of the elution buffer was 200 mM. 
Fractions were run on 10% SDS (sodium dodecyl sulfate) poly-acrylamide gels. 
As detailed previously [1], Akt1 variants were further purified by size exclusion 
chromatography.  
3.7.2 Supporting References 
1. Balasuriya, N.; Kunkel, M.T.; Liu, X.; Biggar, K.K.; Li, S.S.; Newton, A.C.; 
O'Donoghue, P. (2018) Genetic code expansion and live cell imaging reveal 
that thr308 phosphorylation is irreplaceable and sufficient for akt1 activity. 
J Biol Chem, 293, 10744-10756 
2. George, S.; Aguirre, J.D.; Spratt, D.E.; Bi, Y.; Jeffery, M.; Shaw, G.S.; 
O'Donoghue, P. (2016) Generation of phospho-ubiquitin variants by 
orthogonal translation reveals codon skipping. FEBS Lett, 590, 1530-1542 
 
3.7.3 Supporting Tables 
Supplementary Table S3.1 Plasmids used in this study 
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Plasmid ID Plasmid 
backbone 
Selectable 
marker 
Inserted 
genes 
Genetic 
modifications 
Protein product 
(1) WT Akt1 pDS0 (pUC) 
[2] 
Amp AKT1 None. Akt1, unphosphorylated.   
(full-length, inactive)  [1] 
(2) WT Akt1-
PDK1 
pCDF-Duet-1 Strep AKT1 
PDK1 
None. Akt1, phosphorylated at 
position T308.  
(full-length, active)  [1] 
(3) Akt1 
UAG473  
pCDF-Duet-1 Strep AKT1 UAG mutation at 
position 473 in 
AKT1. 
Akt1, phosphorylated at 
position S473.  
(full-length, slightly 
active) [1] 
(4) Akt1-UAG473-
PDK1 
pCDF-Duet-1 Strep AKT1 
PDK1 
UAG mutation at 
position 473 in 
AKT1. 
Akt1, phosphorylated at 
positions T308 and S472.  
(full-length, highly 
active)  [1] 
(5) pSer-OTS pDS-pSer2 Kan tRNAsep 
(5x) 
SepRS9 
EFSep21 
This system is 
comprised of the 
2nd generation 
mutants of the 
pSer incorporation 
system. 
pSer orthogonal 
translation system, 
capable of decoding 
UAG codons and 
incorporating pSer into 
nascent peptides  [2] 
(6) ΔPH-WT Akt1 pDS0 (pUC) 
[2] 
Amp AKT1 Deletion of the PH 
domain from AKT1 
(Δ residues 2-109). 
ΔPH-Akt1, 
unphosphorylated.   
(truncated, inactive) 
(7) ΔPH-WT Akt1-
PDK1 
pCDF-Duet-1 Strep AKT1 
PDK1 
Deletion of the PH 
domain from AKT1 
(Δ residues 2-109). 
ΔPH-Akt1, 
phosphorylated at 
position T308.  
(truncated, active) 
(8) ΔPH-Akt1- 
UAG473  
pCDF-Duet-1 Strep AKT1 Deletion of the PH 
domain from AKT1 
(Δ residues 2-109). 
UAG mutation at 
position 473 in 
AKT1 
ΔPH-Akt1, 
phosphorylated at 
position S473.  
(truncated, slightly 
active) 
(9) ΔPH-Akt1 
UAG473-PDK1 
pCDF-Duet-1 Strep AKT1 
PDK1 
Deletion of the PH 
domain from AKT1 
(Δ residues 2-109). 
UAG mutation at 
position 473 in 
AKT1. 
ΔPH-Akt1, 
phosphorylated at 
positions T308 and S472.  
(truncated, highly active) 
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3.7.4 Supporting Figures 
 
Figure S3.1 Mass spectra confirming genetically encoded phosphoserine in 
ΔPH-ppAkt1. Tryptic digested peptides of ΔPH-ppAkt1T308,S473 were subjected to 
MALDI-TOF mass spectrometry The C-terminal peptide of ΔPH-Akt1 carrying a 
single phosphorylation was readily detected. The isotopic masses of the peptide 
carrying the most abundant peak of 12C isotope (observed m/z = 1845.8923; 
expected m/z = 1845.8378) and the 3 consecutive peaks with 13C isotopes (m/z = 
1846.8923, 1847.8923, 1848.8923, respectively) are shown. 
 
1846.8923
1847.8923
1848.8923
1845.8923
igure S1. Mass spectra onfirmi g genetically encoded phosphoserine in ΔPH-pAkt1. 
Tryptic digested peptides of ΔPH-ppAkt1T308, S473 were subjected to MALDI-TOFF mass 
spec analysis and the C-terminal peptide of ΔPH-Akt1 carrying a single 
phosphorylation was detected. 
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Figure S3.2 Initial velocity measurements for highly active ΔPH Akt1 variants. 
(A) ΔPH-ppAkt1T308, S473 and (B) ΔPH-pAkt1T308 were diluted by 10-fold and 100-
fold, respectively, to obtain a linear range of increasing enzyme activity. Initial 
velocities were calculated using the data points at the linear range of 100-fold 
diluted enzyme. 
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Figure S3.3 Inhibition of the full length Akt1 variants incubated with Akti-1/2 
inhibitor VIII. (A) ppAkt1T308, S473, (B) pAktT308, (3) pAkt1S473 variants were 
incubated with increasing concentrations (0.001 uM to 10 uM) of Akti1/2. Error 
bars indicate 1 standard deviation based on triplicate experiments.  
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Figure S2: Enzyme inhibition curves of the full length Akt1 variants incubated with inhibitor Akti1/2. (A) ppAkt1T308, S473, (B) 
pAktT308, (3) pAkt1S473 variants were incubated with increasing concentrations (0.001 uM to 10 uM) of Akti1/2  and the reactions were 
monitored over a 10 min time period. Different colors represent different concentrations in each variant.
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Figure S3.4 Autoradiographs of Akt1 inhibitor assays with ppAkt1T308, S473. Time 
courses are shown for the reaction catalyzed by ppAkt1T308,S473 with the indicated 
concentrations of inhibitor Akti1/2. Assays were performed in triplicate (as 
indicated by R1-R3). Controls include: C1 without substrate peptide, C2 without 
enzyme, C3 only kinase assay buffer.    
 
C1 C
2
R1         R2     R3 R1        R2       R3 R1    R2      R3
2 min
5 min
10 min
2 min
5 min
10 min
0.5 μM
ppAkt1 DMSO 0.001 μM
1 μM5 μM
5 min 2 min
0.05 μM
2 min
10 min
10 min
5 min0.001 μM
C3
Figure S3: Autoradiographs of Akt1 inhibitor assays with ppAkt1T308, S473 variants. Time courses are shown for the reaction catalyzed by 
ppAkt1T308,S473 with varying concentrations of inhibitor Akti1/2. Assays were performed in triplicate (as indicated by R1-R3). Controls include:
C1 without substrate peptide, C2 without enzyme, C3 only kinase assay buffer.
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Figure S3.5 Autoradiographs of Akt1 inhibitor assays with pAkt1T308. Time 
courses are shown for the reaction catalyzed by pAkt1T308 with the indicated 
concentrations of inhibitor Akti1/2. Assays were performed in triplicate (as 
indicated by R1-R3). Controls include: C1 without substrate peptide, C2 without 
enzyme, C3 only kinase assay buffer.    
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Figure S4: Autoradiographs of Akt1 inhibitor assays with pAkt1T308 variant. Time courses are shown for the reaction catalyzed 
by pAkt1T308 with varying concentrations of inhibitor Akti1/2. Assays were performed in triplicate (as indicated by R1-R3). Controls 
include: C1 without substrate peptide, C2 without enzyme, C3 only kinase assay buffer.
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Figure S3.6 Autoradiographs of Akt1 inhibitor assays with pAkt1S473. Time 
courses are shown for the reaction catalyzed by pAkt1S473 with the indicated 
concentrations of inhibitor Akti1/2. Assays were performed in triplicate (as 
indicated by R1-R3). Controls include: C1 without substrate peptide, C2 without 
enzyme, C3 only kinase assay buffer.    
 
 
Figure S5: Autoradiographs of Akt1 inhibitor assays with pAkt S473 variants. Time courses are shown for the reaction catalyzed by 
pAkt1S473 with varying concentrations of inhibitor Akti1/2. Assays were performed in triplicate (as indicated by R1-R3). Controls include: C1 
without substrate peptide, C2 without enzyme, C3 only kinase assay buffer.
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Chapter 4  
 
 
4 Phosphorylation-dependent substrate selectivity of Akt1 
 
4.1 Abstract 
Protein kinase B (Akt1) is a central node in a signaling pathway that regulates cell 
survival. The diverse pathways regulated by Akt1 are communicated in the cell 
via the phosphorylation of perhaps as many as ~100 different cellular substrates. 
Akt1 is itself activated by phosphorylation at Thr308 and Ser473. We recently 
developed a method to produce Akt1 with programmed phosphorylation at either 
or both key regulatory sites. This breakthrough previously enabled resolution of 
the contribution of each phospho-site to the activation of Akt1. Here we used both 
defined and randomized peptide libraries to map the substrate selectivity of singly 
and doubly phosphorylated Akt1 variants. To globally quantitate Akt1 substrate 
preferences we synthesized two Akt1 substrate peptide libraries: one based on 84 
“known” substrates and a larger oriented peptide array library (OPAL) of 1011 
peptides. The data revealed that each phospho-form of Akt1 has distinct substrate 
requirements. Surprisingly, phosphorylation of Ser473 in the context of a pAkt1T308 
enzyme led to increased activity on some, but not all Akt1 substrates. This is the 
first report that Ser473 phosphorylation does not simply increase Akt1 kinase 
activity, rather we found that phosphorylation at Ser473 modulates global 
substrate preferences by selectively increasing, decreasing or not altering activity 
compared to the kinase singly phosphorylated at Thr308. We also verified a new 
Akt1 target as the terminal nucleotidyltransferase (germline development 2) Gld2. 
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Our data show that Akt1 site-specifically phosphorylates Gld2 at Ser116. Together 
these data suggest new and expanded roles for Akt1 signaling in regulating 
cellular processes. 
4.2 Introduction 
Protein kinase B (PKB, Akt1) is a central node in the Phosphoinositide 3-
kinase (PI3K)/Akt signaling pathway that regulates cell survival. There are three 
isozymes of Akt (Akt1, Akt2, Akt3) identified in mammalian cells (1) with both 
distinct and overlapping roles. Akt1 is an oncogenic kinase that is overactive and 
hyper-phosphorylated in most cancers and a prime target in cancer therapy (2). 
Although direct Akt1 inhibitors have not been generally successful as 
monotherapies (3), Akt1 inhibitors show promise in combination with, e.g., 
mitogen-activated protein kinase inhibitors (4). Activated Akt1 phosphorylates 
downstream targets that regulate many cellular processes including cell survival 
and apoptosis (5). The diverse cellular functions of Akt1 are mediated by its ability 
to phosphorylate perhaps as many as hundreds of cellular substrates, although the 
precise number is not known. Based on a large number of reports from the 
literature, a catalog of ~200 known Akt substrates have been reported (6).  
At present it is unclear if all of these substrates are truly phosphorylated by 
Akt1 or to what extent these substrates are differentially phosphorylated by active 
Akt1. Because the downstream phosphorylation profile of active Akt1 determines 
which cellular programs are turned on or off by the enzyme, the ability to identify 
novel Akt1 substrates will have significant impact on target selection and drug 
discovery in Akt1 mediated chronic diseases such as cancer (1) and diabetes (7).  
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We recently developed an approach to produce Akt1 variants with site-
specific phosphorylation at either or both key regulatory sites (8,9). Here we show 
the method provides an indispensable tool for identifying the role of Akt1 
phosphorylation status in substrate selectivity. The substrate selectivity associated 
with specific Akt1 phospho-forms is challenging to resolve in the complex 
environment of the cells (10). The phosphorylation status of Akt1 substrates  
depend on many factors including the expression level and cellular localization of 
Akt1 substrates as well as the off-rate of phosphate on these substrates as a result 
of phosphatase activity (11). However, there remains a lack of understanding 
regarding how the two key activating phosphorylation sites on Akt1 lead to 
differences in substrate selection and downstream substrate phosphorylation (10).  
The minimal Akt substrate recognition motif is R-5 X-4 R-3 X-2 X-1 S/T0 ϕ+1. X 
represents any amino acid except Thr, Cys; ϕ represents a bulky hydrophobic 
residue (Phe, Tyr etc.) and the phospho-accepting site is a Ser or Thr residue (12). 
This motif was further validated through oriented peptide array library (OPAL) 
screens where the -5 position was Arg and specific amino acids were designated 
to -1, -2, +1 and +2 positions (13). The Akt target consensus was initially determined 
using the amino acid sequences surrounding the phosphorylation site of the first 
reported Akt substrate: glycogen synthase kinase 3 (GSK-3 ) (12). Arg residues at 
position -3 and -5 were found to be specific to Akt whereas other AGC family 
kinases such as the S6 kinase (S6K1), prefer Lys at -3 and -5 positions (10). Peptide 
library screening is a gold standard method that has been widely used to 
determine specific amino acid preferences of the kinase substrate recognition 
motif. Degenerate peptide libraries or OPAL screens provide a systematic 
approach to identify the important residues surrounding the phosphorylation site 
on the substrate (13,14).  
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Here we synthetized designed and randomized (OPAL) peptide libraries to 
define the substrate requirements for differentially phosphorylated Akt1 variants. 
We discovered that the phosphorylation status of Akt1 has a significant impact on 
substrate selectivity and on the specific residue preferences at each location in the 
consensus motif. Akt1 kinase activity data over the OPAL library was used to 
generate a score matrix that we used to rank putative novel Akt1 targets in the 
human proteome. We validated one of these predicted Akt1 targets, the terminal 
nucleotidyl transferase Gld2 (15). 
  
4.3 Materials and Methods 
 
4.3.1 Bacterial strains and plasmids. A codon optimized human AKT1 gene 
lacking the PH domain was synthesize at ATUM (Newark, California, USA) and 
sub-cloned (NcoI/NotI) into an isopropyl β-D-1-thiogalactopyranoside (IPTG) 
inducible T7lac promoter driven pCDF-Duet vector with CloDF13-derived CDF 
replicon and streptomycin/spectinomycin resistance (pCDF-Duet1-ΔPHAkt1). The 
human PDPK1 gene, which was acquired from the Harvard PlasmidID repository 
service (HsCD00001584, Boston, MA, USA), was sub-cloned (KpnI/NdeI) into the 
second multiple cloning site of pCDFDuet-1. The codon for the residue in AKT1 at 
position Ser473 was mutated to the amber (TAG) codon in the synthetic gene from 
ATUM. Successful cloning was verified by DNA sequencing (London Regional 
Genomics Centre, London, ON, Canada and Genewiz, Cambridge, MA, USA).  
 
4.3.2 Protein and phosphoprotein production. Un-phosphorylated and 
phosphorylated forms of Akt1 (pAkt1S473, pAkt1T308, ppAkt1T308,S473) were produced 
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according to previously described methods (8,16) (See also the methods and SI 
sections Chapters 2 and 3). 
 
4.3.3 Library of known Akt1 substrate peptides. Based on reports from the 
literature collated at the Phosphosite database	(6), we selected 84 different peptides 
to generate a library of ‘known’ Akt1 substrates. The substrate motifs derived from 
these Akt1 substrates were synthesized in the following form: biotin-AX-6-X-
1S0/T0X1-X6YRR. The phosphorylation site (Ser or Thr) is located at the 0 position. 
Each individual in-solution peptide was synthesized according to previously 
reported methods (17). 
 
4.3.4 Alanine scanning. In my previous studies of Akt1 (8,12) (Chapters 2-3), the 
GSK-3β substrate peptide was used to assay a wide variety of phosphorylated 
Akt1 variants. To identify critical residues for the activity of each Akt1 phospho--
variant, a series of 12 GSK-3β derived peptides were synthesized with one of the 
positions substituted to alanine. The in-solution peptides were synthesized 
according to previously reported methods (17).  
 
4.3.5 OPAL Akt1 activity screen. An oriented peptide library was designed as a 
series of soluble library pools according to previously reported methods (14). The 
known consensus sequence of Akt1 phosphorylation, which is biotin-AGGX-6X-5X-
4R-3X-2X-1S0X1X2X3, was used as the design for library synthesis. X represents any 
amino acid other than Ser, Thr or Cys. The phosphorylatable residues (Ser, Thr) 
were excluded from the screen to avoid false positive signals when probing 
position S0. Each of the 17 other canonical amino acids are tested in X positions. 
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The -3 and 0 positions were fixed to Arg and Ser, respectively, where 0 position is 
the phosphorylation site and R-3 is essential for substrate phosphorylation by Akt1 
(12). In each of 128 distinct sub-library pools, one of the X positions was fixed to 
one specific amino acid and every other X position was randomized. The total 
library contains 1011 peptides. 
 
4.3.6 Sequence Logos and database searching. Sequence logos of substrates 
corresponding to each Akt1 variant were generated using WebLogo version 2.8.2 
(18) or Seq2Logo 2.0 (19) as indicated.  Using the data in Figure 4.1, we generated 
an alignment of known peptides in which the population of each peptide was 
linearly related to its activity level. The resulting peptide alignment was, thus, 
most populated by the highest active peptides and least populated by the low 
active peptides. This allow us to convert the activity data over known peptides 
using WebLogo (Figure 4.3).  
Using the OPAL data we generated position-specific scoring matrices 
(PSSMs) according to a similar method used in Scansite (20). For each data set, a 
selectivity matrix was calculated by dividing all activity values by the average 
value for the complete array, i.e, a selectivity factor. A scoring matrix was 
computed as the natural log of the selectivity matrix. Finally, the raw scoring 
matrices were scaled by a factor of 10 multiplied by the selectivity factor for each 
data set. The resulting PSSMs based on each OPAL data set were used to produce 
sequence logos with the program Seg2Logo 2.0 (19). The PSSM-Logo was 
computed using default values.  
As an alternate approach to generate a PSSM, we also converted the OPAL 
activity data to a set of Z-score matrices as before (21).  The preference rank of each 
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substrate was statistically determined and assigned a z score. The formula is given 
below. 
 𝑍𝑖	𝑠𝑐𝑜𝑟𝑒 = 𝑋𝑖 − 𝑋′𝑆  
Xi= activity value of ith peptide sub-library, X’= mean activity over entire peptide 
library, S=standard deviation of activity over entire peptide library. 
 
The known human phospho-proteome was scored based on the amino acid 
preferences at each position in the z-score PSSM. The sum z-scores at each position 
in the target peptide was used to rank all peptides covering the human proteome. 
 
4.3.7 NIH 3T3 cell culture. NIH 3T3 cells were purchased from American type 
culture collection (CRL-1658), Manassas, VA, USA. Cells were grown at 37°C with 
5% CO2 in Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 4 
mM L-glutamine, 4.5 g/L glucose, 1 mM sodium pyruvate, 1.5 g/L sodium 
bicarbonate (Wisenet, 319-007-CL), 1% pen-strep solution (Fisher Scientific, 
15140122) and bovine calf serum (ATCC, 30-2030). Cells were grown until 80% 
confluence and passaged. Cells grown to 3 passages were used for the kinase 
assays. Cells were harvested with 0.25% (v/v) trypsin-ethylenediaminetetraacetic 
acid (EDTA) and incubated with cell lysis buffer (50 mM Tris-HCl, 1% Triton-100, 
150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS) pH 7.5) for 5 min on ice. 200 µL 
of lysis buffer was added per well of a 6-well plate. Cell lysate was centrifuged at 
38000 ´ g at 4 °C for 10 min. Supernatants were transferred to sterile micro-
centrifuge tubes and lysate protein concentrations were determined using a 
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Bradford assay according to manufacturer’s instructions (Bio-Rad Laboratories, 
CA, USA). 
 
4.3.8 Kinase assay for peptide libraries. Kinase assays with peptides or peptide 
sub-libraries in dimethyl sulfoxide (DMSO) solution were conducted using 
radiolabeled γ-[32P]-ATP according to previously reported methods (8) with slight 
modifications as following: Akt1 activity was determined using 400 µM substrate 
peptide for the known substrate library. The substrate concentration for the OPAL 
library was 1 mM.  0.3 ng of kinase was incorporated per reaction. Each assay was 
conducted in triplicate. 
 
4.3.9 Kinase assay with NIH 3T3 cell extracts. The NIH 3T3 cell extracts in lysis 
buffer were dialyzed into ATP free kinase assay buffer (25 mM 3-(N-
morpholino)propanesulfonic acid (MOPS) pH 7.0, 12.5 mM β-
glyceraldehydephosphate, 25 mM MgCl2, 5 mM ethylene glycol-bis(β-aminoethyl 
ether-N,N,N’,N’-tetraacetic acid (EGTA), 2 mM EDTA) using an Amicon ultral-0.5 
ml centrifugal device. Cellular proteins (18 µg) from the lysates were incubated 
with 0.1 µg of the indicated Akt1 enzyme variant in 30 µL kinase assay buffer 
containing 0.2 mM unlabeled ATP and 33 nM γ-[32P]-ATP. 10 µL from each 
reaction were taken at 20 min and 80 min time points and boiled for 10 min in 3X 
SDS loading dye (1 M Tris-HCl pH 6.8, 0.38 g/mL sucrose, 0.1 % bromophenol blue, 
20% SDS, 3% (V/V) β-mercaptoethanol) and boiled for 10 min. Samples were 
rissolved on a 10% polyacrylamide SDS gel, wrapped in plastic wrap, and placed 
on a Whatman paper, and wrapped in Ceran wrap. The gel was exposed to a 
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phosphorimaging screen overnight at -80 °C and visualized with a 
phosphorimager (Storm 860 Molecular Imager). 
 
4.3.10 Kinase assay with Gld2 protein substrate. Gld2 was purified as described 
previously (15). 30 µL reaction containing 1.5 µg Gld2 in kinase buffer (20 mM 
MOPS [pH 7.0], 25 mM β-glyceraldehydephosphate, 25 mM MgCl2, 5 mM EGTA 
[pH 8.0], 1 mM Na2VO4, 0.1 mM ATP, 13.2 nM γ-[32P]-ATP) and Akt1 (33 nM) or 
CK2-α (25 nM) kinases were incubated at 37°C shaking for 15 minutes. Samples of 
5 µl were taken after 10 minutes and the reaction was stopped by spotting on P81 
paper. The P81 paper was washed with 1% phosphoric acid, air dried, exposed to 
a phosphor screen over night and visualized with the Storm 860 Molecular Imager. 
Purified CK2-α kinase was used as kinase control and was a generous gift from 
Dr. David Litchfield.  
 
 
4.4 Results 
 
4.4.1 Akt1 phosphorylation status alters selectivity among known substrates. 
Phosphoinositide dependent kinase (PDK1) site specifically phosphorylates Akt1 
at Thr308, while the upstream kinase of S473 is unknown.  Using a combination of 
genetic code expansion to encode phosphoserine at S473 and co-expression of 
PDK1, we were able to produce active full length and PH domain truncated Akt1 
variants in E. coli with either or both Thr308 and Ser473 sites phosphorylated 
(Figure S4.1, (8,9)). In previous work, we discovered that the traditional 
phosphomimetics are incapable of replacing or approximating the functionality of 
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phosphorylated Ser and Thr at the activation sites of Akt1 and that alanine 
substitutions at these sites also disable the enzyme (8). The significance of our 
approach is the ability to generate pAkt1 and ppAkt1 variants without the need 
for amino acid substitutions with phosphomimetics.  
 Our previous studies on pAkt1 and ppAkt1 variants focused on their 
differential activity with a single substrate peptide derived from GSK-3β (8). Here 
we quantified the substrate preference for phosphorylated Akt1 variants using a 
synthetic peptide library of known Akt1 substrates. We found that the deletion of 
the PH domain abolishes its auto-inhibitory activity and leads to more soluble 
enzyme (9) appropriate for larger scale screening studies presented here.  
Currently “known” Akt1 substrates have been identified and in some cases 
validated using multiple different experimental approaches, including in vitro 
biochemical (22) and cell-based activity assays (23), proteomic analysis (24), as well 
as immunoblotting (25) in cells (26) and animals (27).  
Our study allowed the evaluation of these distinctively reported substrates 
using one systematic platform to quantify Akt1 kinase activity. The doubly 
phosphorylated Akt1 was capable of phosphorylating most, but not all, of the 
substrate peptides in the library. The ppAkt1 enzyme showed significantly above 
background activity with 95% of the peptides tested (Figure 4.1A). In our activity 
assays, the initial reaction velocity varied over an 80-fold range; ppAkt1 produced 
between 0.1-8.0 pmol/min of phosphorylated peptide.   
Overall the level of phosphorylation observed was markedly lower with 
pAkt1S473 compared to pAkt1T308 and the ppAkt1T308, S473 (Figure 4.1). Compared to 
the singly phosphorylated variants (Figure 4.1BC), ppAkt1T308, S473 usually 
displayed more activity and was active over the widest range of substrate peptides. 
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Indeed, we observed a clear trend in activity over the library with pAkt1S473 
showing the most restricted substrate range (82% of the library) compared to the 
variants phosphorylated at Thr308 (5% of the library) and ppAkt1 (8 % of the 
library).   
In comparing singly and doubly phosphorylated Akt1, it is clear that the 
three variants have distinct preferences for particular peptides. The highest active 
substrates for pAkt1S473 variant were completely orthogonal to or distinct from the 
most active substrates with pAkt1T308 or ppAkt1T308, S473 (Figure 4.2).  
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Figure 4.1 Phosphorylation of known substrate peptides by Akt1 variants. The 
activity (pmol of phosphorylated peptide following a 10 minute reaction) of (A) 
pAkt1S473 (B) pAkt1T308 (C) and ppAkt1T308,S473  variants with each of the 84 different 
“known” Akt1 substrate derived peptides. Gene names for each substrate are 
provided on the horizontal axis. For substrates with multiple phosphorylation 
sites, separate peptides were synthesized and are indicated by the phosphorylation 
site residue number in parentheses. All experiments were performed in triplicate; 
error bars represent ± 1 SD. A minority of the peptides did not support activity that 
was significantly above background (ns). 
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The pAkt1S473 variant was most active with substrates (Figure 4.2A) that 
were completely distinct from those observed for pAkt1T308 variant. To visualize 
these distinct substrate preferences, we generated a Search Tool for Retrieval of 
Interacting Genes/Protein (STRING) diagram (28), including nodes representing 
all 84 substrates in the library. Overlaid on the STRING diagram we highlighted 
the most (>50% activity) and least (< 10% activity) active substrates associated with 
each of the Akt1 phospho-forms (Figure 4.2).  
The Fork head box O (FOXO) family of transcription factors are well-
established substrates of Akt1 (25,29). The FOXO family transcription factors were 
among the most active substrates with Akt1 phosphorylated only at Thr308.  
Indeed, we found that the FOXO target peptides were among the highest activity 
for both Akt1 variants phosphorylated at Thr308, pAkt1T308 and ppAkt1T308,S473 
(Figure 4.2B, 4.2C). We also observed that while FOXO1 was among the highest 
active peptide substrates with pAkt1S473, the enzyme singly phosphorylated at S473 
displayed low activity with peptides derived from other FOXO family members.  
Certain substrate peptides, e.g., including FOXOs and TSC2, carried more 
than one phosphorylation site, which we represented with distinct synthetic 
peptides. Each Akt1 phospho-variant showed different preferences for the 
multiple sites in these substrates. For example, with pAkt1S473, Ser256 and Ser319 
of FOXO1 showed relatively high activity, but this enzyme showed low activity 
with a peptide derived from FOXO1 Thr24. In contrast, for both pAkt1T308 and 
ppAkt1T308,S473 FOXO1 Ser319 was the least preferred compared to Ser256 and 
Thr24.  
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Figure 4.2 String diagrams showing the interactions among highly active 
peptide substrates of Akt1 variants. (A) Highly active phosphorylated substrates 
of pAkt1S473 shared a unique profile, which was not shared by the other two 
variants (B) pAkt1T308 variant phosphorylated substrates showed a similar profile 
to the doubly phosphorylated variant. (C) Highly active phosphorylated 
substrates of ppAkt1T308,S473 included most of the FOXO transcription factors. 
 
A B 
C 
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Figure 4.3 Comparison of substrate preferences of ppAkt1T308,S473 with pAkt1T308. 
Red bars represent the substrate peptides arranged in increasing order of 
ppAkt1T308,S473 activity. The corresponding pAkt1T308 phosphorylated substrates are 
shown in blue. Gene names of each substrates where the peptides synthesis was 
based on are given in X axis. Phosphorylation sites are given within brackets for 
peptides carrying more than one phosphorylation site. Error bars represent ±1 SD.   
 
To better understand the impact of Ser473 phosphorylation on the activity 
of the doubly phosphorylated Akt1, we plotted kinase activity data of pAkt1T308 
and ppAkt1T308,S473 together (Figure 4.3). We analyzed these comparative data for 
statistically significant differences. Interestingly, we observed that additional 
phosphorylation at Ser473 significantly increased Akt1 activity for many (90%) but 
not all Akt1 substrates.  
In the context of Akt1 phosphorylated at Thr308, we found that addition of 
phosphorylation at Ser473 actually decreased the activity of several competent 
Akt1 substrates. Phosphorylation at Ser473 reduces activity for all four peptides 
derived from distinct sites in the FOXO4 transcription factor, two distinct sites in 
Figure 3: Comparison of substrate preferences of ΔPH ppAkt1T308,S473 with ΔPH pAkt1T308. Red bars represent the substrate 
peptides arranged in increased order of activity. The corresponding ΔPH pAkt1T308 phosphorylated substrates are shown in blue. 
Gene names of each substrates where the peptid s synthesis was based on are given in X axis. Phosphorylation sites are given 
within brackets for peptides carrying more than phosphorylation site. Error bars represent ± 1 SD.
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FOXO1 and FOXO3 as well as sites in cyclin dependent kinase 2 (CDK2), Grb2 
associated binding protein (Gab2), CDC like kinase 2 (CLK2), and TSC complex 
subunit 2 (TSC2). Together the data show that both regulatory phosphorylation 
sites in Akt1 have a significant and unexpectedly complex impact on substrate 
selectivity over a library of known Akt1 substrates.  
 
4.4.2 Phosphorylation dependent changes in the Akt1 target motif. Based on the 
activity data in Figure 4.1, we computed sequence logos for each Akt1 phospho-
form. The logos (Figure 4.4) represent the key residues of importance in 
phosphorylation based on the activity level recorded for each substrate peptide 
(Figure 4.1). The sequence alignments used to generate the logos was populated 
with each of the 84 peptides such that the number of occurrences of each peptide 
in the alignment was linearly related to enzyme activity recorded in Figure 4.1.   
The importance of conserved consensus sequence residues R-5 and R-3 for 
Akt1 substrates (R-5-X-R-3-X-X-S/T) was observed with all three variants. As 
reported previously (12), the presence of a large hydrophobic residue following 
the phosphorylation site (+1 position) was observed among the peptides with all 
three Akt1 variants. Pro occupied the +2 position at the highest frequency in 
pAkt1T308 and ppAkt1T308, S473 variants, and the most active substrates tend to have 
Pro at +2. The +2 position favors amino acids capable of producing tight turns in 
protein structures. According to Obata and others Gly, Ser, Asn and Thr were also 
found to be favorable at this position (13). Peptide substrates showing high activity 
with pAkt1S473 variant were dominated by those peptides with a Ser rather than a 
Thr at the phosphorylation site. For pAkt1T308 and ppAkt1T308,S473, highly active 
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peptides were approximately equally likely to have Ser or Thr at the 
phosphorylation site.  
 
4.4.3 Alanine scanning of Akt1 target peptides. To provide additional data 
regarding essential amino acid residues for kinase activity with each 
phosphorylated Akt1 variant, we next synthesized peptides containing alanine 
substitutions at each position in the consensus motif (Figure 4.4). The consensus 
motif was derived from the activity data on the known substrates (Figure 4.1). For 
these studies, we chose a peptide derived from GSK-3β. Among known substrates, 
GSK-3β shows significant activity (>50% maximal) with each Akt1 phospho-form 
(Figure 4.1); peptides derived from GSK-3β are commonly used to assess Akt 
activity (8,12). 
 
 
Figure 4.4 Sequence logos representing the amino acid preferences adjacent to 
the Akt1 target motif. Sequence logos of (A) pAkt1S473 phosphorylated (B) pAkt1T308 
phosphorylated and (C) ppAkt1T308, S473  are  based on enzyme activity data in Figure 
4.1 as described in methods. The phosphorylation site is denoted by the 0 position. 
Sequence logos were created using the WebLogo server (18).  
 
Figure 4: Web-logos representing the amino acid preferences of the phosphorylation site of Akt1 substrates. Enzyme variants 
of (A) ΔPH pAkt1S473  phosphorylated (B) ΔPH pAkt1T308 phosphorylated and (C) ΔPH ppAkt1T308,S473 phosphorylated substrates 
were used to create the logos. The phosphorylation site is denoted by #0 in x axis.
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The pAkt1T308 and ppAkt1T308,S473 variants showed a similar response to each 
of the alanine substituted peptides, whereas the pAkt1S473 response was distinct 
(Figure 4.5). For each Akt1 variant, alanine mutation at the phosphorylation site 
abolished the enzyme activity to a level indistinguishable from background. R-3 
was essential for all three variants to be active. Arginine at -5 was important for 
pAkt1S473 activity, where an alanine substitution lead to only 0.4 pmol/min activity, 
a 9-fold reduction. pAkt1T308 did not show a significant (p<0.05) difference with the 
control at arginine -5, where in contrast, ppAktT308, S473 showed a 0.8-fold increased 
activity in comparison to the control peptide. Attesting to the robust activity of the 
ppAkt1 enzyme according to our previous studies, ppAkt1 displays higher activity 
for each Ala substitute peptide compared to the singly phosphorylated enzymes.  
 
 
4.4.4 Determination of high-resolution Akt1 target specificity. Our analysis of 
known substrates revealed several new facets of Akt1 enzymology, however, these 
data are biased by our current and perhaps limited knowledge of Akt1 substrate 
selectivity on 84 previously identified Akt1 substrates. We, therefore, designed a 
far larger, unbiased oriented library of peptides to test the most preferred amino 
acid residue at each site of the Akt1 substrate consensus motif. We synthesized 128 
different pools of peptide sub-libraries (see Methods) to cover the complete library 
of 1011 peptides. Using each phospho-form of Akt1, we conducted kinase assays 
with each of the substrate sub-libraries (Figures S4.1, S4.2, S4.3). In each sub-library 
a single amino acid is held constant for a single position in the consensus, while all 
other variable positions are allowed to cover the complete sequence space with the 
exception of Cys, Thr and Ser. The Akt1 activity for singly and doubly 
phosphorylated Akt1 variants over each peptide sub-library pools are shown in 
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terms of activity and overlaid as a heat map indicating relative changes in activity 
(Figure 4.6).  
 
Figure 4.5 Alanine scanning of each residue in the GSK-3β derived peptide. 
Corresponding peptide sequences are shown adjacent to the activities for each 
indicated Akt1 phospho-form. The ‘wild-type’ and unmutated control peptide is 
bolded. Akt1 activity is presented as absolute activity values (pmol p-
peptide/min). Statistically significant changes in comparison to the ‘wild-type’ 
unmutated peptide control are indicated as p < 0.05 (*) or p < 0.01 (**). 
 
To visualize the amino acid preferences and anti-determinants we 
converted the activity data into PSSMs (see Methods). Using Seq2Logo (19) we 
generated sequence logos representing the OPAL data (Figure 4.7). The results 
clearly demonstrate that the substrate selectivity of pAkt1S473 is both more 
restricted and totally distinct from the profile we observed for the pAkt1T308 and 
ppAkt1T308, S473 enzymes. Both ppAkt1T308, S473 and pAkt1T308 preferred large 
hydrophobic residues (Phe, Tyr, Trp) at the +1 position in the target peptide. In 
contrast, pAkt1S473 prefers basic residues (Lys, Arg, His) at the +1 position. Ile at -1 
and +2 positions were the least favorable for both pAkt1T308 and ppAkt1T308,S473 
variants. Phe and Pro are least preferred at -1 and +2 positions for pAkt1S473. The 
least preferred amino acid cluster at position +1 include Pro, Asp, Glu and Gly for 
SGAPRTTSFAESCKP
SGRARTTSFAESCKP
SGRPATTSFAESCKP
SGRPRATSFAESCKP
SGRPRTASFAESCKP
SGRPRTTAFAESCKP
SGRPRTTSAAESCKP
SGRPRTTSFAESCKP
SGRPRTTSFAASCKP
SGRPRTTSFAEACKP
SGRPRTTSFAESAKP
relative normalized activity
0 100
pS473 pT308
pS473 
pT308 
0.4 ± 0.1** 12.7 ± 0.7 30 ± 2*
4.3 ± 0.5 9.6 ± 0.9 17 ± 2**
0.1 ± 0.0** 7.8 ± 0.1* 13 ± 1*
5.1 ± 0.2** 11 ± 2 21.6 ± 0.4
2.5 ± 0.2** 8.1 ± 0.6* 14 ± 1*
0.3 ± 0.1** 3.8 ± 0.4** 6.4 ± 0.4**
1.2 ± 0.1** 16.1 ± 0.8** 26.0 ± 0.8
3.6 ± 0.3 11.8 ± 0.9 24 ± 2
2.1 ± 0.1* 9.7 ± 1.0* 16 ± 4
3.2 ± 0.1 11 ± 1 25.2 ± 0.8
3.8 ± 0.6 11 ± 3 18 ± 2
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pAkt1T308 and ppAkt1T308, S473. Thus the least favoured cluster for pAkt1S473 include 
Asp, Asn, Gln and Pro. Finally, we note that the specific amino acids most 
preferred at each position is distinct between each Akt1 phospho-form (Figure 4.6, 
4.7) in concordance with the unique substrate selective profiles we recoded over 
the library of known substrates (Figure 4.1). 
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Figure 4.6 Oriented peptide array library (OPAL) activity assays. Each cell in the 
above matrix represents activity (amount of pmol or fmol phosphorylated 
peptide/min) with the indicated sub-library in reactions catalyzed by pAkt1S473 (A), 
pAkt1T308 (B) or ppAkt1T308,S473  (C). The red to blue scale of relative activity 
corresponds to the preferences of amino acids at each indicated position substrate 
phosphorylation motif of Akt1. The 0 position is the phosphorylation site which 
was fixed to a Ser residue and was not shown; -3 position also not shown was fixed 
to an Arg.   
-6 -5 -4 -2 -1 1 2 3
K 4 ± 1 13 ± 3 0 ± 0 22 ± 12 93 ± 22 56 ± 15 10 ± 10 8 ± 2
R 1.1 ± 0.3 22 ± 1 34 ± 12 9 ± 3 54 ± 2 53 ± 10 31 ± 6 24 ± 1
H 32 ± 1 18 ± 4 22 ± 3 27 ± 12 124 ± 8 59 ± 9 19 ± 4 17 ± 2
D 6.6 ± 0.4 10.6 ± 0.5 45 ± 7 33 ± 8 141 ± 42 3 ± 2 16 ± 0.9 4 ± 0.6
E 13.1 ± 0.9 9 ± 2 71 ± 14 33 ± 8 34 ± 9 17 ± 7 2 ± 1 6 ± 1
N 15 ± 2 25 ± 7 66 ± 6 8 ± 4 23 ± 12 3 ± 1 7 ± 5 7 ± 2
Q 16 ± 2 13 ± 2 0 ± 0 14 ± 3 20 ± 9 4 ± 1 8 ± 5 13 ± 5
A 23 ± 4 8 ± 4 8 ± 3 27 ± 35 36 ± 16 7 ± 1 19 ± 1 14 ± 3
G 1.6 ± 0.6 8 ± 5 4 ± 6 11 ± 9 44 ± 9 33 ± 5 9 ± 4 36 ± 12
P 29 ± 6 3 ± 2 2 ± 5 4 ± 4 85 ± 34 4 ± 2 2 ± 1 5 ± 3
I 19 ± 5 8 ± 1 17 ± 3 27 ± 5 41 ± 3 5 ± 1 0 ± 0 18 ± 3
L 19 ± 4 14 ± 4 59 ± 7 95 ± 19 105 ± 11 15 ± 4 6 ± 4 22 ± 1
V 18 ± 1 5 ± 1 65 ± 24 65 ± 11 45 ± 21 28 ± 2 11 ± 5 15 ± 3
M 21 ± 4 25 ± 2 59 ± 6 31 ± 18 70 ± 2 28 ± 14 6 ± 8 12 ± 3
F 26 ± 4 44 ± 7 9 ± 12 46 ± 13 5 ± 5 50 ± 20 11 ± 5 42 ± 17
Y 27 ± 4 18 ± 11 15 ± 8 65 ± 22 33 ± 7 12 ± 4 22 ± 0.5 37 ± 9
W 33 ± 2 37 ± 6 21 ± 28 40 ± 9 36 ± 20 30 ± 2 60 ± 15 73 ± 21
pAkt1S473 activity 
(fmol p-peptide)
141
0
-6 -5 -4 -2 -1 1 2 3
K 1.3 ± 0.1 2.2 ± 0.2 1.9 ± 0.1 1.07 ± 0.08 1.3 ± 0.1 1.0 ± 0.2 1.9 ± 0.4 1.8 ± 0.2
R 1.5 ± 0.4 2.9 ± 0.1 2.0 ± 0.1 1.3 ± 0.1 1.05 ± 0.08 0.9 ± 0.2 1.8 ± 0.2 2.29 ± 0.08
H 1.16 ± 0.01 2.1 ± 0.1 1.75 ± 0.09 1.3 ± 0.1 1.5 ± 0.2 1.1 ± 0.2 2.4 ± 0.3 2.3 ± 0.4
D 1.3 ± 0.1 1.4 ± 0.2 1.31 ± 0.04 0.26 ± 0.03 0.9 ± 0.1 0.33 ± 0.05 1.7 ± 0.2 1.11 ± 0.08
E 1.33 ± 0.08 1.47 ± 0.04 1.52 ± 0.06 0.45 ± 0.07 0.91 ± 0.01 0.40 ± 0.07 1.2 ± 0.2 1.07 ± 0.06
N 1.44 ± 0.01 1.4 ± 0.1 1.5 ± 0.1 0.68 ± 0.04 1.3 ± 0.3 0.75 ± 0.06 1.4 ± 0.2 1.17 ± 0.09
Q 1.40 ± 0.09 1.4 ± 0.2 1.1 ± 0.1 0.6 ± 0.1 1.10 ± 0.09 0.7 ± 0.2 1.1 ± 0.1 1.38 ± 0.06
A 1.6 ± 0.3 1.24 ± 0.09 1.21 ± 0.01 0.9 ± 0.1 1.4 ± 0.2 0.90 ± 0.08 1.3 ± 0.2 1.02 ± 0.06
G 1.25 ± 0.02 1.3 ± 0.2 1.3 ± 0.1 0.73 ± 0.03 1.08 ± 0.05 0.07 ± 0.01 1.8 ± 0.3 1.5 ± 0.3
P 1.3 ± 0.3 1.7 ± 0.2 1.5 ± 0.1 0.27 ± 0.04 1.02 ± 0.09 0.07 ± 0.01 1.0 ± 0.2 2.29 ± 0.08
I 1.5 ± 0.1 1.4 ± 0.2 1.2 ± 0.1 0.8 ± 0.2 0.51 ± 0.01 1.17 ± 0.08 1.3 ± 0.2 2.3 ± 0.4
L 1.51 ± 0.01 1.3 ± 0.1 1.2 ± 0.1 1.01 ± 0.02 0.95 ± 0.08 1.4 ± 0.2 1.3 ± 0.2 1.11 ± 0.08
V 1.54 ± 0.08 1.32 ± 0.08 1.5 ± 0.2 0.9 ± 0.2 0.9 ± 0.1 1.5 ± 0.1 1.3 ± 0.2 1.07 ± 0.06
M 1.45 ± 0.04 1.5 ± 0.2 1.31 ± 0.08 0.71 ± 0.03 1.3 ± 0.1 1.67 ± 0.05 1.3 ± 0.1 1.17 ± 0.09
F 1.82 ± 0.08 1.6 ± 0.1 0.81 ± 0.07 0.80 ± 0.03 1.26 ± 0.3 1.93 ± 0.3 1.5 ± 0.1 1.38 ± 0.06
Y 1.53 ± 0.04 1.08 ± 0.1 0.7 ± 0.1 0.58 ± 0.01 1.29± 0.2 1.55 ± 0.1 1.4 ± 0.1 1.02 ± 0.06
W 1.42 ± 0.1 1.42 ± 0.2 0.7 ± 0.3 0.33 ± 0.02 0.78 ± 0.07 1.81 ± 0.1 1.3 ± 0.2 1.5 ± 0.3
pAkt1T308 activity 
(pmol p-peptide)
0
3.0
-6 -5 -4 -2 -1 1 2 3
K 3.64 ± 0.42 4.92 ± 0.39 4.89 ± 0.40 3.68 ± 0.48 4.16 ± 0.14 1.22 ± 0.10 5.12 ± 0.51 6.43 ± 0.64
R 4.17 ± 0.26 5.30 ± 0.79 4.51 ± 0.01 3.65 ± 0.39 3.67 ± 0.76 1.07 ± 0.13 4.73 ± 0.64 5.90 ± 0.56
H 2.34 ± 0.47 7.42 ± 0.25 4.04 ± 0.27 4.34 ± 0.17 4.07 ± 0.14 1.55 ± 0.02 5.66 ± 0.71 4.83 ± 0.65
D 3.76 ± 0.29 2.86 ± 0.80 2.33 ± 0.28 1.23 ± 0.28 3.67 ± 0.76 0.56 ± 0.06 5.48 ± 0.60 3.06 ± 0.37
E 2.93 ± 0.32 4.36 ± 0.40 2.98 ± 0.32 1.34 ± 0.08 2.24 ± 0.25 0.83 ± 0.28 2.75 ± 0.34 2.72 ± 0.29
N 3.58 ± 0.31 3.68 ± 0.20 3.09 ± 0.43 1.81 ± 0.21 3.67 ± 0.76 0.98 ± 0.11 4.31 ± 0.25 3.21 ± 0.29
Q 5.12 ± 0.42 3.05 ± 1.03 3.66 ± 0.37 1.48 ± 0.15 3.02 ± 0.48 1.08 ± 0.05 3.36 ± 0.22 3.51 ± 0.15
A 3.43 ± 0.46 3.28 ± 0.23 3.46 ± 0.46 2.63 ± 0.36 2.92 ± 0.21 1.34 ± 0.23 4.21 ± 0.23 3.20 ± 0.19
G 3.41 ± 0.19 3.39 ± 0.28 3.30 ± 0.41 2.34 ± 0.15 2.82 ± 0.47 0.87 ± 0.12 6.00 ± 0.09 4.87 ± 0.45
P 3.84 ± 0.53 3.00 ± 0.09 2.68 ± 0.19 0.81 ± 0.11 2.38 ± 0.53 0.34 ± 0.08 2.97 ± 0.09 3.05 ± 0.44
I 3.99 ± 0.68 2.98 ± 0.34 2.34 ± 0.48 2.12 ± 0.28 1.64 ± 0.10 2.09 ± 0.12 4.21 ± 0.23 3.93 ± 0.56
L 4.18 ± 0.15 2.99 ± 0.27 2.25 ± 0.18 3.24 ± 0.72 3.15 ± 0.25 2.63 ± 0.16 5.57 ± 0.28 4.05 ± 0.59
V 4.01 ± 0.18 2.51 ± 0.38 2.54 ± 0.56 4.19 ± 0.48 2.23 ± 0.06 2.82 ± 0.46 4.97 ± 0.16 3.95 ± 0.41
M 3.31 ± 0.30 3.53 ±0 .16 2.80 ± 0.41 2.81 ± 0.44 3.15 ± 0.29 4.94 ± 1.02 5.91 ± 0.65 4.33 ± 0.81
F 4.47 ± 0.39 3.77 ± 0.23 2.12 ± 0.11 2.3 ± 1.4 3.19 ± 0.16 6.07 ± 0.69 4.82 ± 0.15 4.05 ± 0.15
Y 3.61 ± 0.64 2.66 ± 0.15 2.44 ± 0.15 2.56 ± 0.57 3.24 ± 0.28 5.06 ± 0.57 4.73 ± 1.18 4.20 ± 1.12
W 3.30 ± 0.13 3.95 ± 0.31 3.31 ± 0.30 1.02 ± 0.17 2.55 ± 0.48 4.72 ± 0.63 4.35 ± 0.23 4.56 ± 0.81
0
7.4
ppAkt1T308,S473 activity 
(pmol p-peptide)
A
B
C
Figure 6: Oriented peptide array library screens (OPAL) for (A) ΔPH pAkt1S473 , (B) ΔPH pAkt1T308 and (C) ΔPH ppAkt1T308,S473 
variants. The red to blue scale of activity represents the preferences of amino acids at substrate phosphorylation motif of Akt1. 
0 position is the phosphorylation site which was fixed to a Ser residue and was not shown. -3 position also not shown was 
fixed to an Arg.  
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Figure 4.7 Sequence logos generated form the OPAL data.  Sequence logos of 
(A) pAkt1S473 (B) pAkt1T308 and (C) ppAkt1T308,S473 are based on the conversion of 
activity values from Figure 4.6 into a PSSM. Seq2Logo was used to convert the 
PSSMs to amino acid preferences as represented by sequence information bits.  
 
Next, we used information from the OPAL experiments to score the known 
human phospho-proteome to identify new Akt1 substrates. We then converted the 
Akt1 activity data into PSSMs based on calculating z-scores (see Methods) as 
before (14). The known human phospho-proteome was scored based on the amino 
acid preferences at each position in the z-score PSSM (Table S4.1). The scoring of 
peptides was performed for data based on each phospho-form of Akt1. We then 
selected the top scoring substrates (normalized sum of z-scores > 3). We included 
all of these high confidence hits in a STRING diagram to identify potential protein 
interactions and functional clusters among the known and predicted substrates 
(Figure 4.8, Table S4.1).   
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Figure 7: Web-logos representin  the amino acid pr ferences of the phosphorylation site of Akt1 substrates based on OPAL 
data. Enzyme variants of (A) ΔPH pAkt1S473 phosphorylated (B) ΔPH pAkt1T308 phosphorylated and (C) ΔPH ppAkt1T308,S473
hosphorylated OPAL substrates were used to create the logos. The phosphorylation site is denoted by #0 in x axis.
-6 -5    -4 -3    -2 -1     0 1    2 3    -6 -5    -4 -3    -2 -1    0 1    2 3    -6 -5   -4 -3    -2 -1    0 1    2 3    
	 151	
 
Figure 4.8 Interactions among highly active known and novel substrates of Akt1 
variants derived from OPAL screen.  (A) String diagram of interactions and (B) 
GO enrichment analysis conducted using Gene Ontology  (30) for the string 
diagram are shown. Red, yellow and green colors are assigned for novel substrates 
identified for pAkt1T308, pAkt1S473 and ppAkt1T308,S473  variants, respectively. Blue 
color denoted known substrates for ppAkt1T308,S473. Novel clusters of substrates 
involved in cell division, (orange), translation (blue), cytoskeleton (purple), RNA 
processing, lipid signaling, chromatin and processing (three gray circles) are 
encircled.  
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The search identified both known and unknown Akt1 substrates among the 
high confidence hits. Interestingly, the prediction suggested the presence of Akt1 
substrate in pathways not previously known to be regulated by Akt1. These 
include clusters of proteins that participate in translation, transcription, cell 
division, cytoskeletal organization, and lipid signaling (Figure 4.8A). The putative 
Akt1 substrates are significantly enriched in gene ontology (GO) (30) molecular 
functions related to protein kinases, RNA binding, and cytoskeletal organization 
according to GO enrichment analysis (Figure 4.8B). Putative Akt1 substrates 
include centromeric proteins involved in cellular mitosis. Chromosome associated 
protein G, boreilin, opa protein 5 and centromere protein O were the identified 
strong candidates for activity with each phospho-form of Akt1. Another novel 
cluster of putative Akt1 targets includes nucleolar proteins involved in ribosomal 
RNA processing. RNA binding motif protein 34, nucleolar protein 10, E3 ubiquitin 
ligase (RB binding protein 6 ubiquitin ligase) and RNA helicase were among this 
functional cluster. 
 
4.4.5 Akt1 variants differentially phosphorylate NIH 3T3 cellular proteins. We 
next measured the overall activity of each Akt1 phospho-form using the soluble 
cellular proteome derived from mammalian cells. We incubated the Akt1 variants 
with NIH 3T3 cell extracts to quantify how Akt1 phosphorylation status impacts 
its kinase activity on natural and full-length protein substrates. The reactions and 
controls contained γ-[32P]-ATP. The phosphorylated cell extracts were separated 
on SDS-PAGE gels and exposed to a phosphor-imaging screen to quantify radio-
labeled proteins. Significant activity was observed with the ppAkt1T308,S473 and 
pAkt1T308 variants (Figure 4.9). In agreement with the peptide experiments, 
pAkt1S473 demonstrated low activity with cellular extracts. The enzyme with a 
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single phosphorylation at Thr308 nearly reaches the maximal activity observed 
with the ppAkt1T308, S473 enzyme, validating our previous findings in COS7 cells 
(Chapter 2, (8) ). 
 
Figure 4.9 NIH 3T3 cell lysates were incubated with the indicated Akt1 
phosphorylated variants and 𝛾-[32P]-ATP. At specified time point, the reactions 
were quenched and (A) visualized 10% SDS-PAGE gel and exposed to phosphor-
imaging screen. (B) The radiolabeled protein intensities were quantified based on 
duplicate measurements. 
 
4.4.6 Validation of a novel Akt1 substrate. One of the novel potential substrates 
of Akt1 derived from the OPAL scan was the nucleotidyltransferase Gld2. Gld2 
adenylates miRNAs and mRNAs to increase their stability, which impacts gene 
expression (31). We used doubly phosphorylated Akt1 to test Akt1 activity on 
recombinantly purified Gld2 in vitro. In comparison to CK2-α, which showed no 
significant activity, Akt1 and protein kinase A (PKA) efficiently phosphorylated 
Gld2 (Figure 4.10, S4.4). These data were including in our recent publication (15). 
Mass spectrometry results revealed that ppAkt1 phosphorylated Gld2 specifically 
at Ser116 (Figure 4.11) (15). We also found that the Gld2 Ser116Ala mutant was not 
a substrate for Akt1 (15). The data demonstrate that Akt1 site-specifically 
phosphorylates Gld2 at Ser116. Strikingly, as found by my colleagues, 
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phosphorylation at this site nearly abolishes Gld2’s ability to catalyze nucleotide 
addition to microRNAs and mRNAs (15). The data suggest Akt1-dependent 
phosphorylation may be a powerful mechanism to regulate mRNA and miRNA 
metabolism. 
 
 
 
  
  
Figure 4.10 Kinase activity assays of Akt1 and CK2-α with Gld2 protein 
substrate. The enzyme activity was plotted over time. Akt1 but not CK2-α showed 
significantly increased reaction velocity with Gld2 as a substrate. All reactions 
were performed in triplicate (see Figure S4.4). 
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Figure 4.11 Akt1 and PKA phosphorylate Gld2 at S116. Mass spectra of 
unphosphorylated Gld2 after incubation with CK2-α and phosphorylated after 
incubation with ppAkt1T308,S473 or PKA. Unphosphorylated peptide is indicated by 
the light pink peak and the phosphorylated peptide by the dark peak. Position 116 
is bolded and underlined (15). 
 
4.5 Discussion 
We recently developed a new method to produce Akt1 with programmed 
phosphorylation at either or both key regulatory sites (8). This breakthrough 
technology enabled resolution of the contribution of each phospho-site to the 
activation (8) or inhibition (9) of Akt1. Because this approach was only recently 
developed, there are still very few studies that report on the function or impact of 
each phosphorylation site on Akt1 substrate specificity (32). Investigations into the 
substrate specificity of Akt have focused on characterizing the isozyme specific 
substrate preferences that differ between Akt1, Akt2, and Akt3  (1,33).  Indeed, the 
previous lack of tools to isolate the function of each Akt1 phospho-form inhibited 
investigations to characterize the impact of each phosphorylation site on substrate 
specificity. Our approach to produce singly and doubly phosphorylated Akt1 
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variants using genetic code expansion with or without co-expression of the 
upstream kinase PDK1 has to overcome this technological barrier (8,9).  
 
4.5.1 Phosphorylation dependent substrate specificity of Akt1. In our previous 
studies (8), we found that phosphorylation at Thr308 was necessary and sufficient 
for maximal Akt1 activity in mammalian cells. The addition or ablation of Ser473 
had some impact on the activity of the kinase in the test tube but did not influence 
phosphorylation of an Akt-specific live cell fluorescent reporter (8). These 
observations lead to our hypothesis that phosphorylation of Ser473 may function 
to tune rather than activate the Akt1.  
Using peptide library approaches, we mapped the substrate preferences for 
each key phospho-form of Akt1. The data presented here revealed that Ser473 
phosphorylation does indeed impact substrate specificity. More generally, we 
found that the phosphorylation status of Akt1 has a global impact on substrate 
preference as determined by kinase activity.  
 A multitude of studies (34,35), including our own (8) have presented 
evidence indicating that Akt1 activity increases monotonically with pAkt1S473 < 
pAkt1T308 < ppAkt1. Based on all of our assays, it remains clear that the pAkt1S473 
enzyme is far less active than the other two. Of the 84 known substrates we tested, 
this rule only holds completely true for half of the peptides (49%). When 
comparing pAktT308 with ppAkt1T308, S473, we found that many substrates (48%) show 
the same level of activity with pAkt1T308 and ppAkt1, while a minority (3%) are 
actually more active with the singly phosphorylated pAkt1T308 compared with the 
doubly phosphorylated enzyme.  
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Our current study further revealed that when only Ser473 is 
phosphorylated the substrate preference profile is distinct in comparison to Thr308 
phosphorylation. This observation was supported by data generated from ‘known’ 
substrates as well as the much larger data set generated using the OPAL approach. 
Several highest active substrates for pAktS473, including MDM2 (Ser188), MDM4, 
EP300 and eNOS (S1177), are members of the p53 mediated apoptotic pathway (36) 
(Figure 4.2A).  Phosphorylation of MDM family members and EP300 by Akt1 leads 
to p53 ubiquitination and degradation and promotes cell survival (36). Akt 
phosphorylates eNOS, which enhances its activity to produce nitric oxide (NO) 
(37). Acting as a signaling molecule, NO promotes angiogenesis in tumors (38), 
however, NO plays a dual role in cancer cell survival (37). Under oxidative stress 
induced cellular environment, NO promotes accumulation of p53 in the nucleus 
leading to apoptosis (38). p53 activates phosphatase and tensin homolog (PTEN) 
which is the phosphatase responsible in dephosphorylating the Akt binding lipid 
second messenger phosphatidylinositol-4, 5-triphosphate (PIP3) which suppresses 
Akt activation (39). 
The significance of Ser473 phosphorylation in differential substrate 
phosphorylation had been highlighted anecdotally. Jacinto et al. (2006) found 
disruption of Ser473 phosphorylation resulted from genetic ablation of sin1. Sin1 
is a component of the TORC2 complex, which phosphorylates Ser473. In mice or 
mammalian cells, downstream Akt1 substrate phosphorylation events were 
subsequently down regulated in a subset of Akt1 substrates, which included 
FOXO1 and FOXO3 (32). Indeed, although many substrates do not show different 
activity with ppAkt1T308,S473 versus pAktT308,  all of the FOXO peptides except the N-
terminal phosphorylation sites T24 and T32 of FOXO1 and FOXO3, respectively 
showed loss of activity in the absence of pS473 phosphorylation (Figure 4.2, 4.3).  
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The next example is related to endoplasmic reticulum stress in mammalian 
cells. Upon ER stress, the ER chaperone protein GRP78 is down regulated and this 
leads to increased phosphorylation of Akt1 at Ser473 but not Thr308 in JEG3 cells. 
As a result, increased Akt1-dependent phosphorylation of HDM2 (pSer166), 
FOXO1 (pSer319) and GSK3-β (pSer9) were observed by Western blotting (40). In 
our study, FOXO1, FOXO3 and GSK3-β demonstrated higher activity with both 
ppAkt1T308, S473 and pAkt1T308 variants in comparison to pAkt1S473 (Figure 4.2, Figure 
4.3).  
Our data clearly indicate that ppAkt1 is normally (but not always) more 
active and has a broader substrate profile than either of the singly phosphorylated 
enzymes. In alignment with the essentiality of pThr308 in the activation of Akt1 in 
vitro and in cells (8,35), we found that the two variants phosphorylated at T308 
showed greatest similarities in substrate preferences in comparison to the pAkt1S473 
enzyme. Manning and Cantley (2007) observed that Ser473 was not essential for 
phosphorylating the non-N-terminal phospho-sites of the FOXO transcription 
factors, TSC2, or GSK-3β (10). These observations are in close agreement with and 
supportive of our findings. The ppAkt1T308, S473 enzyme showed high activity with 
FOXO1 C-terminal phosphorylation sites (S319, S256), TSC2 and GSK-3β (Figure 
4.2, Figure 4.3). For pAkt1T308, all three FOXO1 phospho-sites ranked among the 
highest active substrates, suggesting that Ser473 is not a critical factor in FOXO1 
phosphorylation. In the clinic, phosphorylation of Thr308 was associated with 
poor cell survival with non-small cell lung cancer (41) and acute myeloid leukemia 
(42). According to our data here (8), we suggest that phosphorylation of Thr308 
alone may be capable of switching-on downstream signaling to promote cell 
survival by inhibiting the FOXO group of transcription factors. High level of 
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phosphorylation of Thr308 could contribute to the poor survival rate of lung cancer 
(38) and leukemic patients (39) with tumors characterized by hyper-active Akt1. 
 
4.5.2 Phosphorylation dependent changes in the Akt1 substrate motif. The 
molecular basis for kinase substrate selectivity depends on the residues 
neighboring the phosphorylation site (13). Yet it is important to understand that 
not all substrates identified for Akt isozymes include the same consensus motif 
(10). In the context of the cell, even with an optimal substrate according to the 
consensus motif requirements, phosphorylation by Akt1 will depend on multiple 
factors, including accessibility, cellular localization, and phosphatase activity (11).  
Our data obtained from the OPAL study for ppAkt1T308, S473 was in accord 
with but extended beyond previously reported results (12,13). We fixed the -3 
position to an Arg since the essentiality of Arg at -3 is well established (13). 
According to our results, all Akt1 phospho-forms showed a preference for Arg at 
position -5. ppAkt1T308, S473 and pAkt1T308 showed preference for hydrophobic amino 
acids for position +1. These amino acid preferences are shared by other AGC family 
kinases including protein kinase C. Obata et al. (2000) used degenerative peptide 
library studies to determine the most relevant substrate motif for active Akt1 (13). 
Unlike in our study, active Akt1 was derived from SF-9 insect cells and the 
phosphorylation status of Akt1 enzyme was not precisely defined. The authors 
reported the amino acid preferences derived from a set of known substrates and a 
degenerative peptide library. In comparison with these sequence preferences, we 
observed a strong compatibility with the predicted residues of our OPAL results 
with positions -5 and +1 with pAkt1T308 and ppAkt1T308, S473.  The most preferred 
amino acid at the -5 position was Arg and preferred amino acids at +1 are large 
hydrophobic residues. Both pAkt1T308 and ppAkt1T308, S473 enzyme variants showed 
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preference for Phe at position -6 as observed in the generative library predictions 
of Obata et al. Lys and Arg were predicted to be preferred for position -4 according 
to our OPAL results. According to their predictions position -4 could be any amino 
acid. In contrast to the study by Obata et al, we observed no selection for Ser and 
Thr at +2 with our OPAL data. Thus, Ser and Thr at +2 were the favorable amino 
acids according to our known library data. 
 
4.5.3 Putative substrates derived from OPAL screening. OPAL data lead to a 
predicted consensus sequence for all three Akt1 variants (Figure 4.7). These 
predicted consensus sequences were matched against the human proteome to 
identify potential novel substrates. Zn finger domain carrying proteins (numbered 
211, 251, 484, 668, 773, 792, 835) were abundant among the most likely putative 
Akt1 substrates. The functionality of Zn fingers includes DNA and/or RNA 
binding, protein-protein interactions and membrane binding. Indeed, most 
transcription factors carry Zn finger (43). Since Akt is well known for its 
phosphorylation-based inactivation of transcription factors like FOXO family 
proteins, Zn fingers containing transcription factors are interesting potential 
targets of Akt1. 
Validation of predictions based on our biochemical data using cellular or 
ultimately animal models is warranted in future studies. Our initial investigations 
towards such validations revealed that the E. coli produced Akt1 variants can 
phosphorylate cellular substrates (Figure 4.9). Next, based on the OPAL 
predictions we found that Akt1 may be involved in regulating RNA metabolism 
(Figure 4.8). Gld2, which is a nucleotidyltransferase that regulates RNA stability 
was one of the predicted targets of ppAkt1T308,S473. Gld2 has been implicated in the 
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stabilization and maturation of the tumour suppressor microRNAs miR-122 and 
let-7 (44,45). We found Gld2 was specifically phosphorylated by Akt1 at Ser116, 
which abolished Gld2 activity in 3’-terminal addition of adenine to miRNA and 
mRNA substrates (15). As hyperactivity of Akt1 is common in many cancers (46), 
our results suggest that phosphorylation of Gld2 by Akt1 would be beneficial for 
cancer cells in order to decrease the levels of miRNAs that act as tumour 
suppressors such as miR-122 and let-7 (15). Our data, thus, suggest a novel role of 
Akt1 activity on a miRNA editing enzyme and provides the first link between 
tumor suppressor miRNA regulation and oncogenic signaling.  
 
4.6 Conclusion 
The phosphorylation status of Akt is a commonly used biomarker for 
human cancer (41). Here we found that Akt1 phosphorylation status has a global 
impact on substrate selectivity. Fascinatingly, ppAkt1T308,S473 showed higher activity 
with most but not all substrates compared to Akt1 singly phosphorylated at 
Thr308. Indeed, a select pool of substrates was highly active with pAkt1T308. The 
pAkt1S473 variant had a distinct substrate preference profile compared to Akt1 
variants phosphorylated at Thr308. The role of Ser473 phosphorylation appears to 
involve global tuning of substrate selectivity rather than in truly activating the 
kinase. Indeed, it remains unknown whether Akt1 with only Ser473 
phosphorylated is active in the cell (8,35). Our findings have major implications 
for the use of Akt1 phosphorylation status as a clinical diagnostic (41,47) or a 
marker for cancer biology (46).  			
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4.8 Supporting Information 
 
Table S4.1 OPAL predictions of known and unknown Akt1 substrates 
 
Uniprot_ 
AC/ID 
Protein Name Site Presence at 
phosphosite 
Q9UNQ0 ATP-binding cassette sub-family 
G member 2 (Breast cancer 
resistance protein) (CDw338) 
(Mitoxantrone resistance-
associated protein) (Placenta-
specific ATP-binding cassette 
transporter) (Urate exporter) (CD 
antigen CD338) 
S50 yes 
P12814 Alpha-actinin-1 (Alpha-actinin 
cytoskeletal isoform) (F-actin 
cross-linking protein) (Non-
muscle alpha-actinin-1) 
S763 yes 
Q8IVF2 Protein AHNAK2 S4962 yes 
Q9BT22 Chitobiosyldiphosphodolichol 
beta-mannosyltransferase (EC 
2.4.1.142) (Asparagine-linked 
glycosylation protein 1 homolog) 
(Beta-1,4-mannosyltransferase) 
(GDP-Man:GlcNAc2-PP-dolichol 
mannosyltransferase) (GDP-
mannose-dolichol 
diphosphochitobiose 
mannosyltransferase) 
(Mannosyltransferase-1) (MT-1) 
(hMat-1) 
S239 yes 
Q8IZ07 Ankyrin repeat domain-
containing protein 13A (Protein 
KE03) 
S248 yes 
Q14678 KN motif and ankyrin repeat 
domain-containing protein 1 
(Ankyrin repeat domain-
containing protein 15) (Kidney 
S186 yes 
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ankyrin repeat-containing 
protein) 
Q8NB78 Lysine-specific histone 
demethylase 1B (EC 1.-.-.-) 
(Flavin-containing amine oxidase 
domain-containing protein 1) 
(Lysine-specific histone 
demethylase 2) 
S13 yes 
O94875 Sorbin and SH3 domain-
containing protein 2 (Arg-binding 
protein 2) (ArgBP2) (Arg/Abl-
interacting protein 2) (Sorbin) 
S712 yes 
Q53QZ3 Rho GTPase-activating protein 15 
(ArhGAP15) (Rho-type GTPase-
activating protein 15) 
S64 yes 
O43182 Rho GTPase-activating protein 6 
(Rho-type GTPase-activating 
protein 6) (Rho-type GTPase-
activating protein RhoGAPX-1) 
S264 yes 
Q9BRR9 Rho GTPase-activating protein 9 
(Rho-type GTPase-activating 
protein 9) 
S496 yes 
Q9NR48 Histone-lysine N-
methyltransferase ASH1L (EC 
2.1.1.43) (ASH1-like protein) 
(huASH1) (Absent small and 
homeotic disks protein 1 
homolog) (Lysine N-
methyltransferase 2H) 
S1226 yes 
Q9ULI0 ATPase family AAA domain-
containing protein 2B 
S1138 yes 
O60241 Adhesion G protein-coupled 
receptor B2 (Brain-specific 
angiogenesis inhibitor 2) 
S1543 yes 
Q53HL2 Borealin (Cell division cycle-
associated protein 8) (Dasra-B) 
(hDasra-B) (Pluripotent 
embryonic stem cell-related gene 
3 protein) 
S23 yes 
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Q9HA77 Probable cysteine--tRNA ligase, 
mitochondrial (EC 6.1.1.16) 
(Cysteinyl-tRNA synthetase) 
(CysRS) 
S401 yes 
P55211 Caspase-9 (CASP-9) (EC 3.4.22.62) 
(Apoptotic protease Mch-6) 
(Apoptotic protease-activating 
factor 3) (APAF-3) (ICE-like 
apoptotic protease 6) (ICE-LAP6) 
[Cleaved into: Caspase-9 subunit 
p35; Caspase-9 subunit p10] 
S196 yes 
Q8ND76 Cyclin-Y (Cyc-Y) (Cyclin box 
protein 1) (Cyclin fold protein 1) 
(cyclin-X) 
S83 yes 
Q0P6D6 Coiled-coil domain-containing 
protein 15 
S186 yes 
Q9NXE8 Pre-mRNA-splicing factor 
CWC25 homolog (Coiled-coil 
domain-containing protein 49) 
(Spliceosome-associated protein 
homolog CWC25) 
S381 yes 
Q9Y3X0 Coiled-coil domain-containing 
protein 9 
S349 yes 
O95067 G2/mitotic-specific cyclin-B2 S274 yes 
Q8N7R7 Cyclin-Y-like protein 1 S105 yes 
P50990 T-complex protein 1 subunit theta 
(TCP-1-theta) (CCT-theta) (Renal 
carcinoma antigen NY-REN-15) 
S317 yes 
Q96GN5 Cell division cycle-associated 7-
like protein (Protein JPO2) 
(Transcription factor RAM2) 
S62 yes 
Q96GN5 Cell division cycle-associated 7-
like protein (Protein JPO2) 
(Transcription factor RAM2) 
S321 yes 
Q00536 Cyclin-dependent kinase 16 (EC 
2.7.11.22) (Cell division protein 
kinase 16) (PCTAIRE-motif 
protein kinase 1) 
S146 yes 
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(Serine/threonine-protein kinase 
PCTAIRE-1) 
A8MXV6 CMT1A duplicated region 
transcript 15 protein-like protein 
S205 yes 
Q9BU64 Centromere protein O (CENP-O) 
(Interphase centromere complex 
protein 36) 
S72 yes 
Q6ZU80 Centrosomal protein of 128 kDa 
(Cep128) 
S187 yes 
P68400 Casein kinase II subunit alpha 
(CK II alpha) (EC 2.7.11.1) 
S194 yes 
P19784 Casein kinase II subunit alpha' 
(CK II alpha') (EC 2.7.11.1) 
S195 yes 
P53621 Coatomer subunit alpha (Alpha-
coat protein) (Alpha-COP) (HEP-
COP) (HEPCOP) [Cleaved into: 
Xenin (Xenopsin-related peptide); 
Proxenin] 
S16 yes 
P05813 Beta-crystallin A3 [Cleaved into: 
Beta-crystallin A3, isoform A1, 
Delta4 form; Beta-crystallin A3, 
isoform A1, Delta7 form; Beta-
crystallin A3, isoform A1, Delta8 
form] 
S112 yes 
Q9Y534 Cold shock domain-containing 
protein C2 (RNA-binding protein 
PIPPin) 
S32 yes 
Q8NEV1 Casein kinase II subunit alpha 3 
(CK II alpha 3) (EC 2.7.11.1) 
(Casein kinase II alpha 1 
polypeptide pseudogene) 
S194 No 
P14416 D(2) dopamine receptor 
(Dopamine D2 receptor) 
S148 yes 
O60469 Down syndrome cell adhesion 
molecule (CHD2) 
S860 yes 
P11532 Dystrophin S616 yes 
Q96F86 Enhancer of mRNA-decapping 
protein 3 (LSM16 homolog) (YjeF 
N-terminal domain-containing 
S161 yes 
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protein 2) (YjeF_N2) (hYjeF_N2) 
(YjeF domain-containing protein 
1) 
Q8NDI1 EH domain-binding protein 1 S781 yes 
Q9H329 Band 4.1-like protein 4B (FERM-
containing protein CG1) (Protein 
EHM2) 
S414 yes 
Q14152 Eukaryotic translation initiation 
factor 3 subunit A (eIF3a) 
(Eukaryotic translation initiation 
factor 3 subunit 10) (eIF-3-theta) 
(eIF3 p167) (eIF3 p180) (eIF3 
p185) 
S888 yes 
P23588 Eukaryotic translation initiation 
factor 4B (eIF-4B) 
S230 yes 
Q9HCM4 Band 4.1-like protein 5 S372 yes 
Q9H2F5 Enhancer of polycomb homolog 1 S535 yes 
Q5BKY9 Protein FAM133B S82 yes 
Q7L5A3 Protein FAM214B S268 yes 
Q9NZ56 Formin-2 S624 yes 
 
 
 
 
 
Figure S4.1 Production of △PH Akt1 variants. Purified fractions of (A) 
unphosphorylated Akt1 (lane 1) (B) pAktS473 (lane 1), pAktT308 (lane 2) and (C) 
ppAktT308, S473 (lanes 1-4) visualized on Coomassie stained SDS-PAGE after affinity 
and size exclusion chromatography. 
Figure x: Production of △PH Akt1 variants. 
Purified fractions of (A) unphosphorylated 
Akt1 (lane 1) (B) pAktS473 (lane 1), pAktT308 
(lane 2)  and (C)  ppAktT308, S473 (lanes 1-
4) visualized on SDS-PAGE after affinity 
and size exclusion chromatograp
A B C
75
50
Mol. 
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Figure S4.2 Autoradiographs on OPAL assay conducted for pAktS473. Ax-Hx are 
sub-library pools of peptides where one amino acid has kept unchanged in the 
peptide sequence while the rest is randomized with 17 amino acids except serine, 
threonine and cysteine.Assays were performed in triplicate (as indicated by R1-
R3). Controls include: C1 enzyme without substrate peptide, C2 only kinase assay 
buffer.    
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Figure S4.3 Autoradiographs on OPAL assay conducted for pAktT308. Ax-Hx are 
sub-library pools of peptides where one amino acid has kept unchanged in the 
peptide sequence while the rest is randomized with 17 amino acids except serine, 
threonine and cysteine. Assays were performed in triplicate (as indicated by R1-
R3). Controls include: C1 enzyme without substrate peptide, C2 only kinase assay 
buffer.    
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Figure S4.4 Autoradiographs on OPAL assay conducted for ppAktT308, S473. Ax-Hx 
are sub-library pools of peptides where one amino acid has kept unchanged in the 
peptide sequence while the rest is randomized with 17 amino acids except serine, 
threonine and cysteine. Assays were performed in triplicate (as indicated by R1-
R3). Controls include: C1 enzyme without substrate peptide, C2 only kinase assay 
buffer.    
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Figure S4.5 Kinase activity assays of Akt1 and CK2-α with GLD2 and 𝛾-[32P]-
ATP as substrates. Spot pictures of the activity assays where the reactions were 
spotted  at 5, 10, 15 min time points. The data are plotted in Figure 4.10. 
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Chapter 5 
 
 
5 Summary and future perspectives 
 
5.1 Summary 
The proto-oncogene Akt/PKB is a key regulatory kinase in the PI3K/Akt cell 
survival pathway and belongs to the AGC family of kinase (1). There are three 
isozymes of Akt named Akt1, Akt2 and Akt3. All three isozymes are activated 
upon growth factor stimulation (2). In Akt1, Thr308 and Ser473 are the key 
regulatory phosphorylation sites. Following activation by receptor tyrosine 
kinases at the plasma membrane, phosphoinositide-3-phosphate kinase (PI3K) 
phosphorylates its immediate downstream target, a lipid second messenger called 
phosphatidylinositol-4, 5-bisphosphate (PIP2), converting PIP2 into 
phosphatidylinositol-4, 5-triphosphate (PIP3) (1,3). PIP3 harbors binding sites for 
PH domain carrying proteins like Akt and PDK1. Co-localization of PDK1 with 
Akt at the plasma membrane promotes phosphorylation of Thr308 by PDK1 (1). 
The second site Ser473 in the regulatory domain of Akt is phosphorylated by 
mechanistic target of rapamycin complex 2 (mTORC2).  
Once the activation via phosphorylation is complete, Akt dissociates from 
the plasma membrane and is transported to the cytosol and nucleus to 
phosphorylate additional downstream target substrates (1,3).  The mechanism of 
activation of Akt is well-studied, however, the contribution of each 
phosphorylation site to the activation of Akt1 remained elusive. Technical 
difficulties associated with producing single site phosphorylated variants 
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hindered the characterization of the functionality of each phosphorylation site. 
This phosphorylation status of Akt1 is clinically relevant as in multiple different 
types of cancer the level of phosphorylation of each activation site in Akt has been 
linked with the survival rate of cancer patients (4). 
In my initial experiments, my goal was to determine the contribution of 
each regulatory phosphorylation site to the overall activation of the Akt1 kinase. 
In this first objective, I used a genetic code expansion strategy in a novel 
combination with enzymatic phosphorylation to produce site-specifically 
phosphorylated Akt1 variants (5).  Using these two methods, we produced singly 
phosphorylated Akt1 variants recombinantly in E. coli and confirmed the presence 
of phosphorylation at each site using mass spectrometry and activity assays. We 
compared the activity of the unphosphorylated, singly phosphorylated and 
doubly phosphorylated Akt1 variants using radioactive kinase assays with a Akt1 
substrate peptide derived from GSK-3β. The apparent catalytic rate of the kinase 
when both activation sites are phosphorylated was 1500-fold higher than the 
unphosphorylated Akt1. The contribution of Thr308 in activation of Akt1 was only 
reduced from the doubly phosphorylated enzyme by ~3-fold and was significantly 
more active than pAkt1S473. Live-cell imaging in COS7 cells further confirmed that 
phosphorylation of Thr308 was sufficient and irreplaceable for Akt activation in 
cell (5). 
The traditional method of using phosphomimetics substitutions, such as 
Glu and Asp mutations, to mimic phosphorylation was also tested (6). In both the 
test tube and in mammalian cells, phosphomimetics failed to activate the kinase in 
comparison to true phosphorylation. Mutation of Thr308Ala produced a kinase 
dead mutant, which is not active in vitro despite of the phosphorylation at Ser473. 
In in vitro kinase assays and in COS7 cells, Akt1 Thr308Ser was a partially 
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activated kinase, revealing a critical interaction between the γ-methyl group of 
Thr308 and Cys310 in the activation site of Akt1 (5). 
Once the contribution of each phosphorylation site on activation of Akt1 
was determined, next I investigated the impact of each phosphorylation site on 
releasing the auto-inhibitory effect of the PH domain of Akt1 (7). I used the same 
experimental strategies noted above to produce Akt1 variants without the PH 
domain. Deletion of PH domain increased the enzyme activity of all Akt1 variants. 
Presence of PH domain has inhibited doubly phosphorylated Akt1 by a factor of 
29-fold compared to the non-phosphorylated enzyme and the two singly 
phosphorylated variants i.e.  pAkt1T308 and pAkt1S473 , were inhibited by factors of 
17-fold and 5-fold, respectively.  
Next, I tested the impact of Akt1 phosphorylation status on chemical 
inhibition. A known PH domain dependent Akt inhibitor, Aki1/2 was used (8). 
Our results showed that phosphorylation at Ser473 provided resistance to Akt 
inhibition, increasing the IC50 by 4-fold. These findings highlight the importance of 
selecting the most pathogenic form of the kinase in designing potent inhibitors for 
Akt1 (7). 
The impact of Akt1 phosphorylation status on substrate selectivity was 
unknown. A few reports have suggested a role for Akt1 phosphorylation status in 
modulating substrate selectivity (1,9), yet no systematic investigation has been 
conducted. We, therefore, used peptide library based approaches to investigate the 
substrate selectivity of singly and doubly phosphorylated Akt variants.  
We found that Akt1 p-status has a global impact on substrate selectivity. 
The pAktS473 enzyme has a completely different substrate selectivity profile 
compared to pAkt1T308 or ppAkt1. Amazingly, the doubly phosphorylated 
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enzyme is usually, but not always more active than pAkt1T308. The role of S473 
phosphorylation appears to be involve in globally tuning substrate selectivity 
rather than activating the kinase. From the predicted substrates we verified that 
the terminal nucleotidyltransferase (germline development 2) Gld2 was 
phosphorylated at specifically in its N-terminal domain at Ser116. Phosphorylation 
at Ser116 abolished nucleotide addition activity of GLD2 (10).  
 
5.2 Future directions 
5.2.1 Validation of predicted substrates 
We developed a new method to produce Akt1 with programmed 
phosphorylation on each activation site. Although the scientific literature on Akt 
is vast,  previously, very few studies (9) reported on the specific functionality of 
each phosphorylation site or the relationship between Akt1 phosphorylation status, 
inhibition and substrate specificity. Most previous studies used protein with 
mixed or non-homogenous phosphorylation status. Although such a kinase is 
active it can not reveal the role of each phosphorylation site. Since acidic or alanine 
substitutions at 308 and 473 alter the activity of this enzyme in the test tube and in 
cells (5) such substitutions do not report on the activity caused by actual 
phosphorylation. We have been using a systemic approach to cautiously compare 
and contrast the phosphorylation site dependent substrate specificity.  
The peptide library analysis (Chapter 4) revealed that the phosphorylation 
status of Akt1 modulates substrate specificity on a global or proteome-wide scale. 
Based on data from the OPAL screen, we were able to identify potential novel 
substrates for Akt1. One of the key areas of future directions is validation of these 
predictions. Although the data I have produced alone is not sufficient to validate 
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these predictions, in vitro activity assays are an essential starting point to prove 
the ability of Akt1 to phosphorylate a particular substrate. In the cell, the ability of 
Akt1 to phosphorylate a particular substrate is more complex and will rely on the 
accessibility, secondary interactions with the kinase, cellular localization and the 
physiological status of the cell (3). De-phosphorylation of putative Akt1 substrates 
by phosphatases (3) is another complicating factor.  
 
5.2.2 Targeting Akt1 in cancer treatment 
The significance of Akt activation in cancer has been widely studied during 
the past decades due to the prominent role of Akt in cell growth and survival  
(11,12). In cancer cells, Akt is found to be over-activated and hyper-
phosphorylated, which helps cancer cells to survive (11,13). Therefore, Akt is a 
prominent target in developing anti-cancer drugs. Clinical trials to test Akt 
inhibitors are currently in progress (14,15), yet a unique anticancer agent for Akt 
isozymes has not been successfully designed.  
My studies have wide ranging implications for Akt1 drug design as my data 
suggests that the phosphorylation status of Akt1 impacts is activity, substrate 
selectivity and its ability to be inhibited. The fact that each Akt1 phospho-form has 
distinct substrate preferences, indicates that the phospho-forms can be targeted 
separately. The site-specifically phosphorylated Akt variants are, thus, invaluable 
tools for drug screening and design. These site-specifically programmed kinase 
variants will help to make precise inhibitor screening platforms for Akt and 
ultimately any human kinase of interest. 
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5.3 Conclusion 
Using genetic code expansion and co-expression of a specific upstream 
kinase, I produced site-specifically phosphorylated Akt1 variants. These variants 
are indispensable tools that I used to characterize the functionality of each site 
separately and in combination. These Akt1 phospho-variants were instrumental in 
my investigations of the activation, auto-inhibition, chemical inhibition and 
substrate selectivity of Akt1. Isolating the effect of each phosphorylating site 
allowed a detailed characterization of the individual and unique functional roles 
of each site in activating a major human kinase linked to cancer. 
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